![]() | Stephen V Faraone∗Department of Psychiatry and Behavioral Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210 | Departments of Psychiatry and Neuroscience and ... |
Kol melanjutkan untuk Stephen V Faraone∗
Year | |
---|---|
2022 | Department of Psychiatry and Behavioral Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210 |
2021 | Department of Neuroscience and Physiology, State University of New York Upstate Medical University, Syracuse, New York Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, Massachusetts, USA |
2020 | K.G. Jebsen Centre for Psychiatric Disorders, Department of Biomedicine, University of Bergen, Bergen, Norway Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical Center, Syracuse, NY, USA Department of Psychiatry and of Neuroscience and Physiology, State University of New York (SUNY) Upstate Medical University, Syracuse, NY, United States The full list of authors in the ENIGMA working groups, author affiliations, author disclosures, and acknowledgments are provided in online supplements. |
2019 | Departments of Psychiatry and Neuroscience and Physiology, SUNY Upstate Medical University, New York, USA The Department of Human Genetics, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands (Klein, Bralten, Roth Mota, Arias-Vasquez, Franke); University Medical Center Utrecht, UMC Utrecht Brain Center, Department of Psychiatry, Utrecht, the Netherlands (Klein); the Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Walters, Neale); Program in Medical and Population Genetics (Walters) and Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, Mass (Walters, Neale); the Department of Biomedicine and the Center for Integrative Sequencing, Aarhus University, Aarhus, Denmark (Demontis, Mattheisen, Børglum); the Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Denmark (Demontis, Børglum); the Department of Genetics and the Neuroscience Center, University of North Carolina, Chapel Hill (Stein); the Imaging Genetics Center, USC Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles (Hibar, Thompson); the Department of Epidemiology and the Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, the Netherlands (Adams); the Department of Psychiatry and the Research Institute, Hospital for Sick Children, University of Toronto, Toronto (Schachar); the Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (Sonuga-Barke); the Department of Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany (Mattheisen); the Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institute, Stockholm (Mattheisen); Stockholm Health Care Services, Stockholm County Council, Stockholm (Mattheisen); the Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles (Thompson); the Quantitative Genetics Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Medland); the Department of Psychiatry and the Department of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, N.Y. (Faraone); the K.G. Jebsen Center for Neuropsychiatric Disorders, University of Bergen, Bergen, Norway (Faraone); and the Department of Psychiatry, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands (Roth Mota, Arias-Vasquez, Franke). Department of Psychiatry, Upstate Medical University, Syracuse, New York; Department of Neuroscience and Physiology, Upstate Medical University, Syracuse, New York. SUNY Upstate Medical University, Syracuse, NY |
Stephen V Faraone∗: Statistik pengaruh
Concept | World rank |
---|---|
robust familiality | #1 |
adolescents sud treatment | #1 |
inattention items | #1 |
impact tic disorders | #1 |
ldx bmi | #1 |
adhd iiv | #1 |
parental bpd | #1 |
schizotaxia negative schizotypy | #1 |
bipolar mdd | #1 |
marijuana cocaine crack | #1 |
p27e05 | #1 |
siblings adhd probands | #1 |
p446e08 | #1 |
ptsd adhd probands | #1 |
amses amrs | #1 |
bpd bpd anx | #1 |
copy organization | #1 |
relatives adhd status | #1 |
pain tolerance oih | #1 |
idir aversion | #1 |
clinical features adhd | #1 |
palau early | #1 |
140 adhd | #1 |
neurocognitive traits | #1 |
smoking schizophrenia families | #1 |
adhd snps | #1 |
adhd aes | #1 |
vulnerability indicators schizophrenia | #1 |
bipolar disorder girls | #1 |
disorder attention | #1 |
outcome adhd | #1 |
risk psud | #1 |
children idiopathic adhd | #1 |
galantamine hydrogen bromide | #1 |
stimulant treatment profiles | #1 |
51 genes | #1 |
schizophrenia nonpsychotic relatives | #1 |
motorendophenotype | #1 |
hyperactive impulsive | #1 |
“3 | #1 |
diagnoses relatives | #1 |
individuals attention | #1 |
mitigates stimulant | #1 |
adhd somatosensory functioning | #1 |
paternal smoking conception | #1 |
deficits time | #1 |
adhd comorbid | #1 |
pepple | #1 |
notch4 polymorphisms schizophrenia | #1 |
onset distribution | #1 |
large controlled study | #1 |
girls disorder | #1 |
hyperactivity cross | #1 |
highiq youths adhd | #1 |
nonreferred subjects | #1 |
nonreferred siblings | #1 |
association attention | #1 |
pharmacological treatment adolescents | #1 |
sensitive adhd | #1 |
17year | #1 |
children bpi disorder | #1 |
pdi impulsiveness | #1 |
pdd criteria | #1 |
2327t | #1 |
diagnosis adhd | #1 |
stimulant treatment adhd | #1 |
shlod | #1 |
affective symptoms children | #1 |
paternal over‐transmission | #1 |
adhd desr probands | #1 |
adhd neuroimage study | #1 |
efficacy adderall | #1 |
schizotaxia negative symptoms | #1 |
parents md | #1 |
schizophrenia current knowledge | #1 |
p97e−03 | #1 |
adult adhd diagnosis | #1 |
illness adolescent | #1 |
adolescents genetic risk | #1 |
autistic traits youth | #1 |
hamiltondepression | #1 |
pinslbl | #1 |
odd control | #1 |
sexes bpi disorder | #1 |
subsets linkage | #1 |
clinical response orosmph | #1 |
rate symptoms | #1 |
psychiatric comorbidities adhd | #1 |
schizophrenia families smoking | #1 |
nonmental diseases adhd | #1 |
adults stimulant sizes | #1 |
p81e06 | #1 |
akt1 snp markers | #1 |
genes association studies | #1 |
adhd methods | #1 |
oih pain tolerance | #1 |
smd higher rates | #1 |
vcfs manic symptoms | #1 |
diagnostic criteria adhd | #1 |
suggestive linkage | #1 |
treatment stimulant | #1 |
adhd female individuals | #1 |
growth deficits deficits | #1 |
visual memory deficit | #1 |
lobe mri measures | #1 |
add 73 probands | #1 |
motor problems adhd | #1 |
network‐level assessment | #1 |
future dsm | #1 |
slc9a9 | #1 |
genes disorder | #1 |
familial association adhd | #1 |
adhd adolescent patients | #1 |
lod213 | #1 |
bpd anx bpd | #1 |
diagnoses probands | #1 |
mtbi adhd | #1 |
adhdfamilies | #1 |
bpd relatives | #1 |
disorder meta | #1 |
gene studies | #1 |
adhd medications placebo | #1 |
desipraminestimulants | #1 |
bipolar disorder bpprss | #1 |
cases adhd | #1 |
15q13 deletions | #1 |
stimulant nmu | #1 |
adhd children bpd | #1 |
adhdtd | #1 |
gender adhd | #1 |
adhd drd4 | #1 |
depression symptoms aggregation | #1 |
bpd bpdsud | #1 |
dsmiv subtypes adhd | #1 |
unipolar relatives bipolars | #1 |
pdd mania mania | #1 |
dbds adhd | #1 |
notch4 polymorphisms | #1 |
add opd | #1 |
highiq youths | #1 |
rs7118422 | #1 |
model adult samples | #1 |
inattention shr | #1 |
nplz | #1 |
maoa impulsivity | #1 |
nfspd | #1 |
cortical surface adhd | #1 |
adhd prs rtv | #1 |
nmu nasal nmu | #1 |
shr iiv | #1 |
187 children | #1 |
confusability analyses | #1 |
endosomal genes asds | #1 |
gene attention | #1 |
relszs | #1 |
conduct disorder probands | #1 |
rorb bipolar disorder | #1 |
probands adhd | #1 |
n6979 | #1 |
adhd asd youth | #1 |
depressed children depression | #1 |
siblings antisocial families | #1 |
2276ct | #1 |
schizotaxia schizophrenia | #1 |
memory adults | #1 |
adhd income loss | #1 |
adhd sexes | #1 |
cgsq ermph | #1 |
interviews disease humans | #1 |
autism symptoms adhd | #1 |
adhd risk factors | #1 |
c759t | #1 |
genes etiology | #1 |
severe emotional dysregulation | #1 |
desr siblings | #1 |
snpssnpsa | #1 |
md parents | #1 |
earlyandmoderate | #1 |
adults ldx sizes | #1 |
142 combined subtype | #1 |
mania referred children | #1 |
mddprss | #1 |
competitivep | #1 |
bpd firstdegree relatives | #1 |
adhd depressed children | #1 |
adhd studies | #1 |
affective psychosis hraff | #1 |
add parent report | #1 |
1236a | #1 |
adhd cognition | #1 |
suggestive linkage signals | #1 |
discordant twin study | #1 |
foursnp | #1 |
substantial genetic component | #1 |
genotype calling procedures | #1 |
sp067 | #1 |
psychiatric disorders adhd | #1 |
longitudinal analysis childhood | #1 |
aggregate cutoff score | #1 |
individuals adhd | #1 |
adhd treatment treatment | #1 |
aklt01 adhd | #1 |
daorasd2 | #1 |
h2053 | #1 |
adhd clinical | #1 |
oral nmu nmu | #1 |
2 familial factors | #1 |
sud adolescence | #1 |
hartsough | #1 |
drugplacebo response curve | #1 |
adhd attention | #1 |
disorder | #1 |
snps quantitative phenotypes | #1 |
adhd alcohol dependence | #1 |
stimulant treatment youth | #1 |
adoption studies | #1 |
disorder follow | #1 |
callingalgorithms | #1 |
prss psychiatric disorders | #1 |
subtype adhd | #1 |
diagnoses valid | #1 |
increasing resource demand | #1 |
children growth delays | #1 |
neuropsychological functioning boys | #1 |
“forgetfulness | #1 |
relatives children | #1 |
bpd anx | #1 |
gsprs adhd | #1 |
adult adhd differences | #1 |
p647e07 | #1 |
adhd maoa | #1 |
youth informant source | #1 |
p179e06 | #1 |
pdics | #1 |
nimh genetics initiative | #1 |
gsprss | #1 |
morbidity adhd | #1 |
patterns psychiatric comorbidity | #1 |
chi28783 | #1 |
adhd genetic exome | #1 |
adolescent patients adhd | #1 |
males overweight obesity | #1 |
adhd probands | #1 |
rs6077690 | #1 |
relatives pediatric probands | #1 |
sud bpdsud | #1 |
probands comorbidity | #1 |
valid psychiatric disorder | #1 |
nonverbal social–emotional cues | #1 |
children pdag parents | #1 |
rs1799835 | #1 |
life adult adhd | #1 |
subjects lateonset adhd | #1 |
probands rates | #1 |
disorder adhd | #1 |
longitudinal outcome boys | #1 |
meaningful anxiety phenotype | #1 |
relatives adhd probands | #1 |
kiaa1292 | #1 |
mwq inattention items | #1 |
ldx growth | #1 |
parental suds | #1 |
risk factor psud | #1 |
adolescent response inhibition | #1 |
palauans maps loci | #1 |
subthreshold pediatric | #1 |
ldx sizes adults | #1 |
adhd population | #1 |
adhd clinical trial | #1 |
symptom burden adults | #1 |
relatives default network | #1 |
adhd scores | #1 |
siblings adolescent | #1 |
adhd adoption studies | #1 |
anxiety disorders families | #1 |
drd2 disrupts | #1 |
genomesignificance | #1 |
relatives greater activation | #1 |
new diagnoses age | #1 |
dao gene schizophrenia | #1 |
hyperactivity comorbidity humans | #1 |
comorbid adult adhd | #1 |
adhd mp | #1 |
neuropsychological performance adhd | #1 |
schizophrenic probands1portions | #1 |
adolescent sud | #1 |
attention deficit | #1 |
overlapping symptoms | #1 |
adhd chinese population | #1 |
schizophrenia familybased studies | #1 |
adhd bipolar comorbidity | #1 |
matching fallacy | #1 |
preschool comorbidity | #1 |
rs3792452 | #1 |
adhdtd siblings | #1 |
disability asthma | #1 |
severe dysregulation | #1 |
temperamental risk factor | #1 |
diagnoses adhd | #1 |
dsm5 adult adhd | #1 |
adult samples model | #1 |
thermenos | #1 |
95 hrr | #1 |
parental sud adhd | #1 |
anxious depressed subscales | #1 |
ldx masir | #1 |
male adolescents adhdct | #1 |
maoa neuropsychological functioning | #1 |
pdd subjects mania | #1 |
braingenie | #1 |
rtv adhd prs | #1 |
ldx sizes | #1 |
druggable genome adhd | #1 |
starsadhd | #1 |
manic symptoms vcfs | #1 |
predictors adhd | #1 |
ld addh children | #1 |
impulsive subtype | #1 |
impulsive behavioral aggression | #1 |
mr005 | #1 |
offspring parental adhd | #1 |
training raters | #1 |
adhd genetic studies | #1 |
unfamiliar challenges | #1 |
rs3027400 | #1 |
stimulants abuse potential | #1 |
rs9610449 | #1 |
multi‐stage study | #1 |
rs2272080 | #1 |
genes hallucinations states | #1 |
77e08 | #1 |
relation stress exposure | #1 |
relatives alcohol dependence | #1 |
noninhibited children | #1 |
asd youth adhd | #1 |
childhoodonset mania | #1 |
adhd dat1 gene | #1 |
subthreshold adhd | #1 |
adhd familial | #1 |
convergent functional genomic | #1 |
standardized manner | #1 |
rutters | #1 |
dsm bipolar disorder | #1 |
late‐onset adhd | #1 |
insular lobule | #1 |
studies adhd | #1 |
n55374 | #1 |
age onset criterion | #1 |
combination scientific data | #1 |
age stimulant treatment | #1 |
bipolar disorder parents | #1 |
aadhd hyperactivity biomarkers | #1 |
exposure maternal smoking | #1 |
drug dependence relatives | #1 |
addictive drugs dust | #1 |
interaction adhd | #1 |
sud parents | #1 |
intellectual delays | #1 |
adhd fam | #1 |
comorbid psychopathology childhood | #1 |
np functioning chr | #1 |
genetic variants adhd | #1 |
arch ger psychiatry | #1 |
20183 cases | #1 |
hyperactivity body | #1 |
validity adhd | #1 |
adults neurodevelopmental disorder | #1 |
adhd sex | #1 |
patients attentional disorders | #1 |
genetic heterogeneity adhd | #1 |
hyperactivity comorbidity | #1 |
adhd african | #1 |
adhdrsivinv | #1 |
offspring parental md | #1 |
chi25762 | #1 |
higher pdi | #1 |
ctcata | #1 |
deficit hyperactivity | #1 |
antisocial disorders risk | #1 |
mph adult adhd | #1 |
1 relatives | #1 |
relatives bipolar | #1 |
substance disorders relatives | #1 |
antisocial disorder relatives | #1 |
aggressive symptoms risk | #1 |
learning disorders adhd | #1 |
comorbid odd adhd | #1 |
adhd smoking risk | #1 |
adherence stimulant treatment | #1 |
major depression share | #1 |
hyperactivity cognition | #1 |
week treatment response | #1 |
adhd bpi disorder | #1 |
parental md | #1 |
adhdmethodcurves | #1 |
exposure clinical features | #1 |
adhd druggable genes | #1 |
comt maoa interaction | #1 |
adhd maternal | #1 |
evidence stimulant treatment | #1 |
prescription stimulant nonmedical | #1 |
euphoria cardinal symptom | #1 |
autistic traits presence | #1 |
a409p | #1 |
predicted clinical response | #1 |
parents sud | #1 |
rationaleadhd | #1 |
genetic sexual dimorphism | #1 |
adhd cigarette smoking | #1 |
impulsive drive | #1 |
increased expression methylation | #1 |
31item | #1 |
clinical controls | #1 |
manic symptoms disorder | #1 |
d15s1012 | #1 |
parental polygenic risk | #1 |
association evidence | #1 |
qelbree | #1 |
relbps | #1 |
drd5 vntr | #1 |
s034 | #1 |
adhd antisocial comorbidity | #1 |
adhd symptom counts | #1 |
anxiousdepressed | #1 |
latrophilin 3 gene | #1 |
bmi ldx | #1 |
nonaffected siblings children | #1 |
pair health | #1 |
children mania diagnosis | #1 |
racial heterogeneity | #1 |
adhdassociated alleles | #1 |
anxiety disorders relatives | #1 |
molecular psychiatric genetics | #1 |
adhd stronger connectivity | #1 |
dysfunctional gene | #1 |
apol1 schizophrenia | #1 |
df39 | #1 |
larger samples | #1 |
subthreshold adhd subjects | #1 |
persistent adhd symptoms | #1 |
family‐based association test | #1 |
comt maoa | #1 |
mwq adhd module | #1 |
sud risk offspring | #1 |
persistence adhd | #1 |
120 normal controls | #1 |
adhd antisocial disorders | #1 |
adhd haplotype block | #1 |
familial disorders adhd | #1 |
familially | #1 |
impairments adults | #1 |
expression adhd | #1 |
adulthood genetic architecture | #1 |
potential endophenotypes adhd | #1 |
risk disorder | #1 |
caregiver strain cgsq | #1 |
adhd females | #1 |
adhd total score | #1 |
hyperactivity child child | #1 |
schizotypal relatives | #1 |
“schizotypes | #1 |
smoking wm microstructure | #1 |
bpi sza | #1 |
regions age | #1 |
maoa adhd | #1 |
association evidence schizophrenia | #1 |
groundskeeper | #1 |
comorbid problems adhd | #1 |
reproducibility adolescent | #1 |
stimulant nonmedical | #1 |
dat110 6 | #1 |
adhd maternal smoking | #1 |
rs3916970 | #1 |
prss adhd | #1 |
smd greater severity | #1 |
asds clinical scales | #1 |
neuropsychologic function schizophrenia | #1 |
youth bpi disorder | #1 |
treatment masxr | #1 |
adult samples adhd | #1 |
ermph clinical response | #1 |
covariates dopamine receptors | #1 |
disorder boys | #1 |
children ermph | #1 |
timely renewal | #1 |
adhd pattern | #1 |
hyperactivity disorder | #1 |
variance oppositional symptoms | #1 |
referred parents | #1 |
adhdi prenatal exposure | #1 |
comparison subjects participants | #1 |
bpi disorder youth | #1 |
mdd pdag mdd | #1 |
fbxo33 | #1 |
taf9bp2 | #1 |
rs550818 | #1 |
adhd gsprs | #1 |
suds relatives | #1 |
schizophrenia european samples | #1 |
persistence disorder | #1 |
elaborative verbal encoding | #1 |
adhd serotonin | #1 |
quantitative phenotype snp | #1 |
manic children pdd | #1 |
children antisocial disorders | #1 |
adult adhd treatment | #1 |
low attention | #1 |
abstinence pharmacological treatment | #1 |
pediatric bipolari disorder | #1 |
odd relatives | #1 |
adhd personality traits | #1 |
levels dysfunction | #1 |
multiplex sample | #1 |
adhd prs gwas | #1 |
desr probands siblings | #1 |
disorder familial | #1 |
nonreferred siblings probands | #1 |
adhd module mwq | #1 |
adhd functional | #1 |
pain tolerance fm | #1 |
cbclbp | #1 |
teenage parents individuals | #1 |
pdi hyperactivity | #1 |
asd weaknesses | #1 |
comorbidity major depression | #1 |
hyperactivity female | #1 |
adhd predictors | #1 |
adhd familial disorder | #1 |
school reliability | #1 |
adhd concurrent sud | #1 |
familial risk gender | #1 |
twin adoption | #1 |
bpi disorder children | #1 |
prescription stimulant adults | #1 |
criteria☆ | #1 |
efds bpi disorder | #1 |
adhd alleles | #1 |
drd4 7repeat allele | #1 |
anxiety disorders findings | #1 |
psud controls | #1 |
valid disorder | #1 |
tidqam | #1 |
cyp2d6 hypothesis | #1 |
adhd linkage | #1 |
9r allele | #1 |
112 80 | #1 |
teacher combined | #1 |
comt odd | #1 |
risk female relatives | #1 |
neuroanatomic predictors | #1 |
clock genes rorb | #1 |
229 families | #1 |
adhd findings | #1 |
children motor domain | #1 |
growth delays weight | #1 |
nonreferred samples | #1 |
20183 | #1 |
adhd obesity overweight | #1 |
weaknesses comorbidity | #1 |
odd familial disorders | #1 |
transient financial stress | #1 |
risk factors opd | #1 |
risk subsequent substance | #1 |
cigarette smoking siblings | #1 |
increased adhd symptoms | #1 |
vntr haplotype | #1 |
expected height weight | #1 |
adhd asm snps | #1 |
ldx expected height | #1 |
adhddbds adhd | #1 |
linkage wave | #1 |
git1 association adhd | #1 |
nasal nmu nmu | #1 |
inattentive symptoms adults | #1 |
disorder hyperactivity | #1 |
onset chronological age | #1 |
adhd 5 | #1 |
sud phenotypes | #1 |
dopamine d4 gene | #1 |
tic persistence | #1 |
parents behavioral disinhibition | #1 |
relatives 1 probands | #1 |
nmu oral | #1 |
adhd subjects controls | #1 |
lateonset adhd | #1 |
studies attention | #1 |
adhd dsm | #1 |
adhd oppositional | #1 |
adhd mdd prss | #1 |
asrs‐v11 | #1 |
juvenile antisocial traits | #1 |
adhd conclusions | #1 |
ats siblings | #1 |
n122 | #1 |
highiq adults adhd | #1 |
masir ldx | #1 |
risk suds | #1 |
behaviors substances | #1 |
quantitative analyses treatment | #1 |
genetic correlation adhd | #1 |
parental sud sud | #1 |
scales risk | #1 |
proband child | #1 |
adhd stimulant treatment | #1 |
disorder molecular | #1 |
stimulant therapy youths | #1 |
adhd children exposure | #1 |
male individuals adhd | #1 |
effects lisdexamfetamine dimesylate | #1 |
bpi disorder efds | #1 |
adhd reliability | #1 |
add aff | #1 |
rs552655 | #1 |
psychiatric comorbidity girls | #1 |
infas | #1 |
adhd children mania | #1 |
downward extension adolescents | #1 |
consensus statement combination | #1 |
prodromal overt psychosis | #1 |
haplotypes adhd | #1 |
treatment stimulants | #1 |
learning disabilities girls | #1 |
onset mania | #1 |
trait educational attainment | #1 |
lateandmoderate | #1 |
evidence sud phenotypes | #1 |
peer environmental factors | #1 |
familial vulnerability schizophrenia | #1 |
disorders comorbid mania | #1 |
stimulants height | #1 |
ptsd familial disorders | #1 |
youth adhd prss | #1 |
99item cbs | #1 |
d10s195 | #1 |
drug frequency variables | #1 |
bpprss | #1 |
adhd candidate genes | #1 |
adhd comorbid dbds | #1 |
alcohol disorders offspring | #1 |
relatives adhd girls | #1 |
neural network correlates | #1 |
vivo neuroreceptor imaging | #1 |
relatives 3 probands | #1 |
inattentive hyperactive | #1 |
treating adhd | #1 |
youth adhd | #1 |
key conceptual issues | #1 |
control probands | #1 |
high‐risk adolescent offspring | #1 |
rs1051312 | #1 |
sud nicotine dependence | #1 |
unexplored void | #1 |
efficacy medications | #1 |
time qualitative review | #1 |
type attention | #1 |
stress exposure connectivity | #1 |
adhd sample | #1 |
adult persistence | #1 |
productivity adhd | #1 |
studies depressed children | #1 |
trypotphan | #1 |
adhd gender | #1 |
adhd context | #1 |
parental probands | #1 |
african‐american pedigrees | #1 |
relatives wm performance | #1 |
pdag mdd mdd | #1 |
stimulants childhood | #1 |
depression offspring variables | #1 |
adhd mini | #1 |
adhdoddcd | #1 |
disorder relatives | #1 |
nonreferred sample | #1 |
lifetime adhd | #1 |
height ldx | #1 |
sud adolescent | #1 |
suds genetic studies | #1 |
treatment mts | #1 |
masir | #1 |
firstdegree relatives children | #1 |
referred juveniles | #1 |
european treatment guideline | #1 |
adhd adverse impact | #1 |
findings adhd | #1 |
fhraff | #1 |
risk anxiety disorders | #1 |
relatives bpi probands | #1 |
adhd siblings | #1 |
rates relatives | #1 |
5ht1b receptor gene | #1 |
model ermph | #1 |
stimulant misuse | #1 |
female individuals adhd | #1 |
hyperactivity pdi | #1 |
laboratory driving simulation | #1 |
rs2469758–rs2461489 | #1 |
slc9a9 adhd | #1 |
inattention adhd | #1 |
p0499 | #1 |
differences medications | #1 |
mp adhd | #1 |
desr adhd | #1 |
iiv shr | #1 |
greater risk adhd | #1 |
impaired sensorimotor timing | #1 |
persistence childhood adhd | #1 |
adhd smoking | #1 |
assess adult adhd | #1 |
adherence stimulant medication | #1 |
patients adhdpi | #1 |
desr adults | #1 |
sob adhd | #1 |
4‐year follow‐up study | #1 |
rs11133767 | #1 |
adhd educational deficits | #1 |
symptoms versus impairment | #1 |
adhd community | #1 |
stimulant treatment adults | #1 |
asrs aisrs | #1 |
repeat allele | #1 |
association syp | #1 |
adhd cbcl | #1 |
proband youth bpdsud | #1 |
nfspds | #1 |
genetics adhd | #1 |
adolescent follow youth | #1 |
anterior insular lobule | #1 |
boys social disability | #1 |
rs3746544 rs1051312 | #1 |
or133 | #1 |
treatment effects values | #1 |
clinical correlates ocd | #1 |
ptsd bpi disorder | #1 |
concurrent adhd | #1 |
adhd psychoactive substance | #1 |
ldx adult adhd | #1 |
adhd brain alterations | #1 |
addh dmi | #1 |
aud alcohol disorders | #1 |
relatives conduct disorder | #1 |
odd disruptive behavior | #1 |
adhd vntr | #1 |
motor skills attention | #1 |
adhd highiq youths | #1 |
adhd increased | #1 |
impulsive symptoms | #1 |
remission definition | #1 |
familial underpinnings | #1 |
4q28 | #1 |
vall66 | #1 |
chinese outpatient sample | #1 |
motor preference | #1 |
adverse impact adhd | #1 |
adhd clinical obesity | #1 |
comorbid oppositional | #1 |
regions lgi | #1 |
neurocognitive functions suds | #1 |
neurocognitive marker | #1 |
experts abstinence | #1 |
pediatric bpi disorder | #1 |
ldx sizes children | #1 |
ainslbl | #1 |
add pdics | #1 |
adhd comorbid odd | #1 |
dsmiiir dsmiv adhd | #1 |
cbclbp profile | #1 |
familial subtype | #1 |
adhde | #1 |
familial transmission adhd | #1 |
years adhd | #1 |
metaanalysis controlled study | #1 |
hyperactivity child | #1 |
siblings adhd children | #1 |
twin adoption studies | #1 |
2327ct | #1 |
clinically diagnosed obesity | #1 |
adhd prss | #1 |
sbrv | #1 |
idir proteins siblings | #1 |
stimulant treatment alcohol | #1 |
ptsd siblings | #1 |
growth outcomes adhd | #1 |
lifetime impairment | #1 |
children disorder | #1 |
population screen | #1 |
depressed children adhd | #1 |
suds neurocognitive functions | #1 |
adhd child comorbidity | #1 |
antisocial families | #1 |
familial evidence | #1 |
proband youth bpd | #1 |
distal genomic region | #1 |
adhd drug dependence | #1 |
adolescence longitudinal analysis | #1 |
nonreferred | #1 |
prescription stimulant nmu | #1 |
cdbpd | #1 |
affective symptoms dbds | #1 |
age1542 | #1 |
affs add | #1 |
desr subjects | #1 |
female humans inhibition | #1 |
inattentive subtype adhd | #1 |
adhd slc6a3 genotype | #1 |
persistence pediatric disorder | #1 |
adhd structural abnormalities | #1 |
genetic variation nr3c1 | #1 |
shifting sands | #1 |
2455 controls | #1 |
treatment moderated | #1 |
pediatric panic disorder | #1 |
fhrscz | #1 |
adhd genetic variants | #1 |
symptoms adult | #1 |
adhddbds | #1 |
relatives drug dependence | #1 |
adhd african children | #1 |
bpi relatives | #1 |
bpi disorder relatives | #1 |
disorder report | #1 |
placebo ldx treatment | #1 |
syp female adhd | #1 |
disorder schizotaxia | #1 |
adult persistence adhd | #1 |
opd add | #1 |
83097 | #1 |
mania pdd | #1 |
maf⩾1 | #1 |
10repeats | #1 |
adhd social disability | #1 |
adhd prss adhd | #1 |
bpd anx relatives | #1 |
gene comt | #1 |
fam mothers | #1 |
criteria age | #1 |
hyperactivity case | #1 |
common genetic risk | #1 |
genetic overlap adhd | #1 |
masxr treatment | #1 |
diagnostic continuity adhd | #1 |
items 99item cbs | #1 |
major depression youth | #1 |
adhd gwas | #1 |
families adhd | #1 |
children behavioral | #1 |
oral nmu | #1 |
association tph2 | #1 |
matter volumes volumes | #1 |
rare protective allele | #1 |
motorendophenotypes | #1 |
siblings control probands | #1 |
anx bpd | #1 |
suds crosssectional studies | #1 |
adults adhd subjects | #1 |
efs girls | #1 |
deletioncarrier | #1 |
osa genetic heterogeneity | #1 |
rs1482337–rs2252471 | #1 |
bipolar disorder switches | #1 |
74±77 | #1 |
efds youth | #1 |
children motor competence | #1 |
subcortical volumes adhd | #1 |
adhd diagnosed | #1 |
oih cpt | #1 |
illness child comorbidity | #1 |
adhd clinical characteristics | #1 |
48basepairrepeat | #1 |
mph controls | #1 |
nhe inhibitors adhd | #1 |
efficacy outcome week | #1 |
girls learning disabilities | #1 |
adhd ads | #1 |
daodisc1 | #1 |
schizotaxia subjects | #1 |
9 nhe9 | #1 |
relatives girls | #1 |
conduct bipolar disorders | #1 |
genetic studies sud | #1 |
unique impairments | #1 |
marijuana smoking metaanalysis | #1 |
rf041 | #1 |
genetic correlations schizophrenia | #1 |
cacng2 genes schizophrenia | #1 |
adults cadhd | #1 |
adhd girls | #1 |
adhd probands relatives | #1 |
rf025 | #1 |
motor preference asthma | #1 |
familial moderators | #1 |
authors adhd | #1 |
parental panic disorder | #1 |
odd disorders follow | #1 |
behavioral disinhibition offspring | #1 |
age 7repeat allele | #1 |
adhd control probands | #1 |
aff add | #1 |
discipline problem | #1 |
adult adhd | #1 |
greater risk add | #1 |
emotional problems pmee | #1 |
tova api aklt01 | #1 |
dat1 adhd | #1 |
cohorts age groups | #1 |
relatives risk adhd | #1 |
features adhd | #1 |
diagnostic efficiency analysis | #1 |
genetic frontal schizophrenia | #1 |
nonmental diseases | #1 |
siblings adhd | #1 |
european treatment guidelines | #1 |
2276tc | #1 |
drugplacebo | #1 |
co‐expression modules | #1 |
adhd long term | #1 |
childhood adhd adulthood | #1 |
dust addictive drug | #1 |
pippi longstocking | #1 |
snp quantitative phenotype | #1 |
23 candidate genes | #1 |
child psychiatry referrals | #1 |
pathways adhd | #1 |
unaffected siblings volumes | #1 |
mania pdd subjects | #1 |
21 circadian genes | #1 |
placebo cgsq | #1 |
disorders hypothesis | #1 |
asrs scores | #1 |
offspring sud parents | #1 |
oros methylphenidate orosmph | #1 |
children behavioral inhibition | #1 |
subcortical structure volume | #1 |
adhd genetic | #1 |
comorbid problems | #1 |
qms adhd | #1 |
rels persons | #1 |
adhd efds | #1 |
validity diagnosis | #1 |
diagnosis bpi disorder | #1 |
disorders aa | #1 |
ermph placebo groups | #1 |
benefit‐risk ratio | #1 |
relatives control probands | #1 |
psud adhd probands | #1 |
offspring behavioral disinhibition | #1 |
biased maternal reporting | #1 |
hyperactive impulsive symptoms | #1 |
git1 adhd | #1 |
suds adhd | #1 |
rs9325032 | #1 |
concurrent adhd sud | #1 |
adhd probands adhd | #1 |
pediatric bipolar spectrum | #1 |
risk substance disorders | #1 |
adhd candidate | #1 |
palau scz | #1 |
adhd euphoria | #1 |
pregnancy adhd | #1 |
subjects ldx | #1 |
ldx size children | #1 |
selfreport adhd symptoms | #1 |
neuropsychological probes | #1 |
add antisocial disorders | #1 |
falconer3 | #1 |
longacting medications | #1 |
hyperactivity biomarkers aadhd | #1 |
2064 trios | #1 |
intron8 | #1 |
efficacy outcome adhd | #1 |
persistent adhd adults | #1 |
rs1076560t | #1 |
nonreferred adults | #1 |
overweight obesity males | #1 |
comorbidity conduct | #1 |
adhd youth ld | #1 |
familiar disease | #1 |
hyperactivity | #1 |
loci adhd | #1 |
trypotphan hydroxylase | #1 |
paternal overtransmission | #1 |
elevated risk adhd | #1 |
allele adhd | #1 |
tass internal consistency | #1 |
risk aggressive symptoms | #1 |
administration marijuana | #1 |
expected growth children | #1 |
criteria mania | #1 |
candidate genes adhd | #1 |
adhd gene | #1 |
bpi probands | #1 |
p20e04 | #1 |
relatives diagnoses | #1 |
metabias | #1 |
african children adhd | #1 |
adhd psychiatric conditions | #1 |
adhd seconddegree relatives | #1 |
teacher report | #1 |
adhd | #1 |
adhd susceptibility genes | #1 |
adhd bipolar studies | #1 |
5‐generation | #1 |
persons rels | #1 |
motor preference adhd | #1 |
sob sob association | #1 |
volumes participants | #1 |
serotonin genetic | #1 |
depression adhd child | #1 |
adhd antisocial | #1 |
adhd community sample | #1 |
lifetime impairment survey | #1 |
fsiq comt | #1 |
valid diagnosis | #1 |
based association study | #1 |
distinct subtype | #1 |
association adhd | #1 |
paediatric patients adhd | #1 |
studies method | #1 |
patients adhdct | #1 |
adults life | #1 |
sodasmph | #1 |
onset distributions | #1 |
tass adhdrs | #1 |
normal sexual dimorphisms | #1 |
controls adhd probands | #1 |
rs2469770 | #1 |
fm pain tolerance | #1 |
bmi mts | #1 |
adhdrs5 | #1 |
association behavioral inhibition | #1 |
tass adhd | #1 |
schizophrenia fhrs | #1 |
psychopathology reward dysfunction | #1 |
disorders parents | #1 |
variants aggressive behavior | #1 |
aud adhd | #1 |
aisrs asrs | #1 |
bipolar adhd | #1 |
cortical networks attention | #1 |
adhd symptoms crf | #1 |
ermph cgsq | #1 |
adhd sample model | #1 |
teachers cbt intervention | #1 |
adult probands siblings | #1 |
cbcldesr | #1 |
probands add | #1 |
risk adhd | #1 |
mr006 | #1 |
exposure parental adhd | #1 |
dbds adhddbds | #1 |
personality traits adults | #1 |
cigarette smoking metaanalysis | #1 |
htf9c gene | #1 |
relatives bpi | #1 |
smaller total brain | #1 |
adhd children | #1 |
brain activity flow | #1 |
stimulant treatment | #1 |
chronological age age | #1 |
risk comt gene | #1 |
896 cases | #1 |
compared adhd | #1 |
mania criteria | #1 |
dyscalculia adhd | #1 |
regulation desr | #1 |
12allele | #1 |
adhd 11 years | #1 |
bipolar disorders psud | #1 |
adhd social class | #1 |
adhd genetic receptors | #1 |
association slc6a3 | #1 |
schizophrenia rs1076560t | #1 |
dopamine receptor polymorphism | #1 |
oih fm | #1 |
hamshere | #1 |
qms adult adhd | #1 |
bpd girls | #1 |
anxiety disorders twins | #1 |
measurement invariance study | #1 |
sexdifferentiated effects traits | #1 |
gene aggressive behavior | #1 |
intelligence additive effects | #1 |
cbt intervention adolescents | #1 |
method authors | #1 |
disorganized symptom dimensions | #1 |
molecular genetic studies | #1 |
adolescent psychiatric cohort | #1 |
daily parent rating | #1 |
transmission parents | #1 |
adhd disorders comorbidity | #1 |
comt intelligence | #1 |
clinical interview mania | #1 |
drd4 association | #1 |
groups girls | #1 |
prs58502974 | #1 |
late onset adhd | #1 |
comt fsiq | #1 |
adhd dyscalculia | #1 |
adhd dbds | #1 |
non‐adhd children | #1 |
familybased studies association | #1 |
adhd genetic correlation | #1 |
adhd degree relatives | #1 |
c2orf82 | #1 |
adhd neuropsychological impairments | #1 |
context adhd | #1 |
cbclbp profile children | #1 |
alphaglx | #1 |
scqscore | #1 |
psychiatric risk vcfs | #1 |
risk opioid dependence | #1 |
mania clinical interview | #1 |
vcfsadhd adhd | #1 |
healthy cortical development | #1 |
prs rtv | #1 |
slc6a4 gene risk | #1 |
rs1040399 | #1 |
connectivity executive control | #1 |
predictors persistence | #1 |
paliperidone monotherapy | #1 |
aklt01 tova api | #1 |
neuroleptic nonresponse | #1 |
rs2449340 | #1 |
adhd risk alleles | #1 |
diagnostic continuity | #1 |
opd add opd | #1 |
anx relatives | #1 |
rs12843268 | #1 |
cbcl clinical scales | #1 |
biological schizophrenia stress | #1 |
educational failure | #1 |
adhd screening | #1 |
slc9a9 disease associations | #1 |
smoking cessation controls | #1 |
sob association adhd | #1 |
increased methylation genes | #1 |
adhd rat | #1 |
parents proband youth | #1 |
fiveminutespeechsample | #1 |
sex bpi disorder | #1 |
new psychometric definition | #1 |
gender familial risk | #1 |
bpd probands | #1 |
adhd specific | #1 |
adhd children depression | #1 |
adhd phenotypes | #1 |
zmynd17 genes | #1 |
acting medications | #1 |
transmission adhd | #1 |
bpi disorder sexes | #1 |
adolescent attention | #1 |
cadhd aadhd | #1 |
onset adult subjects | #1 |
conduct disorder aspd | #1 |
distribution child | #1 |
genetic risk severity | #1 |
non‐random error | #1 |
parental panic depression | #1 |
anachronisms | #1 |
ldx amses | #1 |
stress adhd severity | #1 |
children teaes | #1 |
adhd proband | #1 |
schizophrenia notch4 | #1 |
risk tourette spectrum | #1 |
association dopamine receptors | #1 |
35191 controls | #1 |
adults diagnosis | #1 |
psychopathology implications | #1 |
structured interview pdd | #1 |
adhd teenage parents | #1 |
rs9627183 | #1 |
interaction adhd severity | #1 |
dna methylation adhd | #1 |
adhd adhd cases | #1 |
adhd adolescent | #1 |
new phenotype definition | #1 |
morbidity bipolar disorder | #1 |
5q23q31 | #1 |
adolescent outcome adhd | #1 |
sud remittent adhd | #1 |
treatment bsd | #1 |
18 items impairment | #1 |
onset attention | #1 |
medications adult adhd | #1 |
association maoa | #1 |
mania conduct disorder | #1 |
desr adult probands | #1 |
genes adhd | #1 |
endophenotypic construct | #1 |
adhd higher | #1 |
htf9c | #1 |
sample adhd | #1 |
adhd adult disorder | #1 |
motheronly | #1 |
hyperactivity child genome | #1 |
probands clinical status | #1 |
adhd volumetric reductions | #1 |
siblings males | #1 |
adhd valid | #1 |
daonrg1 | #1 |
rs2498799 | #1 |
consensus combination | #1 |
d10s2327 | #1 |
executive functioning adults | #1 |
drd2 risk gene | #1 |
followup assessment | #1 |
controls adhd children | #1 |
neuropsychological impairments relatives | #1 |
adhd switches | #1 |
familial risk analyses | #1 |
druggable genome disorder | #1 |
putamen volume alterations | #1 |
dat1 untranslated regions | #1 |
higher prevalence girls | #1 |
psychiatric conditions adults | #1 |
dat1 vntr | #1 |
24 gm day | #1 |
paediatric adhd | #1 |
adhd conduct disorder | #1 |
adhd comorbid disorders | #1 |
stimulants comorbidity | #1 |
4q3121 | #1 |
snps drd4 gene | #1 |
stimulant treatment differences | #1 |
p758e08 | #1 |
sbrv adhd | #1 |
controls rels | #1 |
structured interview mania | #1 |
subthreshold diagnoses valid | #1 |
adhd desr | #1 |
versus disability | #1 |
adhd module | #1 |
analysis adhd | #1 |
onset criterion adhd | #1 |
psychiatric comorbidity md | #1 |
aadhd cadhd | #1 |
norepinephrine transporter gene | #1 |
phenotype adhd | #1 |
14 children pdd | #1 |
postmortem brain identifies | #1 |
adhd psychiatric | #1 |
adhd baseline assessment | #1 |
adhd learning | #1 |
report adhd | #1 |
1350t | #1 |
35191 | #1 |
adhd neuropsychological | #1 |
self‐reported adhd | #1 |
boys female gender | #1 |
tdt analysis | #1 |
adolescents concurrent adhd | #1 |
adhd oxidative stress | #1 |
hypothesis disorders | #1 |
motor preference disability | #1 |
impactnl | #1 |
criteria pdd | #1 |
adhd follow | #1 |
mania rates | #1 |
interobserver agreement measures | #1 |
tomoxetine adult adhd | #1 |
adhd familial risk | #1 |
schizophrenia hrscz | #1 |
hyperactivity databases | #1 |
adhd adhdtd | #1 |
adhd responders | #1 |
etiology disorder | #1 |
adhd adhd probands | #1 |
bpd parents | #1 |
pdd pdd subjects | #1 |
pdd mania | #1 |
cacng2 gene | #1 |
genetic association rorb | #1 |
neurocognitive dysfunctions | #1 |
odd affective symptoms | #1 |
stimulant treatment risk | #1 |
association snap25 | #1 |
medications adhd | #1 |
oral methylphenidate treatment | #1 |
parental children | #1 |
mania manic features | #1 |
13052159 | #1 |
psychopharmacologic | #1 |
highiq adults | #1 |
female gender boys | #1 |
relatives add probands | #1 |
schizophrenia bipolar psychoses | #1 |
p44e05 | #1 |
adhd single nucleotide | #1 |
loci asd symptoms | #1 |
alcohol dependence relatives | #1 |
relatives multiplex families | #1 |
prsanalyses | #1 |
risk childhood onset | #1 |
chronic emotional dysregulation | #1 |
efds functional outcomes | #1 |
stable behavioral inhibition | #1 |
innovative sms intervention | #1 |
studies adhd children | #1 |
moderating effects patterns | #1 |
adhd background | #1 |
hyperactivity biomarkers | #1 |
etiology adhd | #1 |
adhd girls adhd | #1 |
abnormalities adhd | #1 |
genes sexdifferentiated effects | #1 |
disorder versus disability | #1 |
female adhd | #1 |
prospective datasets | #1 |
smoking adhd | #1 |
dependence controls | #1 |
prevalence attention | #1 |
rs916455 | #1 |
suds nicotine dependence | #1 |
adhd aud | #1 |
cortical thickness adhd | #1 |
scz palau | #1 |
iiv hyperactivity behavior | #1 |
rs2279805 | #1 |
17yearold boys | #1 |
children adolescents cohorts | #1 |
mgh studies | #1 |
hypothesized precursors | #1 |
nonreferred adult | #1 |
adhd pdics | #1 |
subjects adhd | #1 |
rs7124601 | #1 |
anxiety disorders siblings | #1 |
impulsiveness inattention | #1 |
nonpsychotic relatives controls | #1 |
rs3776512 | #1 |
faraone | #1 |
adhd efficacy outcome | #1 |
adhd children ld | #1 |
bpd hypothesis | #1 |
adhd hyperactivity automobile | #1 |
schizophrenia code | #1 |
higher adhd | #1 |
cdh13 memory performance | #1 |
orosmph adult adhd | #1 |
childhood genetic background | #1 |
tourettes syndrome adhd | #1 |
emotional symptoms adhd | #1 |
aspd youth | #1 |
association psychiatric comorbidity | #1 |
psud relatives | #1 |
cognitive endophenotypes adhd | #1 |
fidgety philipp | #1 |
pooleddata | #1 |
bpi disorder | #1 |
adhd highly | #1 |
genetic studies adhd | #1 |
structural differences children | #1 |
maternal inattention anxiety | #1 |
mothers fam | #1 |
rs41084 | #1 |
locus adhd | #1 |
fspds | #1 |
sud adolescent patients | #1 |
hyperactivity disorder adults | #1 |
cardinal symptom mania | #1 |
hyperactivity child humans | #1 |
rs11568324 | #1 |
adherence xr | #1 |
adhd outcome | #1 |
mspi allele | #1 |
ldx growth delays | #1 |
adhd asthma | #1 |
re‐review | #1 |
relatives multiplex | #1 |
bpdsud bpd | #1 |
behavioral inhibition parents | #1 |
135–526 | #1 |
rs1633445 | #1 |
criteria 14 children | #1 |
parental adhd sud | #1 |
childhood predictors adhd | #1 |
expressed emotion children | #1 |
pharmacogenetics predictors | #1 |
–rs2272080 | #1 |
neuropsychological testing individuals | #1 |
familial links | #1 |
antisocial disorders bpd | #1 |
children general psychopathology | #1 |
switches bipolar disorder | #1 |
bpi disorder adhd | #1 |
biomarkers adhd | #1 |
volume alterations | #1 |
relatives control | #1 |
adhd baseline | #1 |
gene interaction comt | #1 |
add relatives | #1 |
bpi disorder aspd | #1 |
symptoms aggregation | #1 |
nr3c1 stress exposure | #1 |
p902e−07 | #1 |
adhd neuropsychological functioning | #1 |
molecular genetics network | #1 |
social adjustment inventory | #1 |
pilot study adhd | #1 |
inflation personal satisfaction | #1 |
adhd france | #1 |
anxiety disorders baseline | #1 |
rs6000200 | #1 |
adhd adult adhd | #1 |
asrs | #1 |
positive peer affiliation | #1 |
methylphenidate efficacy | #1 |
autism‐associated brain regions | #1 |
adhd disorder | #1 |
hyperactivity disorder scores | #1 |
140 adhd probands | #1 |
shared endophenotypes | #1 |
type adhd | #1 |
time reproduction children | #1 |
deficit | #1 |
age groups cohorts | #1 |
bipolars unipolar relatives | #1 |
actual motor performance | #1 |
specific psychopathology children | #1 |
selfreport adhd | #1 |
trait impulsivity adhdct | #1 |
40basepairrepeat | #1 |
deficits expected growth | #1 |
referred samples | #1 |
elevated rates adhd | #1 |
asthma motor preference | #1 |
adhd followup | #1 |
target features | #2 |
key cognitive phenotypes | #2 |
heterogeneity schizophrenia | #2 |
bipolar disorder relatives | #2 |
disorders suds | #2 |
amses | #2 |
deficits adults | #2 |
subjects adults | #2 |
d2s410 | #2 |
life social adjustment | #2 |
subsequent substance | #2 |
antisocial disorders relatives | #2 |
adhd adhd patients | #2 |
youth selfreports | #2 |
n‐acetylcysteine treatment | #2 |
adhd ldx | #2 |
treatment childhood adhd | #2 |
wm deficits | #2 |
adhd risk factor | #2 |
elusive indicators | #2 |
male psychiatric | #2 |
idiopathic adhd | #2 |
blind raters | #2 |
twin studies adhd | #2 |
n17666 | #2 |
hypothetical task | #2 |
stimulants | #2 |
selfmedicating | #2 |
separation attention deficit | #2 |
jackknife procedure | #2 |
odd girls | #2 |
rates bpd | #2 |
psychotic mood disorder | #2 |
adhd surface area | #2 |
adhd neuropsychological tests | #2 |
informant source | #2 |
ratio081 | #2 |
iii attention | #2 |
drug abuse dependence | #2 |
bipolar disorder sud | #2 |
2q143 | #2 |
expanded symptom criteria | #2 |
n1934 | #2 |
n2455 | #2 |
6‐year longitudinal study | #2 |
adults adhd | #2 |
dysfunction offspring | #2 |
association meta analysis | #2 |
large controlled | #2 |
g72 daao | #2 |
efds | #2 |
background attention | #2 |
referred youth | #2 |
neuropsychological function girls | #2 |
acpts | #2 |
schizophrenia genetic studies | #2 |
polygenic resilience score | #2 |
control subjects adhd | #2 |
spectrum phenotypes | #2 |
6p243 | #2 |
genetic transmission | #2 |
deficits executive | #2 |
adhd comorbid problems | #2 |
role adhd | #2 |
efds adults | #2 |
risk factor adhd | #2 |
siblings youth | #2 |
chromosomes 6 14 | #2 |
combinedtype | #2 |
conners adult adhd | #2 |
18 dsm | #2 |
mirsky | #2 |
female probands | #2 |
dsmiv subtypes | #2 |
attention‐deficit hyperactivity | #2 |
age onset distribution | #2 |
stimulants adults | #2 |
eye vergence responses | #2 |
symptoms neuropsychological | #2 |
disorder children | #2 |
n3199 | #2 |
disease humans receptors | #2 |
antisocial disorders | #2 |
youth rates | #2 |
methodological complexities | #2 |
adhd comparison | #2 |
adhd conduct | #2 |
bidirectional overlap | #2 |
cpt oih | #2 |
schizophrenia pedigrees | #2 |
viloxazine extendedrelease | #2 |
aklt01 | #2 |
pediatrically | #2 |
concurrent attention | #2 |
cbcl profile | #2 |
rs6938431 | #2 |
relatives adhd | #2 |
multigenic inheritance | #2 |
adhdprss | #2 |
patterns comorbidity | #2 |
personal satisfaction | #2 |
hantac | #2 |
mood disorders adhd | #2 |
somatosensory functioning | #2 |
adra2a polymorphism | #2 |
n2246 | #2 |
screening diagnosis treatment | #2 |
work needed | #2 |
youth attention | #2 |
methylphenidate attention | #2 |
disorder oppositional | #2 |
specific haplotype | #2 |
diagnosis attention | #2 |
juvenile antisocial | #2 |
childhood adolescent adhd | #2 |
dsm subtypes | #2 |
items screener | #2 |
familial trait | #2 |
naltrexone adults | #2 |
140 girls | #2 |
alleles attention | #2 |
postcleavage | #2 |
adhd odd | #2 |
bias child child | #2 |
aggressive symptoms | #2 |
rates odd | #2 |
unipolar relatives | #2 |
subjects conduct disorder | #2 |
adhd bpd | #2 |
adhd objective | #2 |
findings children | #2 |
n328917 | #2 |
6 17 | #2 |
familial adhd | #2 |
adhd disability | #2 |
activation trigger | #2 |
adhd method | #2 |
young adult years | #2 |
scale asrs | #2 |
consortium neuroscience | #2 |
hyperactivity impulsiveness | #2 |
variants adhd | #2 |
deficit hyperactivity disorder | #2 |
levels comorbidity | #2 |
factors attention | #2 |
parents major depression | #2 |
enigma adventure | #2 |
families schizophrenia patients | #2 |
d0·18 | #2 |
n11221 | #2 |
modest evidence | #2 |
cbsk | #2 |
disorder adults | #2 |
cbcljbd children | #2 |
risk panic disorder | #2 |
adhd lifespan | #2 |
≥210 | #2 |
relatives schizophrenic | #2 |
function deficits | #2 |
iii adhd | #2 |
adhd comparison subjects | #2 |
dsm adhd | #2 |
subjects criteria | #2 |
performancemeasures | #2 |
adhd icv | #2 |
emf impairments | #2 |
deficits efds | #2 |
default network schizophrenia | #2 |
eye vergence | #2 |
adhd subjects | #2 |
morbidity dysfunction | #2 |
studies adderall | #2 |
molecular genetics schizophrenia | #2 |
genome‐wide association data | #2 |
consecutively referred | #2 |
executive function outcome | #2 |
subthreshold diagnoses | #2 |
comparison probands | #2 |
probands relatives | #2 |
s038 | #2 |
dsmiiir adhd | #2 |
add probands | #2 |
child behavioral inhibition | #2 |
6 17 years | #2 |
adhd impact | #2 |
bpd sud | #2 |
serum neuroleptic activity | #2 |
familial risk analysis | #2 |
adhdonly | #2 |
dsmiv adhd | #2 |
probands | #2 |
adhd growth | #2 |
comorbidity disorder | #2 |
stin2vntr | #2 |
disorder studies | #2 |
neuropsychoanalytic treatment | #2 |
psychiatrically | #2 |
pdd overlap | #2 |
relatives add | #2 |
hrscz | #2 |
cacng2 genes | #2 |
status rating scales | #2 |
adults attention | #2 |
nicotine substance | #2 |
diabetes disorders | #2 |
dimesylate treatment | #2 |
relatives | #2 |
childhoodonset adhd | #2 |
prior reports | #2 |
oral prescription | #2 |
bmi adhd symptoms | #2 |
overlap mania | #2 |
clinically referred | #2 |
qualitative review | #2 |
subsyndromal manifestations | #2 |
adolescents substance disorder | #2 |
disorder findings | #2 |
adhd relatives | #2 |
rs1801028 | #2 |
checklist scales | #2 |
models adhd | #2 |
child comorbidity illness | #2 |
schizotaxia discussion | #2 |
comorbidity adhd | #2 |
comorbidity attention | #2 |
adhd adults | #2 |
weaknesses youth | #2 |
genome‐wide association scan | #2 |
rs3746544 | #2 |
relatives simplex families | #2 |
familybased studies | #2 |
disease humans inhibition | #2 |
adhd genetics | #2 |
association mtbi | #2 |
association data | #2 |
shared genetic background | #2 |
parents disorder | #2 |
evidence adhd | #2 |
youth meaningful | #2 |
factors adhd | #2 |
disorder background | #2 |
conjfdr005 | #2 |
adhd physical conditions | #2 |
actively reducing | #2 |
multicenter adhd | #2 |
qualitative literature review | #2 |
adhd psychiatric disorders | #2 |
underlying bipolarity | #2 |
scz data | #2 |
stimulants adhd | #2 |
unweighted screener asrs | #2 |
affective probands | #2 |
adhd acc | #2 |
sud bpd | #2 |
derived diagnosis | #2 |
comorbid conduct disorder | #2 |
adhd autism symptoms | #2 |
assessed structured | #2 |
adhd case subjects | #2 |
variance adult | #2 |
support genetic factors | #2 |
desr children | #2 |
trauma adhd | #2 |
quetiapine monotherapy treatment | #2 |
comorbidity probands | #2 |
disorders similarities | #2 |
correlates adhd | #2 |
adhd lower | #2 |
opioid induced hyperalgesia | #2 |
schizotypy handedness | #2 |
lgi regions | #2 |
deficit sustained attention | #2 |
galantamine hbr placebo | #2 |
allele schizophrenia | #2 |
disorder impact | #2 |
bsfq | #2 |
clinically referred children | #2 |
adhd suds | #2 |
comorbid aggression | #2 |
adhdliability | #2 |
adherence stimulants | #2 |
adult samples | #2 |
testretest reliability screener | #2 |
ppv hyperactivity diagnostic | #2 |
wiatii | #2 |
adhd major | #2 |
treatment sud patients | #2 |
problems adhd | #2 |
preventing schizophrenia | #2 |
enigma adhd | #2 |
child comorbidity | #2 |
scales adolescent | #2 |
schizophrenia parahippocampal gyrus | #2 |
wky ncrl | #2 |
efficacy stimulants | #2 |
parental anxiety disorders | #2 |
617 years | #2 |
derived phenotypes | #2 |
proinflammatory expansion | #2 |
structured diagnostic | #2 |
rs40184 | #2 |
anx bipolar disorder | #2 |
adhd combined subtype | #2 |
candidate genetic pathways | #2 |
systematized delusions | #2 |
regions studies | #2 |
stress adhd | #2 |
disorders adhd | #2 |
adhd control subjects | #2 |
subjects desr | #2 |
consecutively referred children | #2 |
10092 | #2 |
asrs health organization | #2 |
adhd height | #2 |
expert clinician | #2 |
hyperactivity female humans | #2 |
wwwhapmaporg | #2 |
schizophrenia twin studies | #2 |
galantamine hbr | #2 |
manic children | #2 |
cigarette smoking suds | #2 |
actively reducing severity | #2 |
adhd mph response | #2 |
adhd risk gene | #2 |
disorder girls | #2 |
nonpsychotic relatives | #2 |
adhd report | #2 |
5 loci adhd | #2 |
hyperactivity attention deficit | #2 |
suggestive linkage loci | #2 |
adhd combined | #2 |
adhd birth | #2 |
disorder adolescent | #2 |
major depression findings | #2 |
scales sex | #2 |
adhd choice | #2 |
adverse effects subjects | #2 |
immune disorder | #2 |
cnvs copy variants | #2 |
millennium consortium | #2 |
sex differences adhd | #2 |
attentional control effects | #2 |
adhd assessed | #2 |
expanded versions | #2 |
disorder conclusions | #2 |
masxr | #2 |
familial association | #2 |
adhd african americans | #2 |
wky nhsd | #2 |
effects paternal smoking | #2 |
disorder add | #2 |
ncrl wky | #2 |
boys maoa | #2 |
adhd emotional symptoms | #2 |
adhd major depression | #2 |
structure adult adhd | #2 |
cognition youth | #2 |
risk female cases | #2 |
d10s1432 | #2 |
bipolar disorder symptomatology | #2 |
ldsc heritability | #2 |
comorbid conduct problems | #2 |
comorbid oppositional defiant | #2 |
p161e05 | #2 |
dsmjbd | #2 |
hypothalamic abnormalities | #2 |
manic switches | #2 |
euphorigenic effects | #2 |
schizophrenia interactions | #2 |
versus controls | #2 |
morning behavior | #2 |
cbcl desr | #2 |
ldsc genetic correlations | #2 |
internal distractibility | #2 |
comorbidity disorders comorbidity | #2 |
adhd families | #2 |
structured diagnostic interviews | #2 |
hypothesis adhd | #2 |
maternal smoking mothers | #2 |
initial stimulant | #2 |
reward‐related activation | #2 |
tourette spectrum | #2 |
psychoactive substance disorders | #2 |
investigator ratings | #2 |
adhd risk icv | #2 |
disorder inattentive | #2 |
comorbid conduct | #2 |
infancy complications | #2 |
deficits sustained attention | #2 |
strong heritability | #2 |
risk add | #2 |
7point | #2 |
schizophrenia calcineurin | #2 |
age onset distributions | #2 |
disorders findings | #2 |
snp12snp2ctgn | #2 |
neuroleptic dose reduction | #2 |
method subjects | #2 |
health organization asrs | #2 |
girls adhd | #2 |
adhd neuropsychological deficits | #2 |
hyperactivity diagnostic | #2 |
cbcl clinical | #2 |
psychotic relatives | #2 |
psychiatric comorbidity | #2 |
checklist clinical | #2 |
qtl linkage adhd | #2 |
parent rating | #2 |
comparative profile analysis | #2 |
adhd outcomes | #2 |
pilot adult | #2 |
developmental subtype | #2 |
adhd bipolar | #2 |
persistent attention | #2 |
lallele homozygotes | #2 |
bpd adhd | #2 |
maoa comt | #2 |
ermph children | #2 |
rs1800955 | #2 |
chromosomes inclusion | #2 |
rates adhd | #2 |
stimulant therapy | #2 |
adhd genes | #2 |
adhd adhd children | #2 |
case subjects adhd | #2 |
addicted | #2 |
current adult adhd | #2 |
ncrl | #2 |
juvenile bipolar phenotype | #2 |
small literature | #2 |
z280 | #3 |
enigma neuroimaging genetics | #3 |
mania disorders | #3 |
13q222 | #3 |
disabilities male | #3 |
schizotaxia | #3 |
risk panic | #3 |
naltrexone methylphenidate | #3 |
metadoxine extended release | #3 |
smoking probands | #3 |
adhd mdd | #3 |
adolescents mania | #3 |
schizophrenia allele | #3 |
n2271 | #3 |
chromosome 10q22 | #3 |
sexdifferentiated effects | #3 |
27 risk loci | #3 |
alcohol adhd | #3 |
schizoaffective bipolar disorder | #3 |
parental substance disorders | #3 |
excess transmission | #3 |
defined adhd | #3 |
ldx amphetamine | #3 |
cognition comorbidity | #3 |
resilience score | #3 |
cortical thickness cases | #3 |
adhd pairwise correlations | #3 |
adhd psychiatric comorbidity | #3 |
adhd risk | #3 |
clinically referred adults | #3 |
adhd combined type | #3 |
bpd rates | #3 |
atomoxetine response | #3 |
remittent | #3 |
adhd mtbi | #3 |
petronis | #3 |
adhd implications | #3 |
dose response effects | #3 |
studies square | #3 |
impulsivity errors | #3 |
hyperactivity bipolar | #3 |
npl scores | #3 |
cigarette smoking children | #3 |
children vcfsadhd | #3 |
impairment adhd | #3 |
disproportionate impairment | #3 |
enigma global neuroscience | #3 |
european‐american | #3 |
teacher reports | #3 |
deficits height | #3 |
smds scz | #3 |
schizophrenic outpatients | #3 |
adhd wm deficits | #3 |
reln promoter | #3 |
observed age | #3 |
schizophrenia neurocognitive performance | #3 |
n2323 | #3 |
children adhd diagnosis | #3 |
nonpsychotic relatives persons | #3 |
508e7 | #3 |
highly heritable disorder | #3 |
stimulants treatment | #3 |
vcfsadhd | #3 |
zakzanis | #3 |
girls attention | #3 |
drd4 7 | #3 |
n5827 | #3 |
risk factors sud | #3 |
adult psychiatric outcomes | #3 |
comt adhd | #3 |
similarities genetic etiology | #3 |
adhd rare cnvs | #3 |
anxiety disorders parents | #3 |
model adhd | #3 |
genetics initiative | #3 |
nmu prescription stimulants | #3 |
learning disabilities adhd | #3 |
7 repeat | #3 |
psychopathologic conditions | #3 |
adhdpi | #3 |
hyperactivity central | #3 |
probands parental | #3 |
manic symptoms children | #3 |
childhood attention‐deficit | #3 |
adhd common | #3 |
intron13 | #3 |
potential gene | #3 |
simulated workplace laboratory | #3 |
n1777 | #3 |
sibling trait | #3 |
siblings young | #3 |
educational deficits | #3 |
international adhd | #3 |
methylphenidate studies | #3 |
firstdegree relatives | #3 |
comorbidity diagnosis | #3 |
nervous stimulants | #3 |
notch4 schizophrenia | #3 |
association confounders | #3 |
oprm1 variants | #3 |
lambdasib | #3 |
global neuroscience decade | #3 |
familial risk factors | #3 |
schizophrenia schizotaxia | #3 |
intra‐individual variability | #3 |
adolescent adhd | #3 |
syndromatic | #3 |
social perception skills | #3 |
sud children | #3 |
large battery | #3 |
wonderlic personnel test | #3 |
topic adolescent | #3 |
familial nature | #3 |
substances symptoms | #3 |
comt promoter | #3 |
adhd comorbid conditions | #3 |
rs6565113 | #3 |
sud offspring | #3 |
evidence genetic association | #3 |
snps haplotype | #3 |
sirolimus 12 months | #3 |
bipolar disease | #3 |
pdd adhd | #3 |
inattentive subtype | #3 |
mtbi studies | #3 |
md adhd | #3 |
nicotine disorders | #3 |
persistence psychiatric disorders | #3 |
neuropsychiatric disorders similarities | #3 |
adhd systematic review | #3 |
structural imaging findings | #3 |
hyperactivity attention | #3 |
control probands relatives | #3 |
morbidity risk | #3 |
children mania | #3 |
adhd stimulant medication | #3 |
deficient emotional | #3 |
ermph | #3 |
morning school | #3 |
qtl linkage | #3 |
“negativity | #3 |
dmi addh | #3 |
networks adhd | #3 |
asrs v11 | #3 |
adhd metaanalysis | #3 |
enigma wgs wgs | #3 |
adhd emotional | #3 |
psychotic behaviour | #3 |
relatives bipolar disorder | #3 |
manic symptoms youth | #3 |
anxiety disorders authors | #3 |
asd ocd groups | #3 |
abstraction verbal memory | #3 |
drd5 marker | #3 |
adhd mental disorders | #3 |
youths ocd | #3 |
lbw adhd | #3 |
disorder comorbid | #3 |
enuresis adhd | #3 |
amphetamines attention | #3 |
adhd polygenic | #3 |
adhd data | #3 |
weight effects | #3 |
adhd psud | #3 |
adhd ptsd | #3 |
relationship adhd | #3 |
htr1e | #3 |
controls 6 disorders | #3 |
relatives persons | #3 |
common disorders brain | #3 |
dsmiiir diagnosis | #3 |
dat1 | #3 |
variance severity | #3 |
adhd control | #3 |
non500 | #3 |
psychiatric comorbidity adhd | #3 |
9rcarriers | #3 |
substance disorders adhd | #3 |
md females | #3 |
bipolar psychoses | #3 |
major depression comorbidity | #3 |
subjects sud | #3 |
candidate gene studies | #3 |
neurological polymorphism | #3 |
comorbidity panic disorder | #3 |
interactions schizophrenia | #3 |
adhd bipolar disorder | #3 |
temperamental correlates | #3 |
cgsq | #3 |
conduct disorder adhd | #3 |
drug nicotine | #3 |
anxiety behavioral inhibition | #3 |
disorder conduct | #3 |
adhd mania | #3 |
brain methylation | #3 |
desr | #3 |
pairwise correlations disorders | #3 |
impact adhd | #3 |
parents panic disorder | #3 |
growth deficits | #3 |
response methylphenidate | #3 |
parents panic | #3 |
relatives proband groups | #3 |
caarsss | #3 |
predisposition schizophrenia | #3 |
tic disorders adhd | #3 |
longitudinal follow | #3 |
cbcl scales | #3 |
67e07 | #3 |
schizophrenia genotype | #3 |
emotional dysregulation adhd | #3 |
prenatal adversities | #3 |
comorbidities adhd | #3 |
experienced pain | #3 |
tsuang | #3 |
genetic receptors serotonin | #3 |
checklist cbcl | #3 |
mania children | #3 |
faraone reply | #3 |
asthma adhd | #3 |
disorders conclusions | #3 |
ocd groups asd | #3 |
disease humans interviews | #3 |
cpt deficits | #3 |
vulnerability indicators | #3 |
ptsd adhd | #3 |
gsprs | #3 |
7repeat allele | #3 |
adhd presence | #3 |
children adhd | #3 |
sud youths | #3 |
executive function deficits | #4 |
adhd association | #4 |
treatment adhd | #4 |
rutters indicators | #4 |
functioning adhd | #4 |
hemmings | #4 |
developmental improvement | #4 |
disorders attention | #4 |
disorders neuropsychological | #4 |
adults | #4 |
adolescent outcome | #4 |
inattentive adhd | #4 |
report scale | #4 |
anxiety disorders mdd | #4 |
motor coordination problems | #4 |
transporter genotypes | #4 |
acting formulations | #4 |
cbclaps | #4 |
scores adhd | #4 |
impaired intellect | #4 |
comorbidity humans | #4 |
enigmaadhd | #4 |
4th international meeting | #4 |
fmri replication | #4 |
independent transmission | #4 |
genetic heterogeneity schizophrenia | #4 |
psychiatrically referred youth | #4 |
vulnerability schizophrenia | #4 |
adhd pharmacotherapy | #4 |
homogeneous subtypes | #4 |
mts growth | #4 |
addictive drug | #4 |
female probands relatives | #4 |
adhd substance abuse | #4 |
enrichment adhd | #4 |
maoa | #4 |
controls basal ganglia | #4 |
psychiatric comorbidity risk | #4 |
snps intelligence | #4 |
familial vulnerability | #4 |
pediatric mania | #4 |
cbcl | #4 |
cbcljbd phenotype | #4 |
disorders panic | #4 |
adhd etiology | #4 |
risk gene schizophrenia | #4 |
behavior checklist | #4 |
adhd symptom | #4 |
quantitative phenotype | #4 |
jbd | #4 |
risk factors bpd | #4 |
reward dysfunction | #4 |
md individuals | #4 |
disorders comorbidity | #4 |
comorbid attention | #4 |
adhd status | #4 |
treatment seeking patients | #4 |
strattera | #4 |
deficits executive functioning | #4 |
height deficits | #4 |
relatives normal controls | #4 |
bpd sud bpd | #4 |
metaanalyzes | #4 |
primary substance abuse | #4 |
d4s2361 | #4 |
adhd md | #4 |
differences adults | #4 |
poor motor performance | #4 |
children comorbid adhd | #4 |
rs3916968 | #4 |
openlabel studies | #4 |
gender children | #4 |
adhd based | #4 |
adhd pdd | #4 |
offspring sud | #4 |
psc35 | #4 |
comorbid psychiatric | #4 |
total score week | #4 |
rels | #4 |
neuropsychoanalytic | #4 |
adderall methylphenidate | #4 |
snpbased | #4 |
lifetime dimensions | #4 |
handedness schizotypy | #4 |
asd mood disorders | #4 |
mhlod | #4 |
reported adhd | #4 |
suds adolescents | #4 |
expected height | #4 |
adolescent years | #4 |
d4s1644 | #4 |
depression parental depression | #4 |
parents bpd | #4 |
tests psychiatric | #4 |
rate switching | #4 |
adhd subgroups | #4 |
sd133 | #4 |
families girls | #4 |
panic disorder pregnancy | #4 |
support mechanism | #4 |
17q111q12 | #4 |
adhd youth | #4 |
4year followup | #4 |
comorbid aggression adhd | #4 |
subthreshold | #4 |
adhd control children | #4 |
safren | #4 |
intelligence snps | #4 |
relatives controls | #4 |
rates psychiatric | #4 |
adhd brain regions | #4 |
onset adhd | #4 |
notch4 locus | #4 |
treatment stimulant medication | #4 |
adhd impairments | #4 |
coordination problems | #4 |
bipolar disorder linkage | #4 |
preterm sample | #4 |
hypescheme | #4 |
child behavior checklist | #4 |
rutter | #4 |
rs1079727 | #4 |
metadoxine placebo | #4 |
chinese sample | #4 |
disease genome humans | #4 |
image sample | #4 |
quantitative models | #4 |
sud bpd sud | #4 |
subsequent substance disorders | #4 |
attention adhd | #4 |
vcfs sample | #4 |
angerirritability | #4 |
schizophrenia genetic factors | #4 |
gxr adhd | #4 |
substance disorders suds | #4 |
roh risk | #4 |
pavgrnk000417 | #4 |
selenbp1 schizophrenia | #4 |
treatment adult adhd | #4 |
phenotypes adhd | #4 |
rs3916971 | #4 |
46222 | #4 |
rs140700 | #4 |
adhd reported | #4 |
growing literature | #4 |
factors substance | #4 |
remittent adhd | #4 |
maternal smoking alcohol | #4 |
boys higher prevalence | #4 |
risk variants adhd | #4 |
risk factors adhd | #4 |
global neuroscience | #4 |
neuropsychological performance schizophrenia | #4 |
vcfs adhd | #4 |
adhd children mph | #4 |
bpd sud patients | #4 |
psychiatrically referred | #4 |
pord05 | #4 |
findings risk | #4 |
psud | #4 |
adhd pharmacogenetic studies | #4 |
increased neural responses | #4 |
adhd controls | #4 |
humans lisdexamfetamine | #4 |
parental panic | #4 |
anxiety disorders offspring | #4 |
odd adhd | #4 |
reported findings | #4 |
disorder objective | #4 |
health female | #4 |
choice adhd | #4 |
adhd participants | #4 |
presence adhd | #4 |
nonoral routes administration | #4 |
stimulantnaïve | #4 |
psychiatric gene discoveries | #4 |
shr ncrl | #4 |
objective studies | #4 |
subjects schizotaxia | #4 |
receiver operator characteristic | #4 |
distinct disorder | #4 |
aggregation adhd | #4 |
secondary psychotic symptoms | #4 |
achievement goal orientation | #4 |
adhd adulthood | #4 |
rs3785143 | #4 |
adhd individuals | #4 |
adhd neuropsychological performance | #4 |
time reproduction | #4 |
lgi age | #4 |
inhibition anxiety | #4 |
anxiety disorders anx | #5 |
disorder genetic | #5 |
cbcl data | #5 |
social disability | #5 |
study genetic factors | #5 |
kiddieschedule | #5 |
child child behavior | #5 |
aagc | #5 |
pathways association | #5 |
pdmd | #5 |
onset criterion | #5 |
referred sample | #5 |
nonaffected siblings | #5 |
combined subtype | #5 |
zmynd17 | #5 |
adhd treated | #5 |
impairment baseline | #5 |
adhd response | #5 |
screener | #5 |
referred youths | #5 |
shared haplotypes | #5 |
adhd nonaffected siblings | #5 |
adolescent alleles | #5 |
multivariate endophenotypes | #5 |
impairment survey | #5 |
familial distribution | #5 |
adult probands | #5 |
adhdlike symptoms | #5 |
3 probands | #5 |
behavioral inhibition children | #5 |
bipolar disorder bpd | #5 |
risk anxiety | #5 |
sex adhd | #5 |
severe scores | #5 |
highly heritable | #5 |
female individuals | #5 |
3q13 | #5 |
serum neuroleptic | #5 |
clinical obesity | #5 |
interview psychological | #5 |
sud | #5 |
major depression parents | #5 |
effects adhd | #5 |
psychosis velocardiofacial syndrome | #5 |
risk factors schizophrenia | #5 |
hyperactivity caregivers | #5 |
psychiatric disorders study | #5 |
comorbid disorders | #5 |
desipramine placebo | #5 |
conventional medications | #5 |
oosterlaan | #5 |
nonmedical nmu | #5 |
adults adult | #5 |
risk relatives | #5 |
report screening | #5 |
inhibited children | #5 |
dsm age | #5 |
adhd cases | #5 |
asrs screener | #5 |
lifetime impact | #5 |
hyperactivity clinical trials | #5 |
nt5dc1 | #5 |
scale adhd | #5 |
genetic linkage schizophrenia | #5 |
d22s683 | #5 |
psychosis scale | #5 |
intellectually capable adults | #5 |
oppositional defiant disorder | #5 |
depression panic disorder | #5 |
impaired parents humans | #5 |
bipolar disorder pedigrees | #5 |
mothers anxiety disorders | #5 |
adhd youths | #5 |
adhd tic disorders | #5 |
organization adult | #5 |
function adhd | #5 |
desistent | #5 |
sms intervention | #5 |
mania adhd | #5 |
unipolar mdd | #5 |
growth dysregulation | #5 |
pleiotropic effects disorders | #5 |
torture review | #5 |
prembr | #5 |
ppp3cc schizophrenia | #5 |
familial risk adhd | #5 |
resilience project | #5 |
memantine hydrochloride | #5 |
2nd cohort | #5 |
diagnosis mania | #5 |
neuropsychological risk | #5 |
pdd subjects | #5 |
palauan | #5 |
auditory vigilance | #5 |
maternal reports | #5 |
parental sud | #5 |
disorders follow | #5 |
schizophrenia palau | #5 |
ascertainment source | #5 |
adhd comorbid anxiety | #5 |
disorder parents | #5 |
kuntsi | #5 |
criteria schizotaxia | #5 |
symptoms hyperactivity | #5 |
humans interview | #5 |
children ldx | #5 |
elevated rates | #5 |
wcst scores | #5 |
adhd ld | #5 |
large collaborative study | #5 |
parents psychiatric | #5 |
adhd inattentive type | #5 |
year prospective | #5 |
parental adhd | #5 |
grubb | #5 |
adhd adult | #5 |
youth vcfs | #5 |
familial subtypes | #5 |
disorders psychiatric | #5 |
adult attention | #5 |
referred children | #5 |
children dbds | #5 |
hechtman | #5 |
etiopathologies | #5 |
cardinal symptom | #5 |
height weight | #5 |
adhd bupropion | #5 |
rs1799836 | #5 |
mood disorders asd | #5 |
disorder rating | #5 |
methylphenidate adults | #5 |
disorder anxiety | #5 |
neuropsychiatric comorbidity | #5 |
ncrl rats | #5 |
initial responsiveness | #5 |
dopamine risk | #5 |
puwma | #5 |
boys attention | #5 |
adolescence adhd | #5 |
xr adults | #5 |
iiv adhd | #5 |
checklist child | #5 |
inattentive symptoms | #5 |
tass | #5 |
panic disorder parents | #5 |
psychiatric correlates | #5 |
disorder sud | #5 |
proband risk | #5 |
relatives female probands | #5 |
adhd genetic factors | #6 |
hyperactivity child chromosomes | #6 |
environmental adversity | #6 |
prevalence adult adhd | #6 |
life adults | #6 |
psychiatric disorders prss | #6 |
t518 | #6 |
male odds | #6 |
specific predictor | #6 |
irmph | #6 |
disorder combined | #6 |
normal sexual dimorphism | #6 |
children relatives | #6 |
dopamine transporter gene | #6 |
followup studies | #6 |
total gray matter | #6 |
adhd mental retardation | #6 |
parents major | #6 |
males adhd | #6 |
clinical features children | #6 |
prior stimulant treatment | #6 |
large heterogeneous | #6 |
pediatric mood disorders | #6 |
interpreting estimates | #6 |
taan | #6 |
140 children | #6 |
pavgrnk | #6 |
objective marker | #6 |
stimulant treatment children | #6 |
paternal age schizophrenia | #6 |
anxiety disorder relatives | #6 |
genetic linkage genome | #6 |
neuroleptic activity | #6 |
seidman | #6 |
druggable genome | #6 |
relatives probands | #6 |
referred adults | #6 |
altered neural connectivity | #6 |
fspd | #6 |
chromosome 15 locus | #6 |
gxr efficacy | #6 |
schizophrenia spectrum schizophrenia | #6 |
disorders adolescent | #6 |
pediatric bipolar | #6 |
symptoms disorder | #6 |
bpd comorbid | #6 |
individual alleles | #6 |
differences cortical thickness | #6 |
dnajc9 | #6 |
genetic child | #6 |
nhe inhibitors | #6 |
vulnerability indicator | #6 |
adults disorder | #6 |
cognition adults | #6 |
psychopathology children | #6 |
facial memory | #6 |
hyperactivity disease models | #6 |
niacin schizophrenia | #6 |
ascertained | #6 |
oppositional defiant | #6 |
psychoactive substance | #6 |
loci autism | #6 |
enigma wgs | #6 |
maniclike symptoms | #6 |
risk attention | #6 |
combined condition | #6 |
value09 | #6 |
adhd firstdegree relatives | #6 |
teenage parenthood | #6 |
schizophrenia deficit | #6 |
adhd tic | #6 |
t515 | #6 |
parental major depression | #6 |
literature efficacy | #6 |
bpdsud | #6 |
females adhd | #6 |
downward extension | #6 |
concurrent validation | #6 |
adhd variability | #6 |
cpg sites methylation | #6 |
genome‐wide | #6 |
oceanic palau | #6 |
behavioral inhibition | #6 |
schizophrenic probands | #6 |
stimulant prescription | #6 |
adhd compared | #6 |
criteria adhd | #6 |
adhd children adults | #6 |
adhd women | #6 |
schizophrenia g72 | #6 |
cbcljbd | #6 |
nonparanoid schizophrenia | #6 |
mixed amphetamine | #6 |
symptoms adhd | #6 |
combined subtypes | #6 |
pseudocontrols | #6 |
adhd mood disorders | #6 |
association studies schizophrenia | #6 |
unfamiliar situations | #6 |
schizophrenia premorbid | #6 |
placebo response response | #6 |
psychiatric | #6 |
child delayed | #6 |
year recall | #6 |
benefitrisk ratio | #6 |
cognitive impairments adhd | #6 |
adhdia | #6 |
referred children adolescents | #6 |
dsm iii | #6 |
hierarchical factor model | #6 |
xp114p113 | #6 |
adhd life | #6 |
liability schizophrenia | #6 |
bpd controls | #6 |
4634 | #6 |
p1e04 | #6 |
wm performance patients | #6 |
driving simulation | #6 |
scales psychometrics | #6 |
depression panic | #6 |
adhd increased risk | #6 |
groups adults | #6 |
tmcq | #6 |
premorbid cognitive ability | #6 |
clinical scales | #6 |
familial loadings | #6 |
pediatric bpd | #6 |
risk sud | #6 |
neuropsychological functioning | #6 |
disorders relatives | #6 |
ppp3cb | #6 |
nmu | #6 |
parent reports | #7 |
mph adhd adults | #7 |
adhd emotional dysregulation | #7 |
adhdct | #7 |
dimensional measures | #7 |
markov chain analysis | #7 |
nmu prescription | #7 |
methylomics | #7 |
methylphenidate therapy | #7 |
n1031 | #7 |
velo‐cardio‐facial | #7 |
qlesqsf | #7 |
skin flush response | #7 |
flush response | #7 |
neurocognitive performances | #7 |
pdqr | #7 |
controls probands | #7 |
ancestry attention | #7 |
tomoxetine | #7 |
conduct disorder girls | #7 |
seeking substance | #7 |
adhd criteria | #7 |
6 psychiatric disorders | #7 |
spn812 | #7 |
parents psychiatric disorders | #7 |
dependence rates | #7 |
adhd authors | #7 |
implicating | #7 |
adhd substance disorders | #7 |
outpatient child | #7 |
bipolar unipolar disorders | #7 |
measures adhd | #7 |
chromosome workshop | #7 |
children tourettes syndrome | #7 |
adhd boys girls | #7 |
asd asd youth | #7 |
adhd symptoms association | #7 |
adhdrs | #7 |
asd youth | #7 |
drd5 | #7 |
myosin5b | #7 |
hraff | #7 |
attention task | #7 |
relatives risk | #7 |
nalysis | #7 |
members schizophrenia | #7 |
children bpd | #7 |
teachers boys | #7 |
pdag mdd | #7 |
candidate gene schizophrenia | #7 |
relatives schizophrenic patients | #7 |
adhd improvement | #7 |
wonderlic | #7 |
adhd asrs | #7 |
ldx treatment | #7 |
persistence anxiety disorders | #7 |
mdd pdag | #7 |
nrp104 | #7 |
kgas | #7 |
adhd persistence | #7 |
saica | #7 |
pediatric major depression | #7 |
association cdh13 | #7 |
combined type adhd | #7 |
adhd sud sud | #7 |
idir | #7 |
genome‐wide association | #7 |
prevention schizophrenia | #7 |
haplotype schizophrenia | #7 |
development adhd | #7 |
snap25 adhd | #7 |
disorders probands | #7 |
highrisk siblings | #7 |
studies dopamine | #7 |
neuroimage study | #7 |
parents prevalence | #7 |
disorder substance | #7 |
authors goal | #7 |
sensorimotor timing | #7 |
long repeats | #7 |
mph adhd | #7 |
adhd overweight obesity | #7 |
child impaired | #7 |
pmee | #7 |
boys adhd | #7 |
odd | #7 |
polygenic scores adhd | #7 |
children learning disorders | #7 |
hyperactivity brain | #7 |
childhood disorder | #7 |
exome chip analyses | #7 |
adhd symptoms | #7 |
locus haplotypes | #7 |
coming years | #7 |
statistical measure | #7 |
confusability | #7 |
systematic chart review | #7 |
exon15 | #7 |
palauans | #7 |
swedish registry data | #7 |
biederman | #8 |
impulsivity adhd | #8 |
behavior attention | #8 |
therapeutic dilemmas | #8 |
attention deficit adhd | #8 |
volumetric reductions | #8 |
participants adhd | #8 |
adhd boys | #8 |
attention | #8 |
onset bpd | #8 |
behavioral inhibition risk | #8 |
promising directions | #8 |
gender effects | #8 |
adhd adolescence | #8 |
adhdcd | #8 |
adhd inattentive | #8 |
adhd associations | #8 |
offspring trios | #8 |
nonverbal social | #8 |
adhd unaffected | #8 |
disorders baseline | #8 |
avoidant disorder | #8 |
shared familial effects | #8 |
chromosome schizophrenia | #8 |
adhd symptom scores | #8 |
nonpsychotic | #8 |
human aggression | #8 |
mwq | #8 |
analysis association | #8 |
familial aggregation adhd | #8 |
10q223 | #8 |
unaffected siblings adhd | #8 |
childhood mania | #8 |
notch4 | #8 |
differential utility | #8 |
disorders families | #8 |
multigenerational pedigree | #8 |
disease humans polymorphism | #8 |
stimulanttreated | #8 |
sample youth | #8 |
adhd remission | #8 |
studies provide | #8 |
male multifactorial inheritance | #8 |
treatment lead | #8 |
impaired motor performance | #8 |
metaanalysis schizophrenia | #8 |
affairs cooperative | #8 |
link adhd | #8 |
adhd dat1 | #8 |
rs3916966 | #8 |
bpd disorders | #8 |
pvalues005 | #8 |
symptoms behaviors | #8 |
probands risk | #8 |
adhd rtv | #8 |
treatment sirolimus | #8 |
indicators schizophrenia | #8 |
child diagnostic | #8 |
autistic traits children | #8 |
substantial evidence | #8 |
diagnosis major depression | #8 |
biological relatives | #8 |
mph adults | #8 |
ordered subsets | #8 |
adhdhi | #8 |
euphoria | #8 |
aversion adhd | #8 |
diagnosed adhd | #8 |
dimesylate ldx | #8 |
negative symptoms scale | #8 |
schizophrenia polymorphisms | #8 |
rs3916965 | #8 |
cadhd | #8 |
n1314 | #8 |
polygenic associations | #8 |
hemideletion | #8 |
pliszka | #8 |
abbreviated questionnaire | #8 |
subjects children | #8 |
controls relatives | #8 |
psychiatric genomics | #8 |
familybased association study | #8 |
schizophrenia members | #8 |
prescription stimulant | #8 |
behavioral inhibition anxiety | #8 |
control adhd | #8 |
symptoms impairment | #8 |
pempirical | #8 |
crossover comparison | #8 |
adhd manic symptoms | #8 |
adhd stimulant | #8 |
agreement measures | #8 |
presence autistic traits | #8 |
disorder probands | #8 |
dao gene | #9 |
comparison girls | #9 |
stimulant medication | #9 |
schizotaxic | #9 |
adult report | #9 |
male nuclear | #9 |
neuropsychologic function | #9 |
netherlands twin registry | #9 |
hum genet | #9 |
haplotype snps | #9 |
pregnancy depression | #9 |
childhood psychosis | #9 |
snp7 | #9 |
lag sequential analysis | #9 |
schizophrenia resilience | #9 |
endophenotypic | #9 |
ldps | #9 |
adderall | #9 |
39 datasets | #9 |
depression offspring | #9 |
serotonin genes | #9 |
ads individuals | #9 |
adhd article | #9 |
hyperactivity humans | #9 |
blindly | #9 |
nonreplications | #9 |
adhd enuresis | #9 |
hhrr | #9 |
comorbidity female | #9 |
hyperactivity automobile | #9 |
nuremberg code | #9 |
sud bipolar disorder | #9 |
adult symptoms | #9 |
children assessed | #9 |
deficit disruptive | #9 |
festschrift | #9 |
subtypes adhd | #9 |
disruptive behavior disorders | #9 |
n41 | #9 |
extendedrelease methylphenidate | #9 |
moderate sensitivity | #9 |
substantial risk | #9 |
symptoms mania | #9 |
etiologically | #9 |
taiwanese families | #9 |
aisrs | #9 |
rasd2 | #9 |
diagnostic efficiency | #9 |
rs685012 | #9 |
addh | #9 |
disorders sex interaction | #9 |
ecpbhs | #9 |
adhdi | #9 |
gwas psychiatric disorders | #9 |
inattentive | #9 |
serotonin gene polymorphisms | #9 |
rpdr | #9 |
adhd healthy | #9 |
25e07 | #9 |
proband groups | #9 |
adhd loci | #9 |
g×s interaction disorders | #9 |
genes risk factors | #9 |
sustained attention schizophrenia | #9 |
alzheimer disease schizophrenia | #9 |
nonparanoids | #9 |
mdd youth | #9 |
orosmph irmph | #9 |
young adult outcome | #10 |
anxiety disorders children | #10 |
nonpharmacologic treatments | #10 |
adulthood association | #10 |
stimulants child | #10 |
adhd quality | #10 |
probands bpd | #10 |
adhd childhood | #10 |
stimulants humans | #10 |
disorder age | #10 |
adhd substance disorder | #10 |
diminished risk | #10 |
image project | #10 |
comorbidity | #10 |
preschool depressive | #10 |
genetics network | #10 |
bipolar disorder probands | #10 |
adhd difficulties | #10 |
genetic vulnerability schizophrenia | #10 |
amphetamine salts | #10 |
asd tourette syndrome | #10 |
risk md | #10 |
parent‐of‐origin effects | #10 |
caadid | #10 |
adhd sud | #10 |
groups boys | #10 |
aged attention | #10 |
genes disorders | #10 |
normal sexual | #10 |
new specialty | #10 |
adult years | #10 |
d4 receptor gene | #10 |
4th | #10 |
adhd unaffected siblings | #10 |
noninhibited | #10 |
nephews | #10 |
preteen | #10 |
evidence genetic | #10 |
reassessed | #10 |
panic depression | #10 |
psychiatric genetic studies | #10 |
gwas adhd | #10 |
childhood adhd symptoms | #10 |
cbclap | #10 |
psychiatric clinic | #10 |
slod | #10 |
drd4 | #10 |
dms1 | #10 |
irmph orosmph | #10 |
untreated adhd | #10 |
severity adhd | #10 |
association dat1 | #10 |
case identification | #10 |
shared neurobiology | #10 |
comorbid bpd | #10 |
rates abuse | #10 |
sleep problems adhd | #10 |
systematic qualitative review | #10 |
sexual dimorphisms | #10 |
linkage analyses | #10 |
association death | #10 |
kruglyak | #10 |
small effects | #10 |
rorb | #10 |
comorbidity depressive | #10 |
comorbid odd | #10 |
pthreshold | #10 |
deficits adhd | #10 |
conduct disorder | #10 |
ascertainment methods | #10 |
preschool depressive disorder | #11 |
hyperactivity child cross | #11 |
adhd substance | #11 |
female relatives | #11 |
lisdexamfetamine ldx | #11 |
psychiatric disorders youth | #11 |
disorders | #11 |
symptom subtype | #11 |
adhd female humans | #11 |
dimesylate | #11 |
effects genes | #11 |
growth delays | #11 |
disease humans schizophrenia | #11 |
markers adhd | #11 |
youth bpd | #11 |
dopamine d5 receptors | #11 |
adolescents adhd | #11 |
real progress | #11 |
panic disorder comorbidity | #11 |
studies mtbi | #11 |
remission adhd | #11 |
cutraits | #11 |
children addh | #11 |
gene adhd | #11 |
maternal antenatal anxiety | #11 |
n136 | #11 |
differentiated genetic | #11 |
study perspective | #11 |
deficits schizophrenia patients | #11 |
shr model | #11 |
attention deficit disorder | #11 |
prodromal psychosis | #11 |
defiant disorder | #11 |
children bipolar | #11 |
adhd onset | #11 |
cardinal symptoms | #11 |
ppp3cc | #11 |
disorder pedigrees | #11 |
nonadhd controls | #11 |
differences parents | #11 |
hydrochloride attention | #11 |
informativeness | #11 |
rs1137070 | #11 |
achievement adolescent | #11 |
offspring bipolar parents | #11 |
sample adults | #11 |
neuropsychological test scores | #11 |
adhd time | #11 |
release methylphenidate | #11 |
4372 | #11 |
rora rorb | #11 |
familybased association test | #11 |
inhibition adhd | #11 |
inattentive type | #11 |
vcfs | #11 |
multiple domains | #11 |
shared familial | #11 |
adult relatives | #11 |
ldx placebo | #11 |
major depression adhd | #11 |
adhd intellectual disability | #11 |
disorders mothers | #11 |
agoraphobia anxiety | #11 |
comorbidity patterns | #11 |
diagnosis adults | #11 |
pediatric bipolar disorder | #11 |
etiology pathophysiology | #11 |
fbatpc | #11 |
differences adhd | #11 |
serotonin genetic receptor | #11 |
juvenile mania | #11 |
adhd psychopathology | #11 |
polymorphism 5 | #11 |
paternal smoking | #11 |
nosologists | #11 |
sample consisted | #12 |
lossavoidance | #12 |
common disorders | #12 |
nonoral | #12 |
variable age | #12 |
adolescent adult age | #12 |
perceived motor competence | #12 |
unaffected siblings individuals | #12 |
obesity adhd | #12 |
treatment paliperidone | #12 |
treatment attention | #12 |
functional impairments | #12 |
sexually dimorphic effects | #12 |
assessment adhd | #12 |
disorder subjects | #12 |
defiant | #12 |
40–48 | #12 |
disorder adult | #12 |
impaired parents | #12 |
cnvs risk | #12 |
girls relationship | #12 |
deficits attention | #12 |
kappa coefficients | #12 |
sec23ip | #12 |
dat1 polymorphism | #12 |
sud patients adhd | #12 |
comorbid disorder | #12 |
adhd symptoms adults | #12 |
scales treatment | #12 |
adhd offspring | #12 |
digital treatment | #12 |
covid19 restrictions children | #12 |
rs947267 | #12 |
common psychiatric | #12 |
adult outcome | #12 |
thalamic activation | #12 |
psychiatric genetics | #12 |
youths bpd | #12 |
striatal sensitivity | #12 |
multiplex schizophrenia | #12 |
effects time | #12 |
early psychosis study | #12 |
twins humans models | #12 |
epilepsy mothers | #12 |
comorbidity diagnostic | #12 |
stimulant medication children | #12 |
systematized | #12 |
cbcl children | #12 |
metan | #12 |
ksadse | #12 |
test wcst | #12 |
juvenile bipolar | #12 |
genes methylation | #12 |
symptom rating | #12 |
hawi | #12 |
salts extended | #12 |
neurocognitive measures | #12 |
unaffected sibs | #12 |
amfetamine | #12 |
adhd age | #12 |
studies relatives | #12 |
impaired parents child | #12 |
psychiatric clinics | #12 |
impulsivity children | #12 |
response atomoxetine | #12 |
onelevel | #12 |
psychotic behavior | #12 |
rs778293 | #12 |
probands siblings | #12 |
sud adhd | #12 |
obesity risk alleles | #12 |
psychotic mood disorders | #12 |
pleiotropic mechanisms | #12 |
convergent functional | #12 |
nhe9 | #12 |
adhd core symptoms | #12 |
adhd dopamine | #12 |
n1397 | #12 |
risk parents | #13 |
transdermal methylphenidate | #13 |
genomewide significance | #13 |
environment adolescent | #13 |
weight bmi | #13 |
disorder youth | #13 |
studies bipolar | #13 |
pkcm | #13 |
iiv | #13 |
disorder childhood | #13 |
psychiatric risk | #13 |
114 years | #13 |
morbidity risks | #13 |
overanxious | #13 |
label studies | #13 |
rates comorbidity | #13 |
adhd alcohol | #13 |
disorders child | #13 |
longallele | #13 |
adhdodd | #13 |
methods subjects | #13 |
familial risk schizophrenia | #13 |
response inhibition adolescents | #13 |
symptoms attention | #13 |
psychometric measure | #13 |
late onset | #13 |
taiwanese sample | #13 |
chi12 | #13 |
adderall mph | #13 |
adverseevents | #13 |
bpd offspring | #13 |
permutation testing | #13 |
persistence remission | #13 |
cognitive impulsivity | #13 |
girls | #13 |
necrotic death | #13 |
scale studies | #13 |
diagnostic threshold | #13 |
convergent functional genomics | #13 |
ravg | #13 |
risk mood | #13 |
robust effects | #13 |
pair 6 chromosomes | #13 |
colorado springs | #13 |
disorders sud | #13 |
diagnostic concepts | #13 |
humans methylphenidate | #13 |
male samples | #13 |
velocardiofacial syndrome vcfs | #13 |
specific hypotheses | #13 |
adhd alterations | #13 |
adhd cognitive | #13 |
psychotic mood | #13 |
adhd diagnosis | #13 |
nonoral routes | #13 |
psychometrics reproducibility | #13 |
cautiously | #14 |
factors schizophrenia | #14 |
siblings probands | #14 |
ocd scz | #14 |
quetiapine bipolar disorder | #14 |
unaffected siblings controls | #14 |
adhd phenotype | #14 |
early precursors | #14 |
children bipolar disorder | #14 |
children stimulants | #14 |
aadhd | #14 |
stimulant abuse | #14 |
diagnosis mdd | #14 |
subcortical brain volume | #14 |
siblings cases | #14 |
teachers reports | #14 |
adhd symptoms adulthood | #14 |
cnvs park2 | #14 |
associations adhd | #14 |
economic psychology | #14 |
symptoms psychiatric disorders | #14 |
n643 | #14 |
adhd brain | #14 |
disorders comorbid | #14 |
older adults adhd | #14 |
nimh genetics | #14 |
worldwide prevalence | #14 |
studies adults | #14 |
emotional impulsivity | #14 |
mph adderall | #14 |
children criteria | #14 |
social school | #14 |
sud patients | #14 |
disorder child | #14 |
comorbid condition | #14 |
attention executive | #14 |
genetic studies schizophrenia | #14 |
genes schizophrenia | #14 |
familial disorder | #14 |
suds | #14 |
bipolar probands | #14 |
prss mdd | #14 |
hillside | #14 |
wraadds | #14 |
common disorder | #14 |
geschwind | #14 |
differential heritability | #14 |
disorder odd | #14 |
selfcontained | #14 |
mixed amphetamine salts | #14 |
lisdexamfetamine dimesylate ldx | #14 |
relatives male probands | #14 |
lphn3 adhd | #14 |
study design features | #15 |
bipolar schizoaffective disorder | #15 |
zranb2 | #15 |
treatment xr | #15 |
agents attention | #15 |
symptom count | #15 |
disorder evidence | #15 |
adhd study | #15 |
metabolic syndrome obesity | #15 |
interaction genotype | #15 |
chi2 | #15 |
paediatric bipolar disorder | #15 |
rs2652511 | #15 |
mphmlr | #15 |
4669 | #15 |
male mood | #15 |
card sorting | #15 |
tests psychomotor | #15 |
daily living administration | #15 |
pregnancy risk factor | #15 |
adhd disorders | #15 |
nhsd | #15 |
symptoms adulthood | #15 |
snps methylation | #15 |
49 children | #15 |
psychiatric interviews | #15 |
cbclpbd | #15 |
behavior disorders | #15 |
seconddegree relatives | #15 |
asd mdd | #15 |
genderdifferences | #15 |
schizophrenia families | #15 |
adhd diagnostic | #15 |
executive function theory | #15 |
ocd comorbid adhd | #15 |
prodromal symptoms psychosis | #15 |
substance disorder patients | #15 |
velocardiofacial | #15 |
poor perception | #15 |
persons schizophrenia | #15 |
d10s1423 | #15 |
adhd treatment | #15 |
diagnostic interviews | #15 |
sackett | #15 |
adhd performance | #15 |
male relatives | #15 |
adults substance disorders | #15 |
methylation gene expression | #15 |
adhd functional connectivity | #15 |
healthy comparison subjects | #15 |
wfirsp | #15 |
gxr children | #15 |
association schizophrenia | #15 |
disord | #15 |
risk substance | #15 |
adhd obesity | #16 |
longitudinal assessments | #16 |
youths adhd | #16 |
special classes | #16 |
scz risk | #16 |
hyperkinetic disorders | #16 |
parents anxiety disorders | #16 |
adhd diagnoses | #16 |
n424 | #16 |
cprsr | #16 |
ntac | #16 |
geneenvironment interaction | #16 |
control participants participants | #16 |
multiple test | #16 |
familial relationship | #16 |
linkage findings | #16 |
risk psychotic disorders | #16 |
dbds | #16 |
brainbody | #16 |
growth children | #16 |
delayed action | #16 |
rdoc framework | #16 |
dexedrine | #16 |
pervasive developmental disorder | #16 |
adhd anxiety symptoms | #16 |
drug disorder | #16 |
factual factor analysis | #16 |
informant assessment | #16 |
“difficulty | #16 |
adhd symptom severity | #16 |
regional cortical thickness | #16 |
onset anticipation | #16 |
pediatric disorder | #17 |
accn2 | #17 |
ocd age | #17 |
childhood predictors | #17 |
pediatric samples | #17 |
random forest regression | #17 |
relation adhd | #17 |
association markers | #17 |
prevalence adhd | #17 |
association scan | #17 |
psychology schizotypal | #17 |
nonparametric linkage | #17 |
condfdr | #17 |
prospective follow | #17 |
ldx children | #17 |
a161t | #17 |
method participants | #17 |
bipolar disorder subjects | #17 |
depression md | #17 |
response inhibition network | #17 |
disability adhd | #17 |
substance disorders sud | #17 |
larger sample | #17 |
combined type | #17 |
rbfox1 | #17 |
neuropsychiatric evaluation | #17 |
schizophrenia psychosis | #17 |
diagnostic statistical | #17 |
asd ocd | #17 |
young offspring | #17 |
persistent adhd | #17 |
5071 | #17 |
hyperactivity attitude | #17 |
factors siblings | #17 |
study adhd | #17 |
driving behaviors | #17 |
samples children | #17 |
adulthood adhd | #17 |
resultsfirst | #17 |
studies psychiatric | #17 |
parents adhd | #17 |
assessment positive symptoms | #17 |
considerable overlap | #17 |
medication type | #17 |
mania | #17 |
multiple anxiety disorders | #17 |
unemotionality | #18 |
operationalized | #18 |
behavior scale | #18 |
adhd severity | #18 |
hrr 95 | #18 |
neuropsychologic | #18 |
linkage regions | #18 |
psuds | #18 |
single nucleotide severity | #18 |
childhood traumas | #18 |
risk disorders | #18 |
preschool diagnostic | #18 |
prolonged therapy | #18 |
adhd cannabis | #18 |
relatives control subjects | #18 |
adhd sud patients | #18 |
dcdq | #18 |
anxiety mdd | #18 |
schizophrenia patients relatives | #18 |
marijuana age | #18 |
conduct disorder children | #18 |
4286 | #18 |
lisdexamfetamine dimesylate | #18 |
meet criteria | #18 |
illness twins | #18 |
bipolar major | #18 |
schizophrenia dtnbp1 | #18 |
potential contributor | #18 |
bipolar choice trial | #18 |
transporter gene | #18 |
low dose naltrexone | #18 |
primary substance | #18 |
symptom overlap | #18 |
kcnj4 | #18 |
stimulant | #18 |
children vcfs | #18 |
unaffected siblings | #18 |
fullsiblings | #18 |
depression genetic risk | #18 |
adhd groups | #18 |
poor tolerability | #18 |
minisatellite repeats | #18 |
scz ocd | #19 |
hyperconnectivity | #19 |
mental health human | #19 |
action preparations | #19 |
rs3918342 | #19 |
medication trials | #19 |
casecontrol sample | #19 |
addicted patients | #19 |
euphoric effects | #19 |
comorbidity rates | #19 |
adhd neurodevelopmental | #19 |
adolescent age | #19 |
improvement symptoms | #19 |
assessing outcome | #19 |
adhd young adults | #19 |
mcgue | #19 |
substance adhd | #19 |
lod1 | #19 |
disorders adults | #19 |
disconfirmations | #19 |
adolescent age onset | #19 |
nature nurture | #19 |
candidate loci | #19 |
familial transmission | #19 |
symptoms adolescent | #19 |
psychosocial features | #19 |
verbal memory task | #19 |
linkage scans | #20 |
ratings adhd | #20 |
rbfox1 gene | #20 |
transmission ratio distortion | #20 |
sibpair | #20 |
inhibition children | #20 |
pedigree selection | #20 |
neuropsychological function | #20 |
humanhap550v3 | #20 |
neuroleptic dose | #20 |
kiddie | #20 |
deficits children | #20 |
dicap | #20 |
human ortholog | #20 |
slc6a2 | #20 |
parents risk | #20 |
parent origin | #20 |
manual mental | #20 |
response curve | #20 |
adolescent | #20 |
disorders polymorphism | #20 |
nonpsychotic siblings | #20 |
controlled pilot study | #20 |
gsma | #20 |
illness female humans | #20 |
mflynn | #20 |
depression adhd | #20 |
biological families | #20 |
notch4 gene | #20 |
prenatal exposure nicotine | #20 |
outcome attention | #20 |
schizophrenia attention | #20 |
neuropsychologically | #20 |
schizophrenia taiwan | #21 |
schizophrenia united | #21 |
gender comparisons | #21 |
monoamine oxidase maoa | #21 |
11year followup | #21 |
schizophrenia disease humans | #21 |
childhood conduct disorder | #21 |
rat shr | #21 |
motor problems | #21 |
schizotypals | #21 |
prevalent cases | #21 |
chronic tics | #21 |
comorbid adhd | #21 |
children pdd | #21 |
prescription stimulants | #21 |
humans linkage | #21 |
treatment growth | #21 |
genehunterplus | #21 |
prenatal exposure alcohol | #21 |
rs778294 | #21 |
cacng2 | #21 |
agler | #21 |
psychiatric symptoms patients | #21 |
sodium hydrogen exchanger | #21 |
palau | #21 |
bipolar pedigrees | #21 |
linkage chromosomes | #21 |
prospective longitudinal | #21 |
children comorbid | #21 |
male probands | #21 |
methods age | #21 |
life enjoyment | #21 |
risk offspring | #21 |
niacin skin | #22 |
youth bipolar | #22 |
genetic phenotype | #22 |
adhd susceptibility | #22 |
amphetamine methylphenidate | #22 |
depression treatment patients | #22 |
adderall xr | #22 |
study methodology | #22 |
partial replication | #22 |
adhd rating scale | #22 |
association prs | #22 |
adhd anxiety | #22 |
preliminary reliability | #22 |
overtransmission | #22 |
10p | #22 |
6 disorders | #22 |
syndrome vcfs | #22 |
neuropsychological profiles | #22 |
schizophrenia pgc | #22 |
polygenic overlap | #22 |
adhd impulsivity | #22 |
neurocognitive performance schizophrenia | #22 |
familiality | #22 |
diagnostic interview | #22 |
adhd stimulants | #22 |
stimulants children | #22 |
disorders major | #22 |
disruptive | #22 |
amygdala structure | #22 |
ldx | #22 |
youth mdd | #22 |
pre‐school | #22 |
bpd subjects | #22 |
rg022 | #22 |
controls | #22 |
children attention | #22 |
risk studies | #23 |
oppositional | #23 |
interview dsm | #23 |
neuroleptic withdrawal | #23 |
diagnostician | #23 |
siblings | #23 |
genetic investigation | #23 |
anxious mothers | #23 |
snapiv | #23 |
wechsler scales | #23 |
syp | #23 |
mdd anxiety disorders | #23 |
notch4 receptors | #23 |
adhd symptoms childhood | #23 |
disequilibrium male | #23 |
handful | #23 |
asd scq | #23 |
adolescents bpd | #23 |
twins genetic predisposition | #23 |
rs464049 | #23 |
heterogeneity genetic | #23 |
wide linkage | #23 |
serotonin receptor gene | #23 |
scq asd | #23 |
phenotype definition | #23 |
executive functions efs | #23 |
kotkin | #23 |
metadoxine | #23 |
n449 | #23 |
interacting molecules | #23 |
intrinsic curvature | #23 |
propylamines | #23 |
male individuals | #23 |
comprehensively | #23 |
adhd comorbidities | #24 |
15q13 | #24 |
neural activation patterns | #24 |
0535 | #24 |
deficits | #24 |
adhd characteristics | #24 |
refilled | #24 |
sassr | #24 |
aggression anxiety | #24 |
stroop task performance | #24 |
guanfacine extended release | #24 |
female humans illness | #24 |
expected growth | #24 |
actigraphy studies | #24 |
age regions | #24 |
receptor d4 | #24 |
intelligence schizophrenia | #24 |
amrs | #24 |
adra2a | #24 |
nieces | #24 |
lithium bipolar disorder | #24 |
symptoms psychosis | #24 |
statistical manual | #24 |
genome‐wide linkage scans | #24 |
children meeting | #24 |
snorting | #24 |
child female humans | #24 |
ocd asd | #24 |
dsmiiir criteria | #24 |
quantitative phenotypes | #24 |
mental control | #24 |
chromosomes 6 | #24 |
stress exposure | #24 |
conduct problems adhd | #24 |
nonstimulant | #24 |
task patients | #25 |
–environment interactions | #25 |
association snps | #25 |
baseline assessment | #25 |
young relatives | #25 |
behavioral disinhibition | #25 |
clinical interviews | #25 |
maternal criticism | #25 |
dyscalculia | #25 |
bipolar choice | #25 |
psychiatric nosology | #25 |
neurocognitive predictors | #25 |
vietnam twin registry | #25 |
unique profile | #25 |
copy variants schizophrenia | #25 |
efficacy atomoxetine | #25 |
anticipation schizophrenia | #25 |
nudt3 | #25 |
psychometrically | #25 |
slc6a3 gene | #25 |
exposure adhd | #25 |
decreased volume | #25 |
dapple | #25 |
major affective disorders | #25 |
school failure | #25 |
or194 | #25 |
biased transmission | #25 |
splicing regulator | #25 |
d22s283 | #25 |
symptom subtypes | #25 |
wkht | #25 |
screening scale | #25 |
psychiatric disorders children | #25 |
conners parent | #25 |
liker | #25 |
understanding adhd | #25 |
wm microstructure | #26 |
agreement raters | #26 |
htr1d | #26 |
adhd mothers | #26 |
selfmonitor | #26 |
adrenergic uptake | #26 |
label study | #26 |
gender risk | #26 |
voxel based morphometry | #26 |
psychometric measures | #26 |
rs3730358 | #26 |
controls adhd | #26 |
prenatal health | #26 |
affair | #26 |
association allele | #26 |
inrich | #26 |
core symptoms adhd | #26 |
add | #26 |
alcohol drug abuse | #26 |
screening diagnosis | #26 |
social impairment | #26 |
orosmethylphenidate | #26 |
structured interviews | #26 |
maob gene | #26 |
behavioral disorder | #26 |
bipolar phenotype | #26 |
neurodevelopmental genes | #26 |
nonmedical prescription stimulants | #26 |
adults symptoms | #26 |
major depression md | #26 |
twins humans | #26 |
n81 | #26 |
efpc | #26 |
childreniv | #27 |
ptsd adults | #27 |
consecutively | #27 |
rate remission | #27 |
greater severity | #27 |
intelligence male | #27 |
schizophrenia genetic | #27 |
based association | #27 |
international meeting | #27 |
association signals | #27 |
weaker effects | #27 |
genetic susceptibility schizophrenia | #27 |
d22s278 | #27 |
t102c polymorphism | #27 |
offspring risk | #27 |
potential confounds | #27 |
cnvs adhd | #27 |
treatment atomoxetine | #27 |
bipolar disorder comorbidity | #27 |
aff | #27 |
hyperactivity disorder adhd | #27 |
disorders executive | #27 |
mdd asd | #27 |
osterrieth | #27 |
asherson | #27 |
symptoms inattention | #28 |
preliminary findings | #28 |
polysomnography actigraphy | #28 |
adhd differences | #28 |
snp18 | #28 |
genomewide studies | #28 |
6179 | #28 |
sustained attention deficits | #28 |
maternal adhd | #28 |
rest task | #28 |
schizophrenia onset | #28 |
child clinical | #28 |
image study | #28 |
adhd autism | #28 |
parent teacher | #28 |
subjects bpd | #28 |
dopamine transporter binding | #28 |
male methylphenidate | #28 |
new genetics | #28 |
disorder compared | #28 |
ocd disorders | #28 |
genetic etiology | #28 |
symptom reports | #28 |
metaalgorithm | #28 |
persons bipolar disorder | #28 |
emotional dysregulation | #28 |
guze | #28 |
assessment negative symptoms | #28 |
slc6a3 | #28 |
vigilance performance | #28 |
raters | #28 |
adults study | #28 |
families schizophrenia | #28 |
cortical gyrification | #28 |
dopamine receptor d4 | #28 |
clinical correlates | #28 |
adhd patients controls | #29 |
comorbidity ptsd | #29 |
medication misuse | #29 |
disorders offspring | #29 |
hyperactivity impulsivity | #29 |
kcnn3 | #29 |
medication usage | #29 |
male polymorphism | #29 |
etiological heterogeneity | #29 |
offspring parents | #29 |
misuse diversion | #29 |
psychosocial dysfunction | #29 |
infants weight | #29 |
studies genes | #29 |
dsmiiir | #29 |
parents bipolar disorder | #29 |
shared genetic basis | #29 |
african‐american | #29 |
inattention hyperactivity impulsivity | #29 |
bipolar disorder youth | #29 |
childhood diagnosis | #29 |
disorder bipolar | #29 |
childhood antecedents | #29 |
attention‐deficit | #29 |
nicotine pregnancy | #30 |
nonaffected | #30 |
individual studies | #30 |
robust statistical methods | #30 |
juvenile bipolar disorder | #30 |
adhd child | #30 |
nimh | #30 |
specific psychopathology | #30 |
antisocial behavior asb | #30 |
treatment adolescents | #30 |
genetic perspective | #30 |
problems attention | #30 |
hyperactive symptoms | #30 |
diagnosticians | #30 |
comorbid | #30 |
caarsinv | #30 |
bmi growth | #30 |
growth childhood | #30 |
parental predictors | #30 |
structural brain features | #30 |
association paternal age | #30 |
relatives age | #30 |
reanalyzed | #31 |
neuropsychologic deficits | #31 |
prs adhd | #31 |
rgs4 schizophrenia | #31 |
bpd risk | #31 |
twin concordance | #31 |
n305 | #31 |
lodscore | #31 |
95 adhd | #31 |
depression genetic | #31 |
potential endophenotypes | #31 |
discriminates | #31 |
neuroimage | #31 |
nonadhd | #31 |
genotype haplotypes | #31 |
kif16b | #31 |
variable tandem | #31 |
sex effects | #31 |
impulsivity inattention | #31 |
charles river | #31 |
methylphenidate | #31 |
smoking substance | #31 |
extant literature | #31 |
child psychiatric | #32 |
rs206936 | #32 |
studies adolescent | #32 |
psychiatric disorders | #32 |
10p13 | #32 |
attentiondeficit | #32 |
bipolar disorder bpi | #32 |
studies schizophrenia | #32 |
wiscr | #32 |
70–80 | #32 |
gender | #32 |
parents child | #32 |
kremen | #32 |
randomized crossover study | #32 |
asd symptoms children | #32 |
schizophrenia affective psychosis | #32 |
aggression attention | #32 |
psychiatric genetic | #32 |
psychosis youth | #32 |
anterior insular | #32 |
subfields hippocampus | #32 |
slc6a4 | #32 |
impulsecontrol | #32 |
repeat length | #32 |
psdq | #32 |
anxiety disorders | #32 |
adhd adolescents | #32 |
frontopolar | #33 |
animal model adhd | #33 |
children risk | #33 |
qsf | #33 |
comorbidity cross | #33 |
subcortical brain | #33 |
wfirs | #33 |
neuropsychological deficits | #33 |
briefa | #33 |
single snps | #33 |
autism symptoms | #33 |
psychiatric status | #33 |
disorder symptom | #33 |
adhd evidence | #33 |
rhobtb3 | #33 |
prior findings | #33 |
mood anxiety | #33 |
psychiatric sample | #33 |
maternal smoking pregnancy | #33 |
pharmacotherapy trials | #33 |
neuropsychiatric sle | #33 |
ld adhd | #33 |
original study | #33 |
val allele | #33 |
twins factor analysis | #33 |
current adhd | #33 |
adhd patients | #33 |
quetiapine monotherapy | #33 |
rs1130214 | #33 |
aspd bpd | #33 |
association genes | #33 |
10repeat allele | #33 |
youth bipolar disorder | #33 |
neural reward processing | #33 |
gxr | #34 |
disorders mood | #34 |
grm5 | #34 |
linkage studies | #34 |
cognition interaction | #34 |
risk psychiatric disorders | #34 |
snp4 | #34 |
emerging consensus | #34 |
young adults adhd | #34 |
pharmacotherapy adhd | #34 |
disorder traits | #34 |
treatment sud | #34 |
structural brain asymmetries | #34 |
social anxiety children | #34 |
candidate gene polymorphisms | #34 |
md risk | #34 |
psychological tests | #34 |
treatment memantine | #34 |
disorders diagnostic | #34 |
inattention | #34 |
dsm5 dsmiv | #34 |
harvard | #34 |
adhd rating | #35 |
#35 | |
bipolar disorder offspring | #35 |
n64 | #35 |
choice impulsivity | #35 |
catechol‐o‐methyltransferase | #35 |
adhd sleep problems | #35 |
schizophrenia gene | #35 |
htr1b | #35 |
schizophrenia relatives | #35 |
risk females | #35 |
familial risk | #35 |
sample description | #35 |
n265 | #35 |
plink | #35 |
humans intelligence | #35 |
schizophrenia schizotypy | #35 |
bipolar spectrum disorders | #35 |
lifetime rates | #35 |
recall patients | #35 |
complex figure | #35 |
participants bpd | #35 |
lithium quetiapine | #35 |
hyperactive disorder | #35 |
disorder bpd | #36 |
nocebo response | #36 |
neurotransmissions | #36 |
stimulant medications | #36 |
siblings controls | #36 |
retrospective recall | #36 |
adhd drug | #36 |
groups adhd | #36 |
overanxious disorder | #36 |
schizophrenia genes | #36 |
comorbidity children | #36 |
young adult females | #36 |
adult antisocial | #36 |
95 siblings | #36 |
d6s274 | #36 |
adhd control groups | #36 |
annett | #36 |
orosmph | #36 |
intracranial volume icv | #36 |
structure psychopathology | #36 |
gypc | #36 |
neurocognitive markers | #36 |
n185 | #36 |
term neuropsychological | #36 |
infant gender | #36 |
suny | #36 |
adhd asd | #37 |
child behavioral | #37 |
disorder severity | #37 |
studies comorbidity | #37 |
mapping genomic loci | #37 |
slc22a16 | #37 |
offspring association | #37 |
lisdexamfetamine | #37 |
odd dimensions | #37 |
rs5 | #37 |
n278 | #37 |
delayedaction preparations | #37 |
parents adhd children | #37 |
tests schizophrenia | #37 |
functioning adults | #37 |
symptom criteria | #37 |
predictive utility | #37 |
genetics | #37 |
dat1 gene | #37 |
combined sample | #37 |
dsm criteria | #38 |
d15s1360 | #38 |
genetic risk schizophrenia | #38 |
kiddie schedule | #38 |
16 genes | #38 |
genome‐wide search | #38 |
unfamiliar | #38 |
rs2391191 | #38 |
pik4ca | #38 |
height children | #38 |
pediatric adhd | #38 |
boys | #38 |
familial risk depression | #38 |
methylphenidate treatment | #38 |
family‐based | #38 |
polymorphism gene | #38 |
adhd problems | #38 |
school age children | #38 |
git1 | #39 |
onset children | #39 |
iii personality | #39 |
dsm5 criteria | #39 |
female cases | #39 |
nonparanoid | #39 |
markers genetic | #39 |
ocd adhd | #39 |
asthma systematic review | #39 |
washu | #39 |
increased risk adhd | #39 |
pharmacologic treatment | #39 |
test association | #39 |
antisocial traits | #39 |
mdd ocd | #39 |
adhd behavior | #39 |
manic symptoms | #39 |
structural brain abnormalities | #39 |
suggestive | #39 |
wisconsin card | #39 |
mlod | #39 |
mood stabilization | #39 |
behavioral traits | #39 |
genetic studies | #40 |
rare copy variants | #40 |
anx | #40 |
onset | #40 |
gxe | #40 |
brainspan | #40 |
diagnosis bipolar disorder | #40 |
rs2283265 | #40 |
genome scan | #40 |
bipolars | #40 |
familial effects | #40 |
heinrichs | #40 |
dsmiv criteria | #40 |
genetics schizophrenia | #40 |
cardiovascular adverse effects | #40 |
chromosome 10p | #40 |
reln gene | #40 |
methylphenidate response | #41 |
sirolimus patients | #41 |
fhrs | #41 |
pediatric subjects | #41 |
effects growth | #41 |
chromosomes 6q | #41 |
normal comparison subjects | #41 |
neuropsychiatr | #41 |
bdnf adhd | #41 |
schizophrenia severity illness | #41 |
male parents | #41 |
parent‐of‐origin | #41 |
sibpairs | #41 |
psychosocial adversity | #41 |
methodological advances | #41 |
fiveyear followup | #42 |
individual items | #42 |
diagnostic comorbidity | #42 |
dtnbp1 schizophrenia | #42 |
disorder social | #42 |
schizophrenia disorders | #42 |
schizophrenia | #42 |
n262 | #42 |
tic disorders | #42 |
adhd deficits | #42 |
male panic | #42 |
child female | #42 |
gwas meta | #42 |
sorting test | #42 |
serotonergic pathway | #42 |
n176 | #43 |
youngadult | #43 |
p094 | #43 |
candidate endophenotype | #43 |
p023 | #43 |
practitioner review | #43 |
mri study | #43 |
adhd prs | #43 |
n242 | #43 |
brain scans | #43 |
neuropsychological differences | #43 |
children enuresis | #43 |
disorder prevalence | #43 |
digs | #43 |
massachusetts general | #43 |
simplex families | #43 |
adhd depression | #43 |
snp1 | #43 |
neuropsychological tasks | #43 |
n232 | #43 |
secondborns | #44 |
n140 | #44 |
adolescents attention | #44 |
odds ratio association | #44 |
dopamine d5 | #44 |
sidp | #44 |
multidimensionality | #44 |
asd adults | #44 |
prior studies | #44 |
nosologic | #44 |
mental disorders diseases | #44 |
treatment adult | #44 |
immediaterelease | #44 |
pooled size | #45 |
risk reduction strategies | #45 |
baseline adhd | #45 |
inflation rate | #45 |
uncaring | #45 |
cep85l | #45 |
institute mental | #45 |
wnl | #45 |
genetic underpinnings | #45 |
schizophrenia genome | #45 |
suggestive associations | #45 |
risk schizophrenia | #45 |
controls subjects | #45 |
prevalence psychiatric | #45 |
offspring adhd | #45 |
volume reductions | #45 |
altered brain activation | #45 |
adhd parents | #45 |
tcerg1l | #45 |
pharmacogenetic studies | #45 |
genetic loading | #45 |
substance disorder | #45 |
snpbased heritability | #45 |
illness stress | #45 |
behavior rating | #45 |
stronger connectivity | #46 |
natural reward | #46 |
converging evidence | #46 |
response mph | #46 |
adhd effects | #46 |
sex bias | #46 |
lyons | #46 |
machine learning study | #46 |
gender influences | #46 |
n164 | #46 |
previous findings | #46 |
nat genet | #46 |
familial coaggregation | #46 |
neuropsychological performance | #46 |
12 months treatment | #46 |
cbt intervention | #46 |
referral bias | #46 |
10year followup | #46 |
schizophrenia alleles | #47 |
parents depression | #47 |
disorders studies | #47 |
baiap2 | #47 |
n280 | #47 |
ocd mdd | #47 |
childhood disorders | #47 |
abstract objective | #47 |
psychiatric status rating | #47 |
or125 | #47 |
meehl | #47 |
velocardiofacial syndrome | #47 |
trauma risk | #47 |
oppositional symptoms | #47 |
shared polygenic risk | #47 |
loci chromosomes | #47 |
pooled odds ratio | #47 |
genetic study | #47 |
compromised | #47 |
comt | #47 |
association bipolar disorder | #47 |
desipramine dmi | #47 |
shared heritability | #48 |
disorder case | #48 |
adhd dyslexia | #48 |
scientific foundation | #48 |
n103 | #48 |
rtv | #48 |
adhd prevalence | #48 |
mpp3 | #48 |
1711 | #48 |
effects gender | #48 |
revised | #48 |
association test | #48 |
n27 | #48 |
nullhypothesis | #48 |
disorder cognitive | #49 |
drug holidays | #49 |
familial loading | #49 |
anxa7 | #49 |
nurture | #49 |
mental disorders children | #49 |
snap‐25 | #49 |
hyperactivity autism | #49 |
serotonin plasma | #49 |
schizophrenia cognition | #49 |
inbred wky rats | #49 |
negative schizotypy | #49 |
rs2494732 | #49 |
volume differences | #49 |
weak evidence | #49 |
studies biomarkers | #50 |
early onset schizophrenia | #50 |
extended pedigrees | #50 |
rocf | #50 |
parent teacher ratings | #50 |
genomic relationships | #50 |
maoauvntr | #50 |
proteins polymorphism | #50 |
life outcomes | #50 |
wais | #50 |
caseness | #50 |
impulsivity symptoms | #50 |
intergenerational effects | #50 |
n168 | #50 |
wiat | #50 |
vdm | #50 |
pair 6 | #50 |
geneenvironment interactions | #50 |
dsmiv dsm5 | #50 |
1542 | #51 |
common psychiatric disorders | #51 |
psychology adult | #51 |
gender association | #51 |
disorders children | #51 |
manovas | #51 |
adhd knowledge | #51 |
peer affiliation | #51 |
bpd | #51 |
male personality | #51 |
compelling | #51 |
epilepsy adhd | #51 |
substantial role | #51 |
adults ocd | #51 |
combined adhd | #52 |
bipolar disorder children | #52 |
major depression | #52 |
adra1a | #52 |
growth height | #52 |
intracranial volume | #52 |
selenbp1 | #52 |
schizophrenia sex | #52 |
youth asd | #52 |
gray matter alterations | #52 |
chronic schizophrenia patients | #52 |
schizophrenia controls | #52 |
a218c | #52 |
metaanalysis association | #52 |
oros methylphenidate | #52 |
asdadhd | #52 |
mania depression | #53 |
adoption study | #53 |
risktaking behavior | #53 |
parahippocampal gyrus | #53 |
ppm1h | #53 |
psychopathology | #53 |
tourettes disorder | #53 |
scales schizophrenia | #53 |
schizophrenia adolescent | #53 |
n138 | #53 |
snps candidate genes | #53 |
risk analysis | #53 |
smoking schizophrenia | #53 |
dopamine plasma | #53 |
placebo children | #53 |
adhdc | #53 |
extended‐release | #53 |
dnms | #54 |
pregnancy time | #54 |
schizophrenia psychotic disorders | #54 |
risk study | #54 |
ablim1 | #54 |
alcohol drug | #54 |
jackknife | #54 |
chromosome 6p | #54 |
unphased | #54 |
onset bipolar | #54 |
psychlit | #54 |
genetic reproducibility | #54 |
bpd children | #54 |
viloxazine | #55 |
emotional lability | #55 |
longitudinal case | #55 |
neuropsychological studies | #55 |
disorders prevalence | #55 |
tova | #55 |
gene interaction | #55 |
children diagnosis | #55 |
1252 | #55 |
endophenotype | #55 |
child behavior | #55 |
flat affect | #55 |
disorders risk | #55 |
sample children | #55 |
mid adolescence | #55 |
childhood trauma exposure | #55 |
alcohol substance | #56 |
extendedrelease | #56 |
subfield | #56 |
children siblings | #56 |
pair chromosomes | #56 |
entry points | #56 |
tics children | #56 |
cotwin | #56 |
degree relatives | #56 |
hyperactive | #56 |
disorder agoraphobia | #56 |
n43 | #56 |
schizophrenia offspring | #56 |
etdt | #57 |
atomoxetine hydrochloride | #57 |
brain structure function | #57 |
rating inventory | #57 |
model attention | #57 |
oddsratio | #57 |
apol | #57 |
barkley | #57 |
methylphenidate hydrochloride | #57 |
shared genetic etiology | #57 |
zdhhc8 | #57 |
interregional profiles differences | #57 |
vntr polymorphisms | #58 |
single snp | #58 |
100 children | #58 |
conners | #58 |
comorbid psychiatric disorders | #58 |
heritable receptors | #58 |
compelling evidence | #58 |
childhood young adulthood | #58 |
function schizophrenia | #58 |
controls children | #58 |
dbq | #58 |
association comt | #58 |
repeat alleles | #58 |
controlled study | #58 |
adhd atomoxetine | #58 |
children | #58 |
analysis schizophrenia | #58 |
tests attention | #58 |
risk siblings | #59 |
risk psychiatric | #59 |
mdd adhd | #59 |
neuroleptic | #59 |
mdd children | #59 |
comt schizophrenia | #59 |
schizophrenia smoking | #59 |
rtn4r | #59 |
executive functioning | #60 |
reported associations | #60 |
functional remission | #60 |
generalize | #60 |
disruptive behavior disorder | #60 |
duval | #60 |
inattention hyperactivity | #60 |
disorders including | #60 |
3 domains | #60 |
lphn3 | #60 |
abuse dependence | #60 |
uninhibited | #61 |
13q32 | #61 |
study adherence | #61 |
homogeneous subgroups | #61 |
disruptive behavior | #61 |
disorders asd | #61 |
oih | #61 |
dysregulation profile | #61 |
unipolars | #61 |
study adults | #61 |
wide scan | #61 |
uncles | #61 |
comparison subjects | #61 |
cronbachs alpha | #61 |
bipolar youth | #62 |
substantial heritability | #62 |
factors anxiety | #62 |
symptoms | #62 |
maternal psychopathology | #62 |
schizophrenia human | #62 |
tdts | #62 |
relatives schizophrenia | #62 |
mph treatment | #62 |
1537 | #62 |
inhibition memory | #62 |
4 year | #62 |
polygenic risk schizophrenia | #62 |
behavioral dysregulation | #63 |
neurocognitive | #63 |
ksads | #63 |
accounted | #63 |
structured interview | #63 |
stability time | #63 |
disorders bipolar | #63 |
schizophrenia schizophrenic | #63 |
n179 | #63 |
risk severity | #63 |
treatments adhd | #63 |
40 countries | #64 |
children mph | #64 |
methylation cpg sites | #64 |
treatment desipramine | #64 |
endosomal | #64 |
prefrontal dysfunction | #64 |
adhd 95 | #64 |
europeanamerican | #64 |
childhood onset | #64 |
males association | #64 |
diagnostic utility | #64 |
methylphenidate adhd | #64 |
rating scales | #64 |
risk trauma | #64 |
phacking | #64 |
linkage | #64 |
child | #64 |
qlesq | #64 |
methylphenidate mph | #64 |
emotional regulation | #65 |
disorders genetic | #65 |
adhd epilepsy | #65 |
small sample size | #65 |
oxidase gene | #65 |
comorbid diagnosis | #65 |
function female | #65 |
marry | #65 |
etiology schizophrenia | #65 |
emo | #65 |
net gene | #65 |
zcchc4 | #65 |
male siblings | #65 |
prior work | #65 |
temperamental | #65 |
schizophrenic | #65 |
neuropsychological impairments | #65 |
controls siblings | #65 |
occurrence adhd | #65 |
extended release | #66 |
behavioral genetic | #66 |
tourettes syndrome | #66 |
simple phobia | #66 |
afternoons | #66 |
neuropsychological profile | #66 |
tic disorder | #66 |
adhd dcd | #66 |
study studies | #66 |
attention hyperactivity | #66 |
children mental retardation | #66 |
global ratings | #66 |
vswm | #66 |
disorder chromosome | #66 |
ci105 | #66 |
cbcldp | #66 |
chronic tic disorder | #67 |
variance attention | #67 |
substance disorder sud | #67 |
treatment quetiapine | #67 |
mental diseases | #67 |
label trial | #67 |
risk bipolar | #67 |
questionnaires treatment | #67 |
subjects | #67 |
findings association | #67 |
patients bipolar disorders | #67 |
grade retention | #67 |
parents teachers | #67 |
nonrighthandedness | #67 |
entire sample | #67 |
n217 | #67 |
naturalistic | #68 |
qms | #68 |
snparray | #68 |
delay aversion | #68 |
offspring | #68 |
conceptual issues | #68 |
brain gene | #68 |
hypofrontality | #68 |
physical anhedonia | #69 |
humans schizophrenia | #69 |
scale assessment | #69 |
people adhd | #69 |
symptom checklist | #69 |
low adherence | #69 |
polymorphism schizophrenia | #69 |
ctgn | #69 |
panic disorder | #69 |
clarifying | #69 |
illicit substances | #69 |
chronological age | #69 |
regulatory enzymes | #69 |
stress response genes | #69 |
impulsivity hyperactivity | #69 |
interactions genes | #70 |
linkage scan | #70 |
latrophilin | #70 |
core adhd symptoms | #70 |
smoking children | #70 |
oros mph | #70 |
npl | #70 |
a2bp1 | #70 |
neuropsychological consequences | #70 |
subsequent diagnosis | #70 |
new diagnoses | #70 |
nonrandom mating | #70 |
adhd behaviors | #71 |
vergence | #71 |
genes role | #71 |
mspi polymorphism | #71 |
adhd anxiety disorders | #71 |
objective examine | #71 |
genetic | #71 |
treated children | #71 |
neuroimaging genetics | #71 |
molecular genetic | #72 |
digital intervention | #72 |
school functioning | #72 |
genetic receptors | #72 |
methodological issues | #72 |
digital health intervention | #72 |
learning disorders | #72 |
boys age | #72 |
ocd subjects | #72 |
adhd subtype | #73 |
youth | #73 |
patients rest | #73 |
candidate endophenotypes | #73 |
etiological | #73 |
logodds | #73 |
adult | #73 |
disorders childhood | #73 |
anxiety adhd | #73 |
schizophrenia genetics | #73 |
relapse depression | #73 |
kagan | #73 |
3372 | #73 |
poison control centers | #73 |
cortical abnormalities | #73 |
adhd medications | #73 |
cellular models | #73 |
desipramine | #74 |
age schizophrenia | #74 |
allele association | #74 |
pfkfb2 | #74 |
transmission disequilibrium | #74 |
preferential transmission | #74 |
reaction time variability | #74 |
based diagnosis | #74 |
onset anxiety | #75 |
adhd traits | #75 |
referred | #75 |
linkage schizophrenia | #75 |
hyperactivity adhd | #75 |
akl | #75 |
drd4 gene | #75 |
risk sample | #75 |
efficacy outcome | #75 |
weight body mass | #75 |
child china | #75 |
mind wandering | #75 |
neale | #75 |
antisocial | #75 |
impairment children | #75 |
slc1a1 | #75 |
nondeficit | #76 |
positive schizotypy | #76 |
child humans | #76 |
schizophrenia young | #76 |
adhd total | #76 |
centers disease control | #76 |
child depressive | #76 |
disorders brain | #76 |
yates | #76 |
depression pregnancy | #76 |
chronic tic | #76 |
childhood adhd | #77 |
atomoxetine children | #77 |
performance schizophrenia | #77 |
performance adhd | #77 |
wcst performance | #77 |
cortex schizophrenia | #77 |
psychological male | #77 |
lod score | #77 |
local gyrification | #78 |
women antidepressants | #78 |
adhd impairment | #78 |
pharmacologic treatments | #78 |
disorders female | #78 |
predixcan | #78 |
bpi | #78 |
bipolar disorder adhd | #78 |
rare copy | #78 |
disorder panic | #79 |
schizophrenic patients | #79 |
pregnancy mothers | #79 |
student athletes | #79 |
n46 | #79 |
obesity metabolic syndrome | #79 |
patients adhd | #79 |
retrospective assessment | #79 |
additive effects | #79 |
age adhd | #79 |
cardinal | #79 |
nosological | #79 |
studies relationship | #79 |
genetic linkage studies | #79 |
anxiety separation | #79 |
siblings schizophrenia | #80 |
total brain | #80 |
clinical interview | #80 |
adhd drugs | #80 |
maternal smoking | #80 |
adhd rats | #80 |
linkage chromosome | #80 |
endophenotypes | #81 |
hacking | #81 |
body mass diabetes | #81 |
eyhs | #81 |
subcortical brain volumes | #81 |
oral routes | #81 |
treatment adults | #81 |
major diagnostic | #81 |
interregional profiles | #81 |
differences age | #81 |
pathophysiology adhd | #81 |
disliking | #81 |
bipolar disorder | #81 |
children parents | #81 |
comorbidity survey | #82 |
association maternal smoking | #82 |
cumulative evidence | #82 |
auditory verbal | #82 |
gene schizophrenia | #82 |
impaired quality life | #82 |
comorbidity disorders | #82 |
square distribution | #82 |
adults asd | #82 |
frontopolar cortex | #82 |
genes pathways | #82 |
behavior assessment | #82 |
symptoms diagnosis | #82 |
management adhd | #83 |
oros | #83 |
adult form | #83 |
multifactorial inheritance | #83 |
paterson | #83 |
illness | #83 |
neurocognitive functioning | #83 |
disorders anxiety | #83 |
substance disorders | #83 |
unreliability | #83 |
tests risk | #83 |
women adhd | #84 |
adhd adhd symptoms | #84 |
complex disorder | #84 |
15q133 | #84 |
21 months | #84 |
humans risk | #85 |
linkage loci | #85 |
european samples | #85 |
adhd subtypes | #85 |
brain asymmetry | #85 |
adhdrsiv | #85 |
monitoring response | #85 |
hyperkinetic disorder | #85 |
atomoxetine | #85 |
buprenorphine maintenance | #85 |
9r | #85 |
wide significance | #85 |
recycling endosome | #85 |
genomics consortium | #85 |
adhd assessment | #85 |
siblings children | #86 |
humans inhibition | #86 |
paranoid | #86 |
parents | #86 |
affective psychosis | #86 |
findings implications | #86 |
child conduct | #86 |
pord | #86 |
risk alleles | #87 |
synaptosomal protein | #87 |
n203 | #87 |
putamen volume | #87 |
comparison children | #87 |
bipolar spectrum disorder | #87 |
bipolar | #87 |
3utr | #87 |
ptsd trauma | #87 |
drug effects | #88 |
druggable | #88 |
hyperkinetic | #88 |
comorbid psychopathology | #88 |
common risk | #88 |
bonferroni correction | #88 |
machine learning analysis | #89 |
auditory attention | #89 |
prenatal nicotine exposure | #89 |
nucleotide schizophrenia | #89 |
chrna2 | #89 |
22 studies | #89 |
metaanalytic review | #89 |
caars | #89 |
empirically | #89 |
comprehensive identification | #89 |
euphoric | #89 |
2455 | #89 |
association metaanalysis | #90 |
watt | #90 |
linkage genome | #90 |
1month | #90 |
snps haplotypes | #90 |
pervasive | #90 |
attention deficit hyperactivity | #90 |
verbal ability | #90 |
antidepressants pregnancy | #90 |
male neuropsychological | #90 |
242 | #90 |
adhd efficacy | #91 |
identified studies | #91 |
assertion | #91 |
complicates | #91 |
callousness | #91 |
adhd treatments | #91 |
cortical brain | #91 |
naturalistic study | #91 |
wcst | #91 |
adhd males | #91 |
parental socioeconomic status | #91 |
adults schizophrenia | #92 |
raise | #92 |
studies association | #92 |
studies sex | #92 |
h2snp | #92 |
documenting | #92 |
candidate gene | #92 |
treatment mania | #92 |
standardized differences | #93 |
rate adult | #93 |
controls participants | #93 |
narrowly | #93 |
referral consultation | #93 |
ymrs | #93 |
lifetime cannabis | #93 |
gprc5b | #94 |
sustained attention | #94 |
adhd measures | #94 |
gottman | #94 |
hyperactivity autistic | #94 |
cdh13 | #94 |
social development | #94 |
hfasd | #94 |
underachievement | #94 |
performance variability | #94 |
growing body | #94 |
brain case | #94 |
aldh1l1 | #94 |
minisatellite | #95 |
mdd bip | #95 |
studies differences | #95 |
asd study | #95 |
adolescents bipolar | #95 |
executive | #95 |
infa | #95 |
total brain volume | #95 |
cadps2 | #95 |
phenotype polymorphism | #96 |
chromosome 9q34 | #96 |
behavior rating inventory | #96 |
uvntr | #96 |
nxph1 | #96 |
nominally | #96 |
scq | #96 |
7q36 | #97 |
studies asthma | #97 |
adolescent onset | #97 |
genome‐wide association study | #97 |
low cardiorespiratory fitness | #97 |
hcadherin | #97 |
children tics | #97 |
identically | #98 |
single nucleotide receptor | #98 |
bipolar disorder risk | #98 |
linkage study | #98 |
wdpcp | #98 |
induced hyperalgesia | #98 |
oppositionality | #98 |
syn2 | #98 |
nonfamilial | #98 |
massachusetts general hospital | #98 |
hyperactivity brazil | #98 |
concerta | #98 |
driving behavior | #98 |
medication effects | #99 |
psychoactive | #99 |
methodssubjects | #99 |
adhd role | #99 |
disorder diagnosis | #99 |
motor timing | #99 |
metaanalysis trials | #99 |
abuse potential | #99 |
substrains | #99 |
nonspecificity | #99 |
neurodevelopmental processes | #99 |
chd6 | #99 |
xp114 | #99 |
disease genetics | #99 |
obesity abdominal obesity | #100 |
pelham | #100 |
reticence | #100 |
12year | #100 |
hippocampal subfield volumes | #100 |
clinical effects | #100 |
adhd methylphenidate | #100 |
terror | #100 |
diagnostic boundaries | #101 |
neurocognitive impairments | #101 |
schizophrenia psychotic | #101 |
roh | #101 |
torture | #101 |
tsls | #101 |
empirical test | #101 |
addictive drugs | #101 |
upsit | #101 |
advanced paternal age | #101 |
genetic risk scores | #101 |
harlan | #101 |
genomewide | #101 |
slc6a4 gene | #101 |
cosegregation | #101 |
depression pregnant women | #101 |
sob | #102 |
individuals aud | #102 |
disorder psychiatric | #102 |
parents offspring | #102 |
klf13 | #102 |
male neuropsychological tests | #102 |
inhibition psychological | #102 |
treatment seeking | #102 |
functional pathways | #102 |
genetic pedigree polymorphism | #103 |
touchstone | #103 |
patients 12 months | #103 |
symptom profile | #103 |
genome wide association | #103 |
clinical picture | #103 |
schizophrenia mood disorders | #103 |
ocd children | #103 |
pgc | #103 |
genetic mechanism | #104 |
schizophrenia metaanalysis | #104 |
individual sites | #104 |
motor competence | #104 |
1934 | #104 |
genomic region | #104 |
controlled studies | #104 |
tourette disorder | #104 |
school dropout | #105 |
drug dyskinesia | #105 |
dsmiv diagnosis | #105 |
academic problems | #105 |
current article | #105 |
neuropsychological dysfunction | #105 |
schizophrenia probands | #105 |
adhd review | #105 |
humans lod | #106 |
children methylphenidate | #106 |
cogs | #106 |
children odd | #106 |
lenticular | #107 |
chronic tic disorders | #107 |
λs | #107 |
adolescents bipolar disorder | #107 |
functional correlates | #107 |
oral methylphenidate | #107 |
sequential analysis | #107 |
consecutive sample | #107 |
daao | #107 |
ldn | #107 |
matter volumes | #107 |
mothers adhd | #107 |
growth outcomes | #107 |
disorder female | #107 |
918 | #108 |
pediatric psychopharmacology | #108 |
n197 | #108 |
aged psychiatric | #108 |
proband | #108 |
pervasive developmental | #108 |
association cigarette smoking | #108 |
site differences | #108 |
afni | #108 |
antimanic agents | #108 |
symptoms childhood | #108 |
nesarc | #108 |
maternal warmth | #108 |
origin effects | #108 |
psychosis proneness | #109 |
total scores | #109 |
worthy | #109 |
irrespective | #109 |
gabra6 | #109 |
longitudinal trajectories | #109 |
adhd medication | #109 |
risk bipolar disorder | #109 |
neuroleptic medication | #109 |
depression bipolar | #109 |
adult adhd symptoms | #110 |
enlistment | #110 |
markers genome | #110 |
adhd parent | #110 |
rat models | #110 |
linkage association | #110 |
5httlpr genotype | #111 |
selective reporting | #111 |
dimorphisms | #111 |
n107 | #111 |
dao | #111 |
symptom ratings | #111 |
affective psychoses | #111 |
affective symptoms | #111 |
bipolar parents | #112 |
factors social | #112 |
brain gene expression | #112 |
dopamine d4 receptors | #112 |
childhood risk factors | #112 |
independent studies | #112 |
unmedicated | #112 |
pediatric obsessive | #112 |
impact exposure | #112 |
substantial proportion | #112 |
neuropsychological functions | #113 |
cronbach | #113 |
xr | #113 |
male prevalence | #113 |
functional neuroanatomy | #114 |
comorbid anxiety | #114 |
omim | #114 |
analysis statistical | #114 |
liability | #115 |
endorsed | #115 |
n34 | #115 |
nuclear families | #115 |
genet | #115 |
–r | #115 |
schizophrenia severity | #115 |
formulating | #116 |
wm abnormalities | #116 |
diseases twins | #116 |
neuropsychological | #116 |
schizophrenic psychology | #116 |
neurocognitive endophenotypes | #117 |
prenatal smoking | #117 |
unipolar | #117 |
z29 | #117 |
current symptoms | #117 |
polygenic association | #117 |
coordinated analysis | #117 |
trait impulsivity | #117 |
quality life outcomes | #117 |
genetic receptor serotonin | #118 |
major female | #118 |
definitively | #118 |
spm2 | #118 |
satisfaction questionnaire | #118 |
grandfathers | #118 |
prevention science | #118 |
academic functioning | #118 |
grandiosity | #118 |
large study | #118 |
method data | #119 |
dopaminergic genes | #119 |
schizophrenia linkage | #119 |
naa ratio | #119 |
midadolescence | #119 |
efd | #119 |
differences children | #120 |
misunderstandings | #120 |
t01 | #120 |
subfield volumes | #121 |
neurocognitive deficits | #121 |
disorder autism | #121 |
remittance | #121 |
aunts | #121 |
new avenues | #121 |
n108 | #121 |
cgibp | #121 |
levels adhd | #122 |
urvs | #122 |
v11 | #122 |
male risk | #122 |
disregard | #122 |
anxious | #122 |
structural brain alterations | #122 |
disorder depressive | #122 |
brain alterations | #122 |
neuropsychiatric disorders | #122 |
adhd comorbidity | #122 |
pabs | #122 |
refute | #122 |
msit | #122 |
psychopathology symptoms | #122 |
schizoaffective | #122 |
chr psychosis | #123 |
adhd ocd | #123 |
wechsler | #123 |
age initiation | #123 |
clinical status | #123 |
adcy2 | #123 |
longitudinal sample | #124 |
maximum lod score | #124 |
drug placebo | #124 |
laboratory observations | #124 |
g×s interaction | #124 |
treatment subjects | #124 |
attention regulation | #124 |
wechsler intelligence scale | #124 |
p097 | #124 |
trios | #124 |
twothirds | #124 |
9q34 | #124 |
segregation analysis | #125 |
anxiety problems | #125 |
machine learning prediction | #125 |
caregiver strain | #125 |
psychosis individuals | #125 |
patients chronic schizophrenia | #125 |
disorder risk | #125 |
odd conduct disorder | #126 |
memory adhd | #126 |
drug disorders | #126 |
biological parents | #126 |
developmental aspects | #126 |
positive negative symptoms | #126 |
familial influences | #126 |
complex genetics | #126 |
parent version | #126 |
genes | #127 |
drd2 | #127 |
stevenson | #127 |
taiwanese population | #127 |
psychiatric diagnoses | #127 |
attention child | #127 |
adult alleles | #127 |
disinhibited | #127 |
neuropsychological measures | #128 |
aged 6 | #128 |
personality assessment | #129 |
implicate | #129 |
intactness | #129 |
n102 | #129 |
opiate antagonists | #129 |
familial | #129 |
behavioral outcome | #129 |
retrospective data analysis | #130 |
families | #130 |
adhd inattention | #130 |
1990a | #130 |
mood anxiety disorders | #131 |
register study | #131 |
adolescents ocd | #131 |
incapacitation | #131 |
animals attention | #131 |
differed | #131 |
bip mdd | #131 |
moderating effects | #131 |
pair 15 chromosomes | #131 |
kinesthesia | #131 |
snps | #131 |
strong evidence | #131 |
hkd | #132 |
child cognition | #132 |
learning disabilities | #132 |
late adolescents | #132 |
male prospective | #132 |
sodas | #132 |
entire brain | #132 |
large european cohort | #132 |
n79 | #132 |
p074 | #132 |
linkage humans | #132 |
childhood anxiety disorders | #132 |
heroin dependence | #133 |
onset bipolar disorder | #133 |
mph | #133 |
disorders social | #134 |
children adults | #134 |
vntr | #134 |
preliminary examination | #134 |
social deficits | #135 |
association analyses | #135 |
male massachusetts | #135 |
tspan8 | #136 |
risk factors smoking | #136 |
firstborns | #136 |
relied | #136 |
olfactory identification | #136 |
social environments | #136 |
adolescents young | #136 |
sorcs3 | #136 |
longitudinal evidence | #137 |
psychological male memory | #137 |
studies examined | #137 |
adolescent bipolar | #137 |
association asthma | #137 |
gaming | #137 |
expressed emotion | #137 |
schizophrenia affective disorders | #137 |
memantine treatment | #137 |
mtor activation | #138 |
evidence association | #138 |
asds | #138 |
biomarkers diagnosis | #138 |
6q | #138 |
control individuals | #138 |
fhr | #139 |
neuropsychiatric | #139 |
mgh | #139 |
symptoms disorders | #139 |
meet | #139 |
schizophrenia studies | #139 |
n129 | #139 |
intriguing | #140 |
parental anxiety | #140 |
n115 | #140 |
schizotypal traits | #140 |
haplotype block | #141 |
prss | #141 |
disorder comorbidity | #141 |
genetic vulnerability | #141 |
emotional symptoms | #141 |
5ht1b receptors | #142 |
neurotrophic | #142 |
disorders personality | #142 |
covid19 restrictions | #142 |
22q112 deletion syndrome | #142 |
disorders psychotic | #142 |
peripheral biomarkers | #143 |
molecular genetics | #143 |
risk factors obesity | #143 |
conduct | #143 |
fetal movement | #143 |
hydrogen exchangers | #143 |
humans linear | #144 |
elston | #144 |
agents tricyclic | #144 |
rfg | #144 |
child psychopathology | #144 |
diagnosed attention | #144 |
diagnostic procedure | #144 |
blind study | #144 |
statistical female humans | #144 |
g72 | #144 |
genome‐wide association studies | #145 |
n105 | #145 |
common genetic variants | #145 |
affs | #145 |
major psychoses | #145 |
studies depressive | #145 |
pcb exposure | #145 |
early initiation | #145 |
genetic heterogeneity | #145 |
drug alcohol | #145 |
individual symptoms | #145 |
p00018 | #145 |
adult psychopathology | #146 |
intelligence quotient | #146 |
prenatal nicotine | #146 |
twin studies | #146 |
atypicality | #146 |
oppositional behavior | #146 |
genders | #146 |
warranted | #146 |
comprising | #147 |
abbreviated | #147 |
histrionic | #147 |
intraindividual variability | #147 |
lras | #147 |
p0016 | #147 |
adolescent young | #148 |
sabp | #148 |
cognitive variables | #148 |
single locus | #148 |
basc | #148 |
adhd symptoms children | #149 |
brain correlates | #149 |
risk mdd | #149 |
parental substance | #149 |
schizotypy | #149 |
cdrsr | #149 |
nonmedical | #150 |
adhd relationship | #150 |
impulsive | #150 |
chrnb2 | #150 |
highlighting | #150 |
sud treatment | #150 |
categorical | #150 |
synaptic biology | #151 |
higher burden | #151 |
consisted | #151 |
schizophrenia diagnosis | #152 |
large sample | #152 |
copy variants cnvs | #152 |
implicates | #152 |
linkage disequilibrium mapping | #152 |
autistic traits | #152 |
httlpr | #152 |
undegraded | #152 |
placebo subjects | #152 |
functional impairment | #152 |
diagnostic systems | #152 |
increases risk | #152 |
atxn1 | #152 |
parent report | #152 |
metaanalytic | #152 |
xq21 | #152 |
schizophrenia deficits | #153 |
editions | #153 |
demoralization | #153 |
caucasian children | #153 |
5 httlpr | #153 |
schizophrenia bipolar disorder | #153 |
genomewide linkage | #153 |
marginally | #153 |
alcohol conditions | #153 |
humans learning | #153 |
emphasizing | #154 |
disorder phenotype | #154 |
wisc | #154 |
atomoxetine placebo | #154 |
exposure maternal | #154 |
schizophrenia magnetic resonance | #154 |
dsm | #154 |
humans polymorphism | #155 |
snpheritability | #155 |
ncsr | #155 |
clarification | #155 |
year follow | #155 |
genomewide scan | #155 |
tests male | #156 |
interpersonal functioning | #156 |
prospective controlled study | #156 |
600000 | #156 |
n84 | #156 |
genetic risk | #156 |
panic disorder agoraphobia | #157 |
dopamine d4 | #157 |
enigma consortium | #157 |
new knowledge | #157 |
cognitive tempo | #158 |
adolescents | #158 |
clinical diagnostic | #158 |
oprm1 | #158 |
htr2c | #158 |
primary setting | #158 |
greatest | #158 |
sledai | #158 |
ppp2r2b | #158 |
drd4 genotype | #158 |
genetic linkage | #158 |
myo5b | #158 |
adult human brain | #159 |
patients substance | #159 |
teachers parents | #159 |
dav | #159 |
quetiapine treatment | #159 |
selfratings | #159 |
nonpersistent | #159 |
smds | #160 |
medial temporal | #160 |
humans impulsive | #160 |
age onset | #160 |
separation anxiety disorder | #160 |
schizophrenia bipolar | #161 |
behavioral difficulties | #161 |
hyperactivity disorders | #161 |
population samples | #161 |
tic symptoms | #161 |
genetic component | #161 |
adult adhd patients | #161 |
disorder depression | #162 |
empirical tests | #162 |
140 | #162 |
rats wky | #162 |
cooccurring disorders | #162 |
disorder clinical | #162 |
ksadspl | #162 |
paternal age | #163 |
neuropsychological tests | #163 |
sample | #163 |
dsmiv | #163 |
neurobiology | #163 |
dn cells | #163 |
5htt | #163 |
diagnostic status | #164 |
complex phenotype | #164 |
impairments | #164 |
illness schizophrenia | #164 |
anxiety attention | #164 |
familial liability | #164 |
washington university | #165 |
neurocognitive performance | #165 |
risk subsequent | #165 |
boys girls | #165 |
years children | #165 |
alcohol disorders aud | #166 |
antidepressant therapy | #166 |
shared environment | #166 |
cotwins | #166 |
receptor gene | #166 |
symptom reduction | #166 |
domain criteria | #166 |
12–14 | #166 |
earlyonset schizophrenia | #166 |
linkage genetic | #166 |
genetic influence | #166 |
moderates | #167 |
association obesity | #167 |
ipsych | #167 |
leonard | #168 |
children 6 years | #168 |
neurocognitive functions | #168 |
wisciii | #168 |
polygenic architecture | #168 |
perseverations | #169 |
genetic association analysis | #169 |
international congress | #169 |
n111 | #169 |
matter microstructure | #169 |
multifactorial | #169 |
duration illness | #169 |
conditional probability | #170 |
lgi | #170 |
arrb2 | #170 |
traumas | #170 |
disorders young | #170 |
risk gene | #170 |
cfg | #170 |
anxiety child | #170 |
pharmacodynamic properties | #170 |
single nucleotide schizophrenia | #170 |
n91 | #171 |
genesets | #171 |
child psychiatry | #171 |
functional laterality humans | #171 |
immune disorders | #172 |
treatment studies | #172 |
inattention impulsivity | #172 |
enuresis | #173 |
interpersonal sensitivity | #173 |
disorders study | #173 |
gabbr1 | #174 |
male mental | #174 |
tics | #175 |
subsyndromal | #175 |
large samples | #175 |
confounds | #176 |
development schizophrenia | #176 |
mph placebo | #176 |
ascertainment | #177 |
patients opioid | #177 |
confounded | #177 |
suicide death | #177 |
kraepelin | #177 |
independent datasets | #177 |
disorders sex | #177 |
hyperactive children | #177 |
parent rated | #178 |
n78 | #178 |
strong genetic component | #178 |
cortical surface | #178 |
atomoxetine atx | #179 |
pregnancy children | #179 |
behaviorally | #179 |
genetic confounding | #179 |
underpinnings | #179 |
strongest evidence | #179 |
gene interactions | #179 |
cvlt | #180 |
nagelkerke | #180 |
copy variants | #180 |
connectivity networks | #180 |
perceptual disorders | #181 |
combinatory | #181 |
unemotional traits | #181 |
mothers pregnancy | #181 |
271 | #182 |
scz bip | #182 |
structured | #182 |
htr4 | #182 |
control participants | #182 |
phenocopies | #182 |
studies gwas | #183 |
rating | #183 |
genotype humans | #183 |
mechanistic target | #183 |
psychometric testing | #183 |
based morphometry | #184 |
wei | #184 |
effects atomoxetine | #184 |
reading difficulties | #184 |
phenocopy | #185 |
long acting | #185 |
allison | #185 |
pdd | #185 |
genome human | #185 |
n‐acetylcysteine | #185 |
reward sensitivity | #185 |
biomarker studies | #186 |
predominately | #186 |
statistical female | #186 |
hyperactivity symptoms | #186 |
218 | #186 |
risperidone placebo | #187 |
schizophrenia major depression | #187 |
stratifying | #187 |
schizophrenia evidence | #187 |
3 untranslated region | #188 |
depression treatment | #188 |
parahippocampus | #188 |
autocorrelation | #188 |
blood biomarkers | #188 |
enigma | #188 |
differential association | #189 |
bna | #189 |
undertreatment | #189 |
genetic correlations | #189 |
medication adhd | #190 |
scwt | #190 |
childhood | #190 |
linkage evidence | #190 |
functioning children | #190 |
greater activation | #191 |
psychiatric phenotypes | #191 |
clarify | #191 |
mph children | #191 |
implicated | #191 |
dopamine genes | #191 |
schedule female | #191 |
social dysfunction | #191 |
fsiq | #191 |
mood disorder | #191 |
iasp | #192 |
612 years | #192 |
association response | #192 |
freedman | #194 |
inconsistent findings | #194 |
joseph | #194 |
cognitive endophenotypes | #195 |
sza | #195 |
polymorphisms snps | #195 |
placebo p001 | #195 |
clinical global | #195 |
perinatal complications | #197 |
overactivity | #197 |
wm performance | #197 |
arhgef9 | #197 |
neural substrates | #197 |
dependence symptoms | #197 |
ptk2b | #198 |
lifetime diagnosis | #198 |
snps schizophrenia | #198 |
mdd scz | #198 |
g×s | #198 |
developmentally | #198 |
asic1a | #199 |
male | #199 |
male phenotype | #199 |
specific genes | #199 |
bsd | #199 |
childhood symptoms | #199 |
raises | #199 |
mri data | #200 |
small samples | #200 |
disruptive disorders | #200 |
asd adhd | #200 |
childhood attention | #200 |
neuropsychological battery | #200 |
parents schizophrenia | #201 |
functional genomics | #201 |
disorder humans | #201 |
catecholomethyltransferase | #201 |
cognitive flexibility | #202 |
pain tolerance | #202 |
control association | #203 |
neuropsychological correlates | #203 |
childhood adulthood | #203 |
stopsignal task | #203 |
pdq | #203 |
unaffected | #203 |
genetic liability | #203 |
extend | #204 |
microsatellite marker | #204 |
concurrent validity | #204 |
attentional control | #204 |
schizophreniform | #204 |
respond | #204 |
adolescent psychiatry | #204 |
selfdirectedness | #206 |
genes risk | #206 |
nonshared | #206 |
uptodate | #206 |
method drug | #207 |
sluggish cognitive tempo | #207 |
prkg1 | #208 |
susceptibility schizophrenia | #208 |
prolactin levels | #208 |
parental alcohol | #208 |
variable expression | #209 |
baseline follow | #209 |
clinical benefits | #209 |
correspondence | #210 |
5year followup | #210 |
park2 | #210 |
acds | #210 |
maudsley | #210 |
n96 | #210 |
60mg | #210 |
predisposition disease | #211 |
greater risk | #211 |
vntr polymorphism | #211 |
stroop task | #212 |
adult patients adhd | #212 |
grm7 | #212 |
apoe4 allele | #212 |
hkdc1 | #212 |
dimensional models | #212 |
ps005 | #212 |
sampling strategy | #213 |
sought | #213 |
trauma ptsd | #213 |
replication studies | #213 |
negative outcomes | #213 |
humans neuropsychological | #214 |
continuous performance test | #214 |
rare cnvs | #214 |
suggestive evidence | #214 |
cvltii | #214 |
schizophrenia chinese | #214 |
disorders models | #214 |
bilag | #215 |
lifetime version | #215 |
male mental disorders | #215 |
adult cognition | #215 |
vivo correlation | #216 |
functional mri study | #216 |
antisocial personality | #217 |
glr | #217 |
male schizophrenia | #217 |
chromosome 15 | #217 |
trim31 | #218 |
hippocampal subfield | #218 |
gene based | #218 |
panic | #218 |
parental | #218 |
misunderstood | #219 |
polygenic | #219 |
study selection | #219 |
snpa | #220 |
drug double | #220 |
normal controls | #220 |
studies cognition | #221 |
telephone interview | #221 |
irritable mood | #221 |
parental psychopathology | #221 |
symptoms adults | #221 |
triangularis | #221 |
n76 | #222 |
methyltransferase comt | #222 |
score male | #222 |
patient engagement | #222 |
childhoodonset | #222 |
diagnoses | #222 |
learning disability | #223 |
revisited | #223 |
study findings | #223 |
gria2 | #224 |
adhd sleep | #224 |
axis disorders | #224 |
abnormalities schizophrenia | #224 |
effective treatments | #224 |
sensing ion | #224 |
coordination disorder | #225 |
bipolar spectrum | #225 |
default network | #225 |
children placebo | #226 |
inattentiveness | #226 |
subfields | #226 |
hk3 | #226 |
disorder study | #227 |
scales psychotic | #227 |
criteria diagnosis | #227 |
unemotional | #227 |
individual variability | #227 |
dependent variables | #227 |
subcortical regions | #227 |
age subjects | #228 |
male twins | #228 |
atomoxetine treatment | #228 |
comorbid anxiety disorders | #228 |
control based | #228 |
equally | #229 |
birth complications | #229 |
structural abnormalities | #229 |
overlapped | #229 |
psychiatric outcomes | #230 |
international multicenter | #231 |
4years | #231 |
risk indicators | #231 |
heritable | #231 |
commission errors | #231 |
differences prevalence | #232 |
hyperactivity behavior | #232 |
serotonin transporter gene | #232 |
candidate genes | #234 |
study sample | #234 |
worse performance | #234 |
disorder medication | #235 |
discriminating | #235 |
probabilistic forecasts | #235 |
shr wky rats | #236 |
route administration | #238 |
placebo response | #238 |
agoraphobia | #238 |
reliably | #238 |
fifty years | #238 |
allelic heterogeneity | #239 |
pdag | #240 |
healthy siblings | #240 |
scientific data | #240 |
patients siblings | #240 |
acid oxidase | #240 |
nosology | #240 |
disorder asd | #241 |
doubleblind | #241 |
adolescent offspring | #241 |
symptoms quality | #241 |
adequately | #241 |
joint analysis | #242 |
psychiatric comorbidities | #242 |
impulsive choice | #242 |
reward processing | #242 |
neurodevelopmental model | #242 |
sodium hydrogen | #242 |
valid | #243 |
onset obsessive | #243 |
female | #243 |
aggressive behaviors | #243 |
patients relatives | #243 |
giftedness | #244 |
n74 | #244 |
disorder ptsd | #245 |
population differences | #245 |
5ht2a receptor | #245 |
adversity | #245 |
paliperidone | #245 |
interregional | #245 |
cadm2 | #246 |
dsmivtr | #246 |
community controls | #246 |
expression genetic | #246 |
812 | #247 |
motor performance | #247 |
cigarette smoking | #248 |
epigenetic studies | #248 |
studies associations | #248 |
chinese families | #248 |
developmental disorder | #249 |
childs | #251 |
behavioral characteristics | #251 |
german patients | #252 |
hypoactivation | #252 |
female subjects | #253 |
tourette | #253 |
genomewide association | #253 |
iqs | #253 |
intellect | #253 |
schizophrenia adult | #254 |
cpt performance | #254 |
kappas | #254 |
study schizophrenia | #254 |
benzodiazepine | #254 |
studies metaanalysis | #254 |
conduct problems | #255 |
larsson | #256 |
cacna1c gene | #256 |
shared genetic | #256 |
biochemical studies | #256 |
carlson | #257 |
children adhd symptoms | #257 |
endorsement | #259 |
parental depression | #259 |
year study | #259 |
piq | #260 |
n61 | #260 |
pharmacotherapy | #261 |
dexamphetamine | #261 |
diagnosis | #261 |
anxiety depressive disorders | #261 |
obsessive compulsive disorder | #263 |
selfreports | #263 |
sex factors | #263 |
genomewide linkage scan | #263 |
fluid intelligence | #263 |
22q11ds | #263 |
adverse health | #264 |
attention problems | #264 |
distinct subtypes | #264 |
confirm | #264 |
disorder personality | #264 |
conceptualized | #264 |
long term outcomes | #265 |
5090 | #266 |
new models | #266 |
diagnostic validity | #266 |
schizophrenia cases | #266 |
ptsd risk | #266 |
phenotype schizophrenia | #267 |
scz mdd | #267 |
diagnosis schizophrenia | #268 |
neuropsychological impairment | #268 |
strong support | #268 |
genetic approaches | #268 |
diagnostic process | #269 |
years baseline | #269 |
test scores | #269 |
withdrawn | #270 |
phlda1 | #270 |
segregate | #270 |
largest | #270 |
age effects | #270 |
adult psychiatric | #271 |
circadian genes | #271 |
symptoms assessed | #271 |
social adversity | #271 |
genetic overlap | #271 |
sibling pairs | #271 |
diagnostic issues | #272 |
structural brain | #272 |
schizophrenia siblings | #273 |
alcohol smoking | #273 |
rora | #273 |
4year | #273 |
search terms | #273 |
szs | #273 |
statistics topic | #273 |
age | #273 |
444 | #273 |
sleep behavior | #274 |
22 years | #274 |
maf1 | #275 |
underlie | #275 |
surgency | #275 |
reading disability | #275 |
missingness | #276 |
2q | #276 |
t102c | #276 |
familial schizophrenia | #276 |
adolescent risk | #277 |
growing evidence | #277 |
nicotinic schizophrenia | #277 |
adhd healthy controls | #277 |
mania symptoms | #277 |
synaptosomal | #278 |
clinical setting | #278 |
early psychosis | #278 |
manual | #278 |
nr3c1 | #278 |
ocd | #279 |
nicotine dependence | #279 |
silico approach | #279 |
intelligence scale | #279 |
polygenic risk | #280 |
acting | #280 |
cognition female | #280 |
brain volumes | #280 |
child parent | #280 |
remitted | #280 |
rating scale | #280 |
abuser | #280 |
n47 | #280 |
disorders adult | #281 |
phenotyped | #281 |
premature death | #281 |
individuals | #281 |
psychotic bipolar | #281 |
response inhibition | #282 |
onset ocd | #282 |
reading problems | #282 |
collaborative analysis | #282 |
5ht1b | #282 |
continue | #283 |
titrated | #283 |
antisocial behaviors | #283 |
velo | #283 |
aspd | #284 |
normal variation | #285 |
3untranslated region | #285 |
neoffi | #285 |
quantitative traits | #285 |
gria3 | #285 |
neuroanatomical | #285 |
explication | #286 |
scale children | #286 |
siblings patients | #286 |
quantitative analyses | #286 |
swanson | #286 |
clues | #286 |
effects age | #287 |
deficit schizophrenia | #288 |
schizophrenia abnormalities | #288 |
postmortem brain | #289 |
bmisds | #289 |
22q112 | #290 |
disease haplotypes | #290 |
pediatric ocd | #290 |
psychiatric traits | #290 |
subcortical volumes | #291 |
low serum levels | #291 |
publication bias | #291 |
substrain | #292 |
modest | #293 |
groups children | #293 |
hypertensive rat | #294 |
cognition disorders | #294 |
subjective responses | #294 |
salary | #294 |
post‐traumatic stress disorder | #295 |
interference control | #295 |
psychosis schizophrenia | #295 |
dtnbp1 | #295 |
risk factors children | #295 |
european populations | #295 |
adverse impact | #295 |
continuous performance | #296 |
ldsc | #296 |
executive functions | #296 |
obesity overweight | #297 |
anxiety disorder | #297 |
early onset | #297 |
asd traits | #297 |
discriminated | #298 |
diagnostic approach | #298 |
reanalysis | #298 |
negative symptom | #299 |
predisposition | #299 |
qvalues | #300 |
effects stress | #300 |
cortical thickness | #300 |
psychiatric hospitalization | #301 |
roc analysis | #301 |
cognitive measures | #301 |
emotional problems | #302 |
published literature | #302 |
states adolescent | #302 |
intrasubject variability | #302 |
prefrontal function | #302 |
height body | #303 |
permuted | #303 |
psychometrics | #303 |
795 | #304 |
psychiatric conditions | #304 |
dsm5 | #305 |
ats | #305 |
manifest | #305 |
case subjects | #305 |
affective disorders | #305 |
interviewers | #305 |
aggressive behavior | #305 |
early morning | #306 |
dopamine transporter | #306 |
learning disorder | #307 |
n62 | #307 |
general psychopathology | #308 |
membrane transport | #309 |
documented | #309 |
omission errors | #309 |
gene environment | #309 |
perseveration | #309 |
myh9 | #309 |
spencer | #309 |
memory wm | #310 |
life social support | #310 |
adolescent aggression | #310 |
efficacy treatment | #310 |
genetic schizophrenia | #310 |
motor domain | #310 |
rdoc | #311 |
mainstays | #312 |
stroop test | #312 |
childhood adolescence | #312 |
gender age | #312 |
npsr1 | #313 |
mapping female | #313 |
genetic analyses | #314 |
underscore | #314 |
risk estimation | #315 |
bedtimes | #315 |
asb | #317 |
dorsolateral prefrontal cortex | #317 |
replicated | #317 |
schizophrenia review | #318 |
demonstrable | #318 |
5ht2c | #319 |
n55 | #319 |
individual genes | #319 |
adolescent adrenergic | #320 |
addictive disorders | #321 |
shared genetic influences | #321 |
gene | #321 |
intelligence tests | #321 |
robins | #322 |
127 | #322 |
humans longitudinal | #322 |
risperidone treatment | #322 |
bipolar type | #322 |
abusers | #323 |
time variability | #323 |
guanfacine | #324 |
nolan | #324 |
conceptual models | #324 |
manic | #325 |
neonatal abstinence syndrome | #326 |
yielded | #326 |
sex characteristics | #326 |
spurious | #327 |
status female | #327 |
xq26 | #327 |
impaired | #327 |
comprised | #328 |
etiologic | #328 |
disorders pervasive | #329 |
8q | #329 |
sexdifferences | #330 |
overrepresented | #330 |
metaanalyses | #330 |
drug response | #331 |
scores patients | #331 |
htr2a | #331 |
women schizophrenia | #332 |
expression brain | #333 |
txndc5 | #333 |
naltrexone | #333 |
familial factors | #333 |
obesity diabetes | #334 |
cognitive dysfunctions | #334 |
multiple comparisons | #334 |
mood disorders | #335 |
forthcoming | #335 |
adler | #335 |
24weeks | #335 |
inferior parietal lobule | #336 |
humans mental | #336 |
persist | #336 |
methylphenidate placebo | #336 |
rey | #336 |
tph2 | #337 |
mobp | #337 |
neuropsychological test | #337 |
asd individuals | #337 |
777 | #337 |
disentangle | #338 |
psychopathological | #339 |
patients attention | #339 |
replications | #339 |
evening | #339 |
disorder ocd | #340 |
evidence linkage | #340 |
exclusion criteria | #340 |
consistently | #340 |
pnmt | #340 |
intelligence | #341 |
encompassing | #341 |
placebo effects | #341 |
treatment bipolar | #341 |
visual memory | #342 |
phobic | #342 |
bipolarity | #342 |
maoa genotype | #342 |
multicenter analysis | #342 |
neuroimaging studies | #342 |
schizoaffective disorder | #344 |
tbv | #344 |
integrated analysis | #344 |
frontal pole | #344 |
comorbid diagnoses | #344 |
mood problems | #344 |
systematically | #345 |
casecontrol studies | #345 |
catechol methyltransferase | #345 |
gifts | #346 |
864 | #346 |
study genotype | #347 |
confused | #347 |
mdd bpd | #347 |
psychotic | #348 |
tic severity | #348 |
converging | #348 |
collaborative study | #349 |
schizotypal personality disorder | #349 |
temporal processing | #349 |
methylphenidate atomoxetine | #350 |
aetiological | #350 |
adolescent anxiety | #350 |
suspiciousness | #351 |
distractibility | #352 |
receptor genes | #352 |
disequilibrium | #352 |
adults children | #352 |
impairing | #353 |
disease genome | #353 |
child attention | #354 |
executive attention | #354 |
maob | #354 |
reln | #354 |
disorders middle | #354 |
gabra1 | #354 |
genetic environmental | #354 |
brain atlas | #354 |
substantial | #354 |
male adolescent | #355 |
dsmiii | #355 |
prodh | #355 |
rgs4 | #355 |
schizophrenia data | #356 |
heterogeneous disorder | #356 |
phobic disorders | #356 |
chrna7 | #357 |
measures attention | #357 |
children anxiety disorders | #357 |
gottesman | #358 |
persists | #359 |
disorder patients | #359 |
maternal cigarette smoking | #359 |
deviant | #359 |
psychiatric symptoms | #359 |
linkage analysis | #360 |
symptom scores | #360 |
neuroleptic treatment | #361 |
chromosomal regions | #361 |
n54 | #361 |
social adjustment | #362 |
dorsolateral prefrontal | #363 |
genetic findings | #364 |
tid | #365 |
paralimbic | #365 |
elevated risk | #366 |
confirmation | #366 |
core symptoms | #366 |
memory load | #367 |
pediatric populations | #367 |
771 | #367 |
bpd mdd | #368 |
comparison groups | #368 |
study entry | #368 |
risk psychopathology | #368 |
young adulthood | #369 |
702 | #369 |
hyperactivityimpulsivity | #369 |
differential involvement | #369 |
differential susceptibility | #370 |
representativeness | #370 |
nervousness | #370 |
current concepts | #371 |
schizophrenia risk | #371 |
damphetamine | #371 |
comt gene | #372 |
replicate | #372 |
endorse | #372 |
prevention strategies | #372 |
executive function | #373 |
5httlpr | #373 |
genomewide association studies | #373 |
driving performance | #374 |
small sample | #374 |
snp heritability | #374 |
916 | #375 |
scz | #375 |
dozens | #375 |
wide analysis | #375 |
medication children | #376 |
emphases | #376 |
teenage | #376 |
memory short | #377 |
child adolescent | #377 |
sas | #377 |
children medication | #377 |
genetic architecture | #377 |
data studies | #377 |
impression | #378 |
children adolescents | #378 |
schizotypal personality | #378 |
control adults | #379 |
marriages | #379 |
pearson | #380 |
converged | #380 |
ht1b | #380 |
opd | #380 |
youths | #380 |
disorder diagnostic | #381 |
methylphenidate children | #381 |
receptors dopamine | #381 |
overlap | #381 |
relevant articles | #381 |
culmination | #381 |
invaluable | #381 |
general cognitive ability | #381 |
chisquare | #382 |
adolescent patients | #382 |
psychopharmacological treatment | #383 |
antimanic | #383 |
carefully | #383 |
psychopathologies | #383 |
researched | #384 |
summary statistics | #384 |
7r | #385 |
gad2 | #385 |
18p | #386 |
multigenerational | #386 |
treatment children | #386 |
neural activation | #387 |
chinese subjects | #387 |
contrasted | #388 |
evenings | #388 |
npas2 | #388 |
versa | #388 |
childhood depression | #389 |
adhd symptomatology | #389 |
brain circuits | #390 |
lefthandedness | #390 |
perinatal morbidity | #390 |
studies children | #390 |
handedness | #390 |
disorder symptoms | #390 |
interaction genetic | #391 |
genetic predisposition | #391 |
comorbid substance | #392 |
schizophrenia susceptibility | #392 |
lambert | #392 |
p54 | #393 |
substance users | #394 |
genes expression | #394 |
function humans | #395 |
hippocampal subfields | #395 |
dopamine norepinephrine | #395 |
adolescents adults | #396 |
disorders schizophrenia | #397 |
schizophrenia disorder | #397 |
psychometric | #397 |
fbat | #397 |
mental health children | #397 |
3methoxy4hydroxyphenylglycol | #397 |
earlier onset | #398 |
spm8 | #398 |
wandering | #398 |
clinical risk psychosis | #398 |
neuropsychological testing | #400 |
control sample | #401 |
core symptom | #402 |
inattention symptoms | #402 |
academic outcomes | #402 |
suffocation | #402 |
inconsistencies | #403 |
relations male | #403 |
implications findings | #403 |
hyperparameter | #405 |
psychostimulants | #405 |
parahippocampal | #406 |
n52 | #406 |
diagnosis children | #406 |
neuropsychiatric conditions | #406 |
vntrs | #406 |
attending | #407 |
childhood risk | #408 |
cognitive inhibition | #408 |
behavior genetics | #409 |
0038 | #409 |
communitybased | #409 |
substance | #410 |
distinct subsets | #410 |
dextroamphetamine | #411 |
twin study | #411 |
children studies | #411 |
reading comprehension | #411 |
impulsive behavior | #411 |
interview | #412 |
apoe4 | #412 |
tourette syndrome | #412 |
psychotic disorders | #412 |
consistent evidence | #412 |
childhood anxiety | #412 |
neanderthal | #412 |
systematic literature search | #413 |
anticipation | #413 |
moderated | #413 |
performance tests | #414 |
151 | #414 |
reviewing | #414 |
polymorphism snp | #415 |
volition | #415 |
schizotypal | #416 |
elucidating | #416 |
genetic receptor | #416 |
effects brain | #417 |
functional effects | #417 |
conferred | #418 |
adolescent psychiatric | #418 |
adult intelligence | #418 |
questionnaires adolescent | #419 |
deletion syndrome | #419 |
srsa | #419 |
genetic association | #419 |
antidepressive agents | #420 |
kdm4a | #420 |
daily doses | #420 |
dopamine d4 receptor | #420 |
adult subjects | #421 |
modestly | #421 |
sexes | #421 |
operating characteristic | #422 |
drug dependence | #422 |
cdis | #422 |
iccs | #422 |
reliability validity | #423 |
tricyclic | #423 |
medicated | #423 |
gcta | #424 |
characteristic curve | #424 |
transport proteins | #425 |
discovery sample | #425 |
subtests | #425 |
cardiff | #426 |
parent ratings | #426 |
attain | #427 |
hum | #427 |
diversion | #428 |
brain volume | #428 |
spectrum disorders | #428 |
persistent symptoms | #429 |
male obsessive | #430 |
personality development | #431 |
disentangling | #431 |
operating characteristics | #432 |
teacher | #432 |
uniquely | #433 |
peps | #434 |
wistarkyoto | #435 |
cprs | #436 |
frequency genotype | #436 |
perceptual organization | #436 |
1433 | #436 |
12q | #436 |
relatives patients | #437 |
grin2a | #437 |
lower scores | #437 |
disorder brain | #437 |
toddlerhood | #438 |
correlation coefficients | #438 |
visual learning | #438 |
adolescent psychopathology | #438 |
srs2 | #438 |
impulsiveness | #438 |
risk psychosis | #439 |
genetic genetic predisposition | #439 |
nominal | #439 |
digit span | #439 |
22q112ds | #439 |
major risk factor | #440 |
snps association | #440 |
aged neuropsychological | #440 |
method female | #440 |
trex | #441 |
corroborated | #441 |
gmo | #441 |
post hoc analysis | #441 |
meaningful | #441 |
allelic association | #441 |
white matter microstructure | #441 |
logistic regression model | #442 |
virtual histology | #442 |
adult analysis | #442 |
female functional | #442 |
planum temporale | #442 |
disorders autism | #442 |
n80 | #443 |
disorders surveys | #444 |
emphasize | #444 |
10 year | #444 |
conferring | #444 |
differential female | #444 |
pcdh10 | #445 |
nucleotide receptors | #446 |
534 | #446 |
statistic | #446 |
ntrk3 | #446 |
862 | #446 |
holland | #447 |
originally | #448 |
motor coordination | #448 |
genome wide | #448 |
behavior child | #448 |
earlier age | #449 |
expressiveness | #449 |
wistar kyoto | #450 |
risk variants | #450 |
early response | #450 |
sex | #451 |
exceptions | #451 |
clinical expression | #452 |
brain abnormalities | #452 |
subsequent risk | #452 |
prevalence correlates | #452 |
chat | #456 |
children adolescent | #456 |
79 | #457 |
zscores | #457 |
psychiatry | #457 |
independently | #458 |
masse | #458 |
preliminary study | #458 |
structural magnetic | #458 |
polygenic risk score | #460 |
522 | #460 |
psychotic disorders schizophrenia | #460 |
genetic correlation | #460 |
lander | #460 |
22q112 deletion | #460 |
smoking pregnancy | #461 |
hyperkinesis | #461 |
jw | #462 |
d4 | #463 |
neuroanatomy | #465 |
pregnancy complications | #465 |
life treatment | #465 |
affection | #465 |
decrements | #465 |
runs | #466 |
gene sets | #466 |
control rates | #466 |
inbred wky | #467 |
mini | #467 |
anxiety depressive | #467 |
bpad | #468 |
subjects patients | #469 |
cacna1c | #470 |
patient adherence | #470 |
genetic effects | #470 |
disorders treatment | #470 |
receiver operating | #471 |
remission relapse | #471 |
psychology adolescent | #472 |
risk allele | #472 |
response remission | #473 |
chrna4 | #473 |
environmental risk factors | #474 |
plp1 | #474 |
norepinephrine transporter | #474 |
developmental coordination | #476 |
cautious | #476 |
opioid addiction | #476 |
multiple measures | #477 |
obesity children | #477 |
broader | #478 |
multiplex families | #479 |
dysthymia | #479 |
5th | #479 |
humans | #480 |
symptom | #480 |
genetic risk variants | #480 |
adds | #480 |
semistructured | #481 |
cortex child | #481 |
diagnostic categories | #481 |
data extraction | #482 |
maternal anxiety | #482 |
genotyped | #482 |
etiology | #483 |
arithmetic | #483 |
treatment methylphenidate | #484 |
nfil3 | #484 |
sml | #484 |
verbal learning | #484 |
conception | #484 |
adulthood | #485 |
agents bipolar | #485 |
756 | #485 |
epidemiologically | #486 |
outcome variables | #486 |
baseline age | #486 |
123 | #487 |
evaluates | #487 |
adult anxiety | #487 |
symptom dimensions | #487 |
spontaneity | #488 |
unpublished | #489 |
longterm effects | #489 |
genetic disorders | #489 |
female adolescents | #489 |
administration schedule | #490 |
neuropsychiatric disorder | #490 |
schizophrenia autism | #490 |
shared environmental | #490 |
smoking prevention | #492 |
schizophrenia age | #492 |
common variant | #492 |
pnds | #493 |
overlapping | #493 |
frequency genetic | #495 |
antisocial personality disorder | #495 |
late adolescence | #495 |
anxiety | #497 |
schizophrenia patients | #497 |
psychobiology | #497 |
separation anxiety | #497 |
pair human | #497 |
restlessness | #497 |
longitudinal studies | #498 |
bonferroni | #498 |
addressed | #499 |
genetic mechanisms | #499 |
placebos | #499 |
daoa | #499 |
candidate | #499 |
comt val158met polymorphism | #500 |
identifying | #500 |
case reports | #500 |
d4 receptors | #501 |
rat strains | #501 |
nocebo | #501 |
additional evidence | #503 |
verbal memory | #503 |
865 | #503 |
circadian clock genes | #505 |
child executive | #505 |
n26 | #506 |
fallacy | #506 |
subscale | #506 |
continued | #507 |
cooperativeness | #507 |
tobacco disorder | #508 |
reflecting | #508 |
developing schizophrenia | #509 |
delay discounting | #509 |
agg | #510 |
educational status | #511 |
shared | #511 |
dichotomous | #511 |
obsessive compulsive | #512 |
identifiable | #512 |
p80 | #512 |
95 death | #512 |
lod | #513 |
risk haplotype | #513 |
disproportionate | #514 |
coaggregation | #514 |
assessments | #515 |
phis | #515 |
morning | #515 |
disorders depression | #515 |
total sample | #516 |
normal control | #516 |
contributing | #517 |
n39 | #517 |
cognitive traits | #517 |
15q | #518 |
missing link | #519 |
pbat | #520 |
fn1 | #520 |
environmental influences | #520 |
dichotic | #521 |
specificity ppv | #521 |
gyrus cinguli | #521 |
polymorphism single | #522 |
selfreport | #522 |
disorder obsessive | #522 |
social class | #522 |
dibenzothiazepines | #523 |
attention memory | #523 |
dedication | #524 |
assortative | #524 |
adult bipolar | #524 |
dmi | #524 |
phg | #524 |
pacific island | #525 |
sciencedirect | #525 |
covariates | #525 |
disorder treatment | #525 |
clinical diagnoses | #525 |
affiliations | #526 |
persistence | #527 |
functioning | #527 |
criminality | #527 |
depression anxiety disorders | #528 |
adverse life events | #528 |
design study | #528 |
adolescent children | #528 |
symptomatic remission | #528 |
ruled | #529 |
community samples | #529 |
parental reports | #529 |
flnc | #529 |
compulsive disorder | #529 |
abrupt | #529 |
control children | #530 |
tagsnps | #530 |
medications | #531 |
strongest | #531 |
increased burden | #531 |
n40 | #532 |
existing studies | #532 |
autism schizophrenia | #532 |
clinical sample | #533 |
subjects age | #533 |
analyses conducted | #534 |
temperament character | #534 |
intercorrelations | #535 |
asd | #535 |
selective review | #535 |
global impression | #537 |
parsing | #537 |
models genetic | #538 |
child adhd | #538 |
autistic symptoms | #538 |
d4 receptor | #539 |
personality factors | #541 |
milder | #541 |
lobe humans | #542 |
single nucleotide | #543 |
disease genotype | #543 |
taiwanese | #543 |
complexities | #544 |
severe symptoms | #544 |
independent samples | #544 |
ld | #545 |
population sample | #545 |
cognitive impairments | #546 |
choice behavior | #546 |
genetic influences | #547 |
healthy control subjects | #548 |
computer program | #548 |
functional variant | #548 |
clash | #549 |
dichotomized | #549 |
oral route | #549 |
risk children | #549 |
behavior male | #549 |
schizophrenia study | #549 |
patients schizophrenia | #549 |
nonclinical sample | #549 |
765 | #550 |
genetic pathways | #550 |
fam | #550 |
define | #551 |
ideally | #551 |
motor inhibition | #551 |
case control | #551 |
performance test | #552 |
major diagnosis | #552 |
verbal | #553 |
n29 | #553 |
preadolescent | #554 |
release oral | #555 |
viewed | #555 |
suggests | #555 |
prs schizophrenia | #555 |
spectrum disorder | #556 |
phenotypic features | #556 |
neuropsychiatric diseases | #557 |
nogo task | #557 |
child anxiety | #557 |
africanamerican | #558 |
neurodevelopmental | #558 |
equivocal | #558 |
justify | #559 |
gray matter volumes | #560 |
response variability | #560 |
higher rate | #561 |
profoundly | #563 |
caregivers children | #563 |
risk smoking | #565 |
adolescents risk | #565 |
risky behaviors | #566 |
4th edition | #566 |
patients sud | #566 |
twins female | #566 |
intermediate phenotypes | #566 |
3050 | #567 |
neurocognitive impairment | #567 |
haplotype | #567 |
unaffected relatives | #568 |
replication study | #569 |
onsets | #570 |
10−8 | #570 |
environment interaction | #570 |
diverging | #570 |
risk genes | #571 |
birthday | #571 |
keywords | #571 |
dose reduction | #573 |
irritability | #574 |
obesity body mass | #574 |
white matter abnormalities | #574 |
questionnaires adult | #575 |
inbred shr | #575 |
spaced | #576 |
gyri | #576 |
asd diagnosis | #576 |
parent | #577 |
schizophrenia sample | #577 |
individually | #577 |
medical genetics | #577 |
chromosomes human | #577 |
finetuning | #578 |
82 | #578 |
impulsivity | #578 |
symptoms children | #579 |
subsample | #579 |
5httlpr polymorphism | #580 |
cold pressor test | #580 |
development anxiety | #580 |
preschool age | #580 |
haplotype analysis | #581 |
rdc | #582 |
psychiatric association | #582 |
apol1 | #582 |
drd1 | #582 |
delinquent behavior | #583 |
3rd | #583 |
new approaches | #584 |
hk1 | #584 |
separately | #585 |
fine mapping | #585 |
data children | #585 |
neuroanatomical correlates | #586 |
traumatized | #587 |
defaultmode network | #588 |
compared controls | #588 |
nback task | #588 |
examine | #588 |
138 | #589 |
haplotypes humans | #590 |
40mg | #591 |
estonian | #591 |
patients comorbid | #591 |
behavior adult | #591 |
criticism | #593 |
2005 | #594 |
concordant | #594 |
brain child | #595 |
cognition schizophrenia | #596 |
overrepresentation | #596 |
generalizable | #597 |
snap25 | #597 |
discounted | #597 |
nonpharmacologic | #597 |
new directions | #598 |
899 | #598 |
affymetrix | #598 |
differences brain | #600 |
genetic factors | #601 |
specific phobia | #603 |
diagnosing | #604 |
diagnostic specificity | #604 |
clinical settings | #604 |
disorganized | #606 |
clinician | #606 |
cognitive outcomes | #606 |
performance children | #606 |
personality traits | #607 |
social environment | #607 |
sizeable | #608 |
small fraction | #608 |
4 6 | #608 |
gold standard | #609 |
true | #609 |
antisocial behavior | #609 |
executive dysfunctions | #609 |
functional outcomes | #610 |
polygenic risk scores | #610 |
informant | #611 |
pleiotropic | #612 |
complex disorders | #612 |
chromosome 6 | #613 |
educational achievement | #614 |
grandmothers | #614 |
schizophrenia brain | #614 |
disease etiology | #615 |
curve analysis | #615 |
snp markers | #615 |
behavior disorder | #615 |
genetic epidemiology | #616 |
prevalence severity | #616 |
memory deficits | #616 |
tscores | #617 |
genome scans | #617 |
differ | #618 |
val158met | #618 |
genetic associations | #618 |
african children | #618 |
correcting | #619 |
digeorge | #619 |
genetic markers | #620 |
vigilance | #620 |
md | #621 |
antisocial behaviour | #621 |
confer | #622 |
adverse health outcomes | #623 |
receptor serotonin | #624 |
juvenile delinquency | #624 |
misconceptions | #625 |
executive control | #625 |
executive dysfunction | #625 |
mood stabilizers | #626 |
seeks | #627 |
attentional deficits | #627 |
hrr | #627 |
fibromyalgia | #629 |
treatment disorder | #629 |
child gender | #629 |
schizophrenia findings | #630 |
deficits schizophrenia | #631 |
reject | #631 |
teacher ratings | #632 |
needed | #633 |
girls boys | #634 |
genetic basis | #635 |
tiny | #637 |
icv | #638 |
generalisability | #638 |
obsessivecompulsive disorder | #638 |
disease genotype humans | #639 |
longitudinal | #640 |
advertisement | #641 |
adult outcomes | #641 |
ranks | #641 |
illness duration | #642 |
gateway | #643 |
inconsistent | #643 |
expression genes | #644 |
twin pairs | #645 |
premorbid | #645 |
functioning autism | #646 |
subjects schizophrenia | #646 |
exacerbate | #647 |
methodological | #648 |
17 years | #649 |
galantamine | #650 |
gene association | #652 |
treatment effects | #652 |
avoidant | #652 |
hyperactivity inattention | #653 |
physical conditions | #653 |
128 | #653 |
stroop | #654 |
federation | #654 |
intergenerational transmission | #655 |
bipolar disorder schizophrenia | #656 |
random allocation rats | #656 |
reward anticipation | #656 |
studies evidence | #657 |
psychosocial treatment | #658 |
boldness | #658 |
groups compared | #658 |
impairment | #658 |
hypomanic | #659 |
volumes | #659 |
association exposure | #660 |
core feature | #661 |
poorer performance | #661 |
structural alterations | #662 |
referrals | #662 |
peer relations | #662 |
digeorge syndrome | #665 |
permission | #665 |
lowlevel | #665 |
subcortical | #666 |
dacc | #666 |
psychiatric illnesses | #667 |
mood | #668 |
prominent | #669 |
swedish population | #669 |
phenotypic expression | #672 |
neurobiological | #675 |
time children | #676 |
impulsive behaviors | #677 |
unselected | #678 |
disorders memory | #678 |
sleep difficulties | #679 |
129 | #679 |
middle childhood | #680 |
mental disorders humans | #680 |
psychopathological symptoms | #680 |
neurotic | #681 |
gene frequency | #681 |
trait | #682 |
semantic fluency | #682 |
quetiapine | #682 |
soviet union | #682 |
severe phenotype | #683 |
remitting | #685 |
east asian | #685 |
scales | #685 |
p0019 | #687 |
children groups | #688 |
17q | #688 |
chromosomal region | #688 |
postmortem brains | #689 |
younger children | #689 |
fibromyalgia patients | #689 |
tcas | #694 |
disorder schizophrenia | #694 |
average age | #694 |
testretest reliability | #695 |
participants | #696 |
parcellation | #696 |
cortical surface area | #696 |
pharmacokinetic profile | #697 |
5years | #697 |
4–5 | #697 |
drug abuse | #699 |
122 | #699 |
relevant studies | #699 |
effects methylphenidate | #700 |
nonrandom | #701 |
adult mental | #701 |
quota | #701 |
illness surveys | #701 |
treatmentnaïve | #704 |
gwa studies | #704 |
pleiotropic effects | #704 |
follow studies | #705 |
preschool years | #706 |
pathogenesis schizophrenia | #706 |
adaptive functioning | #706 |
autism spectrum | #708 |
school settings | #709 |
p009 | #709 |
children diagnosed | #710 |
chronic schizophrenia | #713 |
informative | #713 |
maternal report | #714 |
misuse | #714 |
prs | #714 |
dysphoric | #714 |
eric | #714 |
ethanol consumption | #715 |
728 | #715 |
stress disorder | #715 |
disorders substance | #715 |
641 | #716 |
3 weeks | #716 |
contradictory | #717 |
abstraction | #719 |
groundwork | #719 |
meta‐analysis | #720 |
clinical population | #721 |
multiple genes | #721 |
recurrence risk | #722 |
household income | #722 |
memory | #723 |
cognitive load | #724 |
cinguli | #725 |
proponents | #725 |
lateonset | #726 |
gender dysphoria | #726 |
male adolescents | #726 |
common snps | #726 |
schizophrenics | #727 |
attention deficits | #727 |
statistical | #728 |
dizygotic | #728 |
assortative mating | #729 |
structured clinical interview | #729 |
fmri study | #730 |
786 | #730 |
metabotropic glutamate | #731 |
prevention programs | #732 |
correlates | #733 |
git | #733 |
voxel based | #733 |
phenotypic heterogeneity | #734 |
finding | #734 |
wky | #735 |
gyrification | #737 |
life cycle | #737 |
health intervention | #737 |
opioid dependence | #738 |
substancerelated disorders | #738 |
inflation | #739 |
polygenic score | #739 |
validating | #740 |
rapid cycling | #741 |
boston | #742 |
caudate | #742 |
refill | #742 |
time task | #743 |
amphetamines | #744 |
comparators | #744 |
soviet | #745 |
topic twins | #745 |
bupropion | #745 |
compulsive | #746 |
neuropsychological status | #746 |
manifested | #747 |
duplications | #748 |
child interaction | #748 |
adrb1 | #749 |
934 | #750 |
examining | #750 |
fulfilling | #752 |
twins dizygotic | #752 |
molecular genetic analysis | #754 |
347 | #754 |
comt val158met | #755 |
post hoc | #755 |
mental disorders | #756 |
recalled | #756 |
bipolar depression | #756 |
neuroleptics | #756 |
schizophrenia scz | #757 |
nhe | #757 |
disease haplotypes humans | #759 |
renewal | #760 |
sads | #761 |
variation genome | #762 |
artifact | #763 |
matter abnormalities | #764 |
workday | #764 |
likelihoods | #765 |
humans logistic | #765 |
autism asd | #766 |
people schizophrenia | #767 |
substance misuse | #768 |
disinhibition | #769 |
comt polymorphism | #772 |
emerged | #772 |
performance patients | #774 |
parent reported | #776 |
birth rates | #776 |
human pair | #777 |
depressive | #777 |
behavioral phenotypes | #777 |
phenotypes | #778 |
euthymic | #779 |
deletion polymorphism | #779 |
risky behavior | #780 |
weaknesses | #780 |
schizophrenia relationship | #780 |
inheritance | #781 |
wky rats | #782 |
iowa gambling task | #782 |
fourth edition | #783 |
combined analysis | #783 |
questioning | #783 |
emerging roles | #784 |
mega | #784 |
reformulation | #785 |
teaes | #785 |
faced | #786 |
963 | #787 |
pbd | #787 |
adolescence | #787 |
niacin | #788 |
child temperament | #789 |
medial temporal lobe | #790 |
cgi | #791 |
behavioral | #791 |
spelling | #791 |
subtypes | #792 |
clinical criteria | #793 |
individuals schizophrenia | #793 |
association polymorphisms | #794 |
symptom burden | #794 |
motivations | #794 |
delinquent | #796 |
caveats | #796 |
separate | #797 |
additional studies | #800 |
363 | #800 |
genomic regions | #802 |
dopamine d1 receptors | #803 |
prenatal exposure | #803 |
randomized clinical trials | #804 |
stimulant drugs | #804 |
superior frontal | #805 |
dysfunction | #805 |
clinically | #805 |
dorsolateral | #806 |
latent classes | #806 |
novelty seeking | #806 |
male memory | #806 |
developmental perspective | #807 |
lobule | #808 |
hdrs | #809 |
dopamine function | #810 |
ucla | #810 |
phonemic | #811 |
dopamine serotonin | #811 |
adjusting | #811 |
preschool female humans | #811 |
blind | #813 |
coadministration | #815 |
declarative | #816 |
mhpg | #816 |
lasting | #817 |
quantitative measures | #817 |
breakthroughs | #817 |
tryptophan hydroxylase | #817 |
cfb | #817 |
substance dependence | #818 |
single gene | #818 |
epigenetic factors | #818 |
memory attention | #818 |
meeting | #820 |
cortical development | #820 |
counties | #821 |
patients psychotic disorders | #821 |
rated | #821 |
switches | #822 |
hme | #822 |
prefrontal regions | #824 |
transcriptomic analysis | #824 |
parental report | #824 |
common genetic | #825 |
rare coding variants | #825 |
adolescents asd | #827 |
humans models | #827 |
s100a6 | #828 |
treatment interventions | #829 |
timeframe | #830 |
multipoint | #830 |
lifetime prevalence | #831 |
multiple testing | #831 |
prevalent | #831 |
conduct disorders | #832 |
association tests | #832 |
liabilities | #833 |
college students | #834 |
gray | #837 |
sleep disorder | #837 |
n60 | #837 |
aversion | #838 |
matter humans | #838 |
inbred shr rats | #838 |
prescription | #839 |
symptom profiles | #839 |
obstetric complications | #839 |
neurocognition | #841 |
parenthood | #842 |
participants completed | #843 |
sporadic cases | #843 |
biological basis | #844 |
consensus statement | #844 |
facial emotion recognition | #845 |
n35 | #846 |
dnm | #847 |
exception | #847 |
dysregulated | #848 |
gwas summary | #848 |
dgcr8 | #848 |
factor model | #851 |
prefrontal | #855 |
putative | #857 |
nonsignificant | #857 |
heightened risk | #858 |
estimated prevalence | #858 |
putamen | #858 |
schizophrenia healthy | #858 |
nineteen | #859 |
6p | #859 |
preschool | #861 |
handbook | #862 |
heterogeneity | #863 |
delayed effects | #865 |
global assessment | #866 |
seventy | #866 |
glossary | #866 |
crosssectional studies | #867 |
mental | #869 |
nnt | #869 |
hypothesized | #869 |
neurobiological basis | #870 |
specialized | #872 |
753 | #873 |
pediatric | #874 |
shr rats | #874 |
perseverative errors | #874 |
existing evidence | #875 |
comorbidity depression | #875 |
manova | #876 |
genetic counseling | #876 |
positive symptoms | #876 |
hypotheses | #876 |
test performance | #877 |
gender differences | #879 |
externalizing disorders | #879 |
sizes | #881 |
memory functions | #882 |
association genetic | #883 |
altered | #884 |
psychedelics | #886 |
12p | #886 |
171 | #887 |
dynamism | #888 |
delayed | #890 |
cpts | #891 |
n17 | #893 |
n95 | #893 |
obsessive | #893 |
bonn | #894 |
decade | #894 |
veterans affairs | #895 |
480 | #897 |
164 | #898 |
cortical thinning | #902 |
anterior cingulate | #903 |
biological psychiatry | #903 |
bipolar illness | #904 |
genetic contribution | #904 |
aptitude | #904 |
reinforcer | #904 |
sibling | #904 |
weight body | #904 |
visit | #905 |
late childhood | #906 |
826 | #906 |
psychosocial functioning | #906 |
adult aggression | #907 |
standardized difference | #909 |
morphometric | #910 |
ggc | #911 |
symptom control | #911 |
psychosocial | #912 |
pedigrees | #912 |
amygdala reactivity | #912 |
visuospatial memory | #913 |
complications pregnancy | #913 |
underlying pathophysiology | #914 |
versions | #914 |
association age | #916 |
disorder specific | #917 |
school performance | #917 |
cousins | #918 |
sleep children | #920 |
177 | #923 |
pharmacogenetic | #924 |
screening tool | #924 |
dysthymic | #925 |
vulnerability | #925 |
wide | #926 |
dividing | #927 |
developmental trajectories | #927 |
affective disorder | #928 |
nucleotide | #930 |
cpg sites | #930 |
participating | #930 |
permutation | #933 |
heroin addiction | #933 |
194 | #933 |
20mg | #934 |
adolescence young adulthood | #935 |
d5 | #935 |
environment interactions | #936 |
smoking risk | #936 |
3040 | #937 |
study designs | #938 |
female genotype | #938 |
diagnostic | #938 |
irrs | #940 |
robustly | #940 |
critics | #941 |
severe form | #941 |
tdt | #943 |
brain regions | #946 |
gwas | #946 |
22q | #948 |
sles | #948 |
risk developing | #949 |
fetal exposure | #950 |
albeit | #950 |
subtest | #952 |
relapsers | #954 |
amphetamine | #954 |
personality disorder | #954 |
behavioral treatment | #955 |
prompted | #956 |
effects sex | #956 |
112 | #959 |
qam | #960 |
clinical disorders | #960 |
cytoarchitecture | #962 |
clinical assessment | #963 |
children epilepsy | #963 |
female frontal | #963 |
tandem repeat | #965 |
dopamine uptake | #965 |
scores | #965 |
cgis | #965 |
body height | #966 |
scarce | #966 |
heritability estimates | #967 |
splicing factor | #968 |
cuneus | #968 |
freesurfer | #969 |
examined | #970 |
mtbi | #970 |
schizophrenia association | #970 |
pharmacological treatment | #970 |
medication treatment | #971 |
risky sexual behavior | #972 |
aggression | #972 |
262 | #973 |
chromosome mapping | #974 |
diva | #975 |
autism spectrum disorder | #976 |
fluphenazine | #977 |
psychosis risk | #978 |
resolve | #978 |
vmat2 | #978 |
2–4 | #980 |
neurodevelopmental disorder | #980 |
educational | #982 |
pertaining | #982 |
459 | #982 |
seriousness | #985 |
logistic regression models | #986 |
alleles | #986 |
symptoms age | #986 |
patients sle | #987 |
difficulties | #988 |
tci | #990 |
ranked | #990 |
small proportion | #990 |
depressed mothers | #991 |
polymorphism genetic | #994 |
pathway analysis | #995 |
temporal stability | #996 |
colleagues | #996 |
internal consistency | #997 |
comorbid conditions | #998 |
detoxification | #999 |
keystone | #999 |
diathesis | #999 |
adolescent analysis | #1000 |
child child | #1001 |
interviews | #1003 |
stata | #1003 |
comparative efficacy | #1004 |
haplotypes | #1006 |
confounding factors | #1007 |
long‐term outcome | #1007 |
0016 | #1007 |
preschool cohort | #1007 |
allele | #1007 |
daughter | #1007 |
norms | #1008 |
structural mri | #1008 |
posttraumatic stress disorder | #1009 |
risk alcohol | #1009 |
multiplex | #1009 |
qualifications | #1009 |
discriminant | #1010 |
genes environment | #1012 |
7 years | #1014 |
ltc | #1014 |
maturational | #1020 |
metabotropic | #1020 |
conclusive | #1021 |
risk prediction | #1024 |
relates | #1024 |
insufficient | #1026 |
pharmacotherapies | #1027 |
004 | #1027 |
obsessive – | #1028 |
persistent | #1028 |
pharmacologic | #1029 |
weiss | #1030 |
wwwclinicaltrialsgov | #1031 |
analytic | #1031 |
frontostriatal | #1031 |
patients panic disorder | #1032 |
symptoms child | #1032 |
– compulsive | #1034 |
predicted | #1034 |
73 | #1034 |
preface | #1034 |
negative symptoms | #1035 |
total score | #1035 |
brain disorders | #1035 |
rodent models | #1035 |
eventual | #1037 |
exploratory analyses | #1037 |
major depressive episode | #1039 |
general framework | #1040 |
general intelligence | #1041 |
serotonin | #1041 |
twin | #1043 |
mental health treatment | #1044 |
gaf | #1044 |
heightened | #1045 |
relate | #1045 |
antecedents | #1046 |
inv | #1046 |
ffi | #1050 |
late gestation | #1051 |
onset schizophrenia | #1052 |
subtle | #1052 |
benzodiazepines | #1053 |
disorders post | #1054 |
school age | #1055 |
vice | #1056 |
psychiatric morbidity | #1056 |
major humans | #1058 |
nogo | #1058 |
youth report | #1060 |
obscure | #1060 |
adolescence adulthood | #1061 |
bipolar disorders | #1062 |
illicit | #1063 |
199 | #1063 |
genes involved | #1063 |
memory disorders | #1064 |
europe female | #1065 |
paediatric patients | #1065 |
heritability | #1068 |
paranoia | #1068 |
pooled | #1068 |
childhood trauma | #1068 |
awakenings | #1068 |
negative impact | #1069 |
emotional | #1069 |
memantine | #1069 |
memory impairments | #1070 |
human genetics | #1070 |
word reading | #1070 |
reading ability | #1071 |
social problems | #1071 |
genetic model | #1071 |
risk scores | #1071 |
controlled clinical | #1071 |
single nucleotide receptors | #1071 |
4q | #1072 |
character inventory | #1072 |
validity | #1073 |
associations | #1073 |
obesity risk | #1074 |
3′utr | #1075 |
studying | #1075 |
general hospital | #1076 |
mapping chromosomes | #1077 |
schizophrenia spectrum disorders | #1078 |
transdiagnostic | #1080 |
exposure delayed | #1080 |
adult antipsychotic | #1082 |
schizophrenia social | #1082 |
anxiety children | #1083 |
contiguous | #1084 |
onset psychosis | #1086 |
autoreceptors | #1086 |
psds | #1086 |
european continental | #1088 |
alcohol marijuana | #1089 |
subtype | #1090 |
distinctive | #1090 |
polygenic scores | #1092 |
development disorders | #1092 |
obsessivecompulsive disorder ocd | #1093 |
gifted | #1094 |
scientific literature | #1096 |
irritable | #1096 |
semistructured interview | #1096 |
smoking | #1099 |
metaanalysis | #1102 |
future work | #1103 |
daughters | #1103 |
external validity | #1103 |
cnvs | #1104 |
odds | #1106 |
10 weeks | #1107 |
diagnostic groups | #1107 |
psychosis | #1107 |
emotional behavioral | #1108 |
bip | #1108 |
psychoses | #1110 |
prioritized | #1110 |
experimental test | #1110 |
share | #1111 |
10−5 | #1111 |
male children | #1112 |
depressive disorder | #1113 |
new developments | #1114 |
effects children | #1116 |
discusses | #1117 |
schizophrenia subjects | #1119 |
psychotropic | #1121 |
children anxiety | #1122 |
exchangers | #1123 |
632 | #1123 |
556 | #1124 |
mts | #1125 |
coexisting | #1125 |
projects | #1127 |
dysthymic disorder | #1128 |
similarities | #1128 |
quantifies | #1128 |
enriched | #1128 |
investigator | #1129 |
weighting | #1130 |
adult alcoholism | #1130 |
n28 | #1134 |
attention performance | #1134 |
psychiatric diagnosis | #1135 |
birth outcomes | #1136 |
independent sample | #1136 |
laterality humans | #1138 |
blood pressure response | #1138 |
susceptibility loci | #1139 |
social phobia | #1142 |
clinical samples | #1142 |
signal task | #1144 |
prodromal | #1145 |
early adolescent | #1145 |
cognitive domains | #1145 |
demographic factors | #1146 |
normal volunteers | #1147 |
measurement invariance | #1147 |
emotionality | #1147 |
refine | #1149 |
discounting | #1150 |
humans intellectual | #1150 |
discriminability | #1150 |
children association | #1150 |
developmental model | #1152 |
quick | #1152 |
continents | #1152 |
refinements | #1153 |
generalizability | #1153 |
normals | #1153 |
clinical profiles | #1154 |
alspac | #1154 |
sensory gating | #1154 |
differential humans | #1160 |
ht2c | #1160 |
uncorrected | #1160 |
phenotype | #1161 |
review findings | #1163 |
” “ | #1163 |
studies data | #1164 |
phobia | #1164 |
neurocognitive function | #1165 |
deteriorated | #1166 |
affective | #1166 |
clinical groups | #1166 |
congress | #1167 |
catecholaminergic | #1168 |
medication status | #1169 |
social outcomes | #1170 |
292 | #1171 |
quality measures | #1174 |
mspi | #1175 |
cohen | #1176 |
gwas data | #1176 |
bpd patients | #1176 |
nicotine exposure | #1177 |
genetic risk factors | #1177 |
clinical validation | #1178 |
male subjects | #1178 |
study gwas | #1179 |
persisting | #1182 |
cinguli humans | #1182 |
childhood exposure | #1182 |
reward | #1182 |
nonverbal | #1183 |
paradox | #1184 |
triads | #1184 |
addressing | #1184 |
standardized | #1187 |
functional polymorphisms | #1188 |
dysbindin | #1189 |
hydrochloride | #1189 |
64 | #1190 |
child preschool | #1192 |
psychology | #1193 |
assess | #1194 |
parenting behavior | #1197 |
compulsivity | #1198 |
addictions | #1198 |
onequarter | #1198 |
wm | #1199 |
placebo | #1199 |
230 | #1200 |
asian continental | #1200 |
wisconsin | #1201 |
morbidity | #1202 |
sib | #1204 |
systematic search | #1204 |
millennium | #1207 |
nationwide cohort study | #1209 |
externalizing symptoms | #1209 |
problems children | #1209 |
conceptualizations | #1210 |
neuropsychology | #1210 |
p004 | #1211 |
term treatment | #1215 |
sample sizes | #1218 |
male mass | #1219 |
underlying | #1220 |
lbw | #1220 |
antecedent | #1221 |
child cognitive | #1222 |
prospects | #1222 |
study role | #1224 |
profile | #1226 |
partly | #1227 |
approximated | #1227 |
0011 | #1229 |
refining | #1232 |
subgroup | #1232 |
molecular alterations | #1232 |
poster | #1233 |
pregnancy prenatal | #1234 |
health organization | #1234 |
children ages | #1235 |
gprotein | #1235 |
shortcomings | #1237 |
educational attainment | #1239 |
brain structure | #1242 |
tandem repeats | #1242 |
interpersonal relations | #1244 |
short form | #1245 |
risk asthma | #1247 |
kf | #1247 |
enjoyment | #1247 |
avenues | #1247 |
psychosocial outcomes | #1248 |
cidi | #1248 |
cpg islands | #1249 |
roc | #1251 |
delineate | #1251 |
debilitating | #1252 |
alcohol disorders | #1255 |
risk ratio | #1256 |
summarize | #1256 |
serotonin transporter | #1256 |
dysfunctions | #1257 |
nervous | #1257 |
goal | #1257 |
onset depression | #1259 |
combine | #1260 |
consensus statements | #1263 |
characterize | #1266 |
onset age | #1267 |
likewise | #1270 |
logistic regression analyses | #1271 |
child mental | #1273 |
statistical methods | #1274 |
entire | #1277 |
386 | #1277 |
developmental pathways | #1277 |
n24 | #1278 |
04 | #1281 |
study evidence | #1281 |
priori | #1282 |
paternal | #1282 |
neuroimaging | #1283 |
increased rates | #1283 |
behavior adolescent | #1283 |
hopes | #1283 |
variance | #1284 |
spontaneously hypertensive | #1285 |
087 | #1286 |
general cognitive | #1286 |
male nerve | #1288 |
somatic complaints | #1288 |
orbitofrontal | #1288 |
warmth | #1289 |
aspect | #1289 |
1hmrs | #1291 |
unmyelinated | #1291 |
posttraumatic | #1291 |
dual psychiatry | #1291 |
animal conditioning | #1292 |
quantitative trait | #1292 |
misclassification | #1292 |
clomipramine | #1292 |
negative emotion | #1295 |
136 | #1297 |
pvalue | #1297 |
chromosomes | #1298 |
cures | #1301 |
atx | #1303 |
935 | #1305 |
1520 | #1305 |
cortical volume | #1306 |
sgas | #1309 |
prediction accuracy | #1309 |
extant | #1310 |
vin | #1310 |
risperidone | #1311 |
arrests | #1312 |
factor analyses | #1313 |
motor speed | #1313 |
criteria | #1314 |
76 | #1315 |
factors smoking | #1316 |
minds | #1317 |
class analysis | #1317 |
adolescents children | #1318 |
current findings | #1320 |
hypothetical | #1321 |
predictability | #1322 |
short | #1323 |
parents adolescents | #1323 |
polymorphism | #1324 |
hypothesis | #1325 |
response treatment | #1327 |
confusion | #1330 |
influencing | #1330 |
defining | #1331 |
measures | #1334 |
polysubstance | #1334 |
253 | #1335 |
psychopharmacology | #1335 |
genetic background | #1336 |
authors | #1336 |
nonuse | #1337 |
obsessive–compulsive disorder | #1338 |
fronto | #1338 |
clinical phenotypes | #1342 |
longterm outcome | #1342 |
registry data | #1344 |
542 | #1344 |
llysine | #1345 |
explaining | #1345 |
interpretation statistical | #1349 |
compared children | #1353 |
early adulthood | #1353 |
psychoticism | #1355 |
diagnostic tool | #1356 |
cocaine abuse | #1356 |
loci genetic | #1356 |
variabilities | #1357 |
simon | #1357 |
flush | #1357 |
seekers | #1358 |
antidepressive | #1359 |
gene discovery | #1359 |
broad spectrum | #1361 |
mammalian target | #1362 |
middle frontal gyrus | #1362 |
intergenerational | #1365 |
abcd | #1367 |
neuronal development | #1369 |
uptake inhibitors | #1369 |
unexplored | #1369 |
school teachers | #1369 |
reliance | #1370 |
intellectual functioning | #1371 |
observer variation | #1374 |
covert | #1377 |
larger | #1378 |
pallidum | #1380 |
inositol | #1382 |
ghr | #1385 |
thought disorder | #1386 |
highlighted | #1386 |
new onset | #1386 |
dimensional approach | #1389 |
6 years | #1391 |
treatment depression | #1391 |
prodrome | #1391 |
familial aggregation | #1391 |
illicit drugs | #1393 |
vendors | #1394 |
satisfying | #1395 |
rats shr | #1395 |
manuscripts | #1395 |
thalamic | #1395 |
racial | #1398 |
emotional stimuli | #1399 |
timely | #1399 |
suggesting | #1400 |
lability | #1400 |
17 | #1402 |
sufficient | #1403 |
blinded | #1403 |
brain region | #1404 |
hippocampal volumes | #1405 |
placebo treatment | #1407 |
hama | #1408 |
create | #1409 |
preparations | #1410 |
personality inventory | #1412 |
1998 | #1413 |
shyness | #1414 |
issue | #1414 |
independent | #1415 |
prepubertal children | #1416 |
impressions | #1416 |
332 | #1417 |
logical | #1419 |
carry | #1419 |
humans memory | #1421 |
discoveries | #1422 |
parents children | #1422 |
exploratory factor analysis | #1423 |
greater | #1426 |
dosed | #1427 |
linkage disequilibrium | #1430 |
taps | #1431 |
163 | #1431 |
cognitive profiles | #1432 |
interaction effects | #1432 |
affairs | #1434 |
social perception | #1436 |
publication adult analysis | #1438 |
bche | #1439 |
academic | #1443 |
holidays | #1444 |
personality | #1447 |
psychotic illness | #1448 |
443 | #1448 |
chp | #1449 |
hydroxylase | #1450 |
prevalence obesity | #1450 |
ratings | #1451 |
height | #1453 |
square | #1453 |
78 | #1453 |
ewas | #1453 |
hypermethylation | #1454 |
population stratification | #1454 |
switching | #1455 |
collaborations | #1457 |
replicability | #1457 |
dorsal striatum | #1457 |
generalized anxiety | #1458 |
comparisons | #1459 |
severe depression | #1462 |
stronger | #1463 |
biological pathways | #1463 |
treatment duration | #1464 |
discordant | #1467 |
principal | #1467 |
valuable | #1468 |
untranslated | #1468 |
partial remission | #1468 |
groups differences | #1469 |
hippocampi | #1469 |
contrast effects | #1472 |
openlabel | #1474 |
statistically | #1474 |
cognition patients | #1474 |
amygdala volume | #1477 |
risk relapse | #1479 |
conducted | #1480 |
medication | #1481 |
cortex dlpfc | #1487 |
prodromal symptoms | #1488 |
issues | #1489 |
apt | #1492 |
adrb2 | #1493 |
hypomethylation | #1495 |
mri studies | #1497 |
allele carriers | #1497 |
smaller | #1497 |
twins monozygotic | #1499 |
small sample sizes | #1499 |
lifespan | #1499 |
converge | #1500 |
populationbased study | #1501 |
patients bipolar | #1502 |
cpt | #1503 |
ddc | #1505 |
male mothers | #1505 |
multisite | #1505 |
examination | #1508 |
manifestation | #1510 |
salience network | #1510 |
existing literature | #1511 |
objectivity | #1511 |
reports | #1513 |
emotions female | #1513 |
attained | #1513 |
messaging | #1514 |
cognitive ability | #1515 |
pedigree | #1516 |
eicosapentaenoic acid | #1517 |
screening instrument | #1517 |
repeat | #1518 |
criminal behavior | #1519 |
165 | #1521 |
114 | #1523 |
topic | #1523 |
cna | #1523 |
bipolar patients | #1526 |
inconsistency | #1526 |
inferior frontal | #1528 |
psychiatric disorder | #1528 |
nacetylaspartate | #1528 |
symptomatology | #1530 |
512 | #1535 |
began | #1536 |
arntl | #1540 |
nucleotide risk | #1541 |
default | #1541 |
dopamine receptor | #1542 |
adult life | #1542 |
poses | #1542 |
stress disorders | #1543 |
gwass | #1544 |
treatment schizophrenia | #1545 |
yale | #1545 |
omission | #1547 |
traits | #1549 |
card | #1551 |
problem behaviors | #1554 |
influenced | #1554 |
857 | #1556 |
automobile | #1556 |
early exposure | #1559 |
failed | #1559 |
loci | #1560 |
0009 | #1561 |
0013 | #1564 |
subscales | #1565 |
insular | #1565 |
475 | #1565 |
interpersonal | #1566 |
humans interpersonal | #1569 |
wise | #1570 |
swedish | #1573 |
191 | #1573 |
consortium | #1573 |
depression children | #1574 |
neurochemistry | #1575 |
attempted | #1576 |
life quality | #1579 |
meta | #1579 |
selfreport questionnaires | #1580 |
gene networks | #1580 |
located | #1582 |
findings studies | #1582 |
single nucleotide polymorphism | #1582 |
network dmn | #1583 |
models male | #1583 |
cutoffs | #1583 |
social functioning | #1584 |
hyperactivation | #1587 |
firstepisode schizophrenia | #1588 |
rs4680 | #1588 |
major depressive | #1588 |
genetic data | #1589 |
pain patients | #1589 |
edinburgh | #1590 |
advent | #1591 |
55 | #1592 |
phobias | #1593 |
temperament | #1594 |
subcortical structures | #1596 |
162 | #1596 |
symptom presentation | #1598 |
moderators | #1599 |
tpv | #1599 |
psychotropic medications | #1601 |
statistics nonparametric | #1601 |
jan | #1602 |
managed | #1603 |
utr | #1604 |
suffer | #1604 |
spontaneously | #1605 |
heritabilities | #1606 |
classifying | #1608 |
academic achievement | #1609 |
proneness | #1610 |
1979 | #1610 |
monoamine oxidase | #1611 |
alcoholism | #1613 |
emotional faces | #1613 |
status | #1614 |
ancestry female | #1615 |
male maternal | #1616 |
drawn | #1619 |
broadly | #1620 |
large body | #1622 |
risk mental | #1622 |
distinguishing | #1622 |
childhood asthma | #1624 |
hbr | #1624 |
paucity | #1626 |
snp | #1626 |
spatial organization | #1627 |
ht2a receptor | #1627 |
dysphoria | #1628 |
louis | #1628 |
genomics humans | #1629 |
verbal behavior | #1629 |
study children | #1630 |
kyoto | #1630 |
emrs | #1631 |
ambiguous | #1631 |
memory task | #1631 |
198 | #1633 |
susceptibility gene | #1634 |
supporting | #1635 |
mental illnesses | #1637 |
positive predictive | #1638 |
lag | #1639 |
brain female | #1640 |
social communication | #1643 |
tendency | #1643 |
rack1 | #1643 |
alpha7 | #1643 |
bprs | #1644 |
potential effects | #1646 |
socially | #1647 |
interrelations | #1649 |
treating | #1650 |
controlled | #1653 |
rea | #1653 |
nucleotide polymorphisms | #1655 |
adolescents age | #1657 |
detect | #1658 |
maximize | #1658 |
psychotic disorder | #1659 |
require | #1659 |
personality disorders | #1661 |
symptom severity | #1662 |
presentations | #1663 |
comorbid depression | #1663 |
asm | #1664 |
510 | #1665 |
chronic patients | #1666 |
dlpfc | #1666 |
mood symptoms | #1666 |
association analysis | #1667 |
indexed | #1670 |
human rights | #1670 |
bipolar disorder patients | #1671 |
13 years | #1672 |
transmitted | #1673 |
asd symptoms | #1674 |
early signs | #1675 |
alcohol spectrum | #1675 |
statements | #1675 |
53 | #1677 |
introns | #1678 |
registers | #1678 |
calling | #1678 |
homogeneous | #1679 |
social anxiety | #1679 |
seat | #1680 |
beagle | #1680 |
mathematical models | #1682 |
mildly | #1684 |
prescribed | #1684 |
46 | #1684 |
ancestries | #1685 |
memory deficit | #1685 |
github | #1689 |
mdd | #1689 |
autistic disorder | #1689 |
psychotropic drugs | #1692 |
agenda | #1692 |
impulse control | #1693 |
motor skills | #1698 |
recruited | #1698 |
diagnose | #1699 |
91 | #1702 |
item | #1704 |
memory consolidation | #1704 |
conceptualization | #1705 |
middle frontal | #1710 |
reduced activation | #1711 |
rater | #1712 |
neuroscience | #1712 |
health records | #1712 |
personality characteristics | #1712 |
schizophrenia spectrum | #1713 |
net | #1716 |
perpetrators | #1725 |
nhe1 | #1728 |
autistic | #1729 |
epigenetics | #1730 |
107 | #1731 |
inhibitory control | #1731 |
cbs | #1732 |
hindered | #1733 |
machine | #1735 |
highlight | #1735 |
identical | #1736 |
stand | #1736 |
aimed | #1739 |
predictors | #1739 |
dopamine receptors | #1741 |
sex age | #1743 |
curated | #1746 |
forum | #1746 |
longitudinal analysis | #1747 |
cognitive difficulties | #1748 |
pds | #1749 |
occipital lobe | #1750 |
tremors | #1752 |
selfreport measures | #1753 |
02 | #1753 |
questionnaires young | #1755 |
sertraline | #1756 |
326 | #1756 |
5ht2a | #1758 |
120 | #1758 |
genetic models | #1761 |
ventral striatum | #1761 |
social | #1761 |
drowsiness | #1763 |
bipolar affective | #1763 |
includes | #1765 |
chance | #1765 |
adult onset | #1766 |
mystery | #1768 |
operant | #1768 |
reflects | #1769 |
sisters | #1770 |
dopamine | #1772 |
dizygotic twins | #1773 |
treatment implications | #1773 |
depressive episode | #1775 |
patients systemic | #1775 |
267 | #1776 |
patients adult | #1776 |
mental recall | #1777 |
establishing | #1777 |
utrs | #1779 |
10−7 | #1780 |
early childhood | #1781 |
commonalities | #1786 |
major | #1786 |
higher doses | #1786 |
social anxiety disorder | #1787 |
defined | #1789 |
frustration | #1791 |
male motor | #1791 |
transdermal | #1793 |
disorder mdd | #1795 |
harbor | #1796 |
causal variants | #1797 |
positive association | #1797 |
disabilities | #1797 |
autism spectrum disorders | #1800 |
aged models | #1801 |
reporters | #1801 |
members | #1801 |
genetic variance | #1802 |
chapters | #1803 |
shr | #1804 |
females | #1805 |
families children | #1806 |
based analysis | #1807 |
covariation | #1807 |
168 | #1809 |
nucleotide polymorphism | #1812 |
expanded | #1812 |
146 | #1813 |
aetiology | #1813 |
european descent | #1813 |
frequently | #1815 |
internationality | #1815 |
purchases | #1816 |
brain imaging | #1816 |
cohens | #1819 |
lds | #1819 |
hippocampal volume | #1819 |
correlate | #1823 |
suicide attempt | #1825 |
endpoint | #1827 |
followup | #1830 |
splenium | #1831 |
foundation | #1833 |
binocular | #1833 |
psychotic patients | #1837 |
suggested | #1838 |
94 | #1840 |
patterns | #1841 |
neural activity | #1841 |
trauma exposure | #1842 |
assessment tools | #1842 |
distinctions | #1845 |
initiative | #1845 |
twins | #1845 |
literacy | #1846 |
pertinent | #1847 |
psychological | #1847 |
warrant | #1848 |
environmental risk | #1848 |
polymorphisms | #1849 |
limited | #1850 |
fearful | #1851 |
individual | #1851 |
vocabulary | #1851 |
nonparametric | #1852 |
brainderived neurotrophic factor | #1853 |
differentiating | #1853 |
young | #1853 |
persons | #1855 |
abuse | #1856 |
auditory hallucinations | #1856 |
tph | #1859 |
prevalence | #1859 |
incentives | #1860 |
behavioral measures | #1860 |
affiliation | #1861 |
cnb | #1861 |
8p | #1862 |
obstacle | #1864 |
poison | #1865 |
multilevel | #1865 |
vocalization | #1865 |
switch | #1865 |
severely | #1867 |
18 | #1869 |
structural functional | #1875 |
constitute | #1876 |
manuscript | #1877 |
roc curve | #1879 |
histograms | #1879 |
animal model | #1880 |
shrs | #1880 |
delusions | #1881 |
afb | #1882 |
longer duration | #1882 |
common genetic variation | #1883 |
genome | #1885 |
differs | #1888 |
false | #1888 |
substance abuse | #1890 |
metaanalysis studies | #1890 |
spanning | #1894 |
heterogeneous | #1894 |
susceptibility genes | #1896 |
latent class analysis | #1899 |
maintained | #1899 |
correspondences | #1901 |
psychostimulant | #1902 |
analyses | #1903 |
chinese | #1903 |
illicit drug | #1904 |
actigraphy | #1905 |
specific symptoms | #1907 |
increasingly | #1907 |
emotion | #1908 |
epidemiologic | #1909 |
majority | #1909 |
ads | #1910 |
support vector machine | #1911 |
disorders mental | #1911 |
structural differences | #1912 |
generation antipsychotics | #1913 |
africanamericans | #1915 |
χ2 | #1916 |
10h | #1920 |
inform | #1921 |
liking | #1923 |
satisfied | #1923 |
association maternal | #1923 |
aggregate | #1926 |
child cross | #1926 |
overview | #1927 |
251 | #1928 |
sleep problems | #1928 |
advertising | #1928 |
empirical studies | #1929 |
ssri | #1930 |
95 cis | #1934 |
asd children | #1934 |
borderline personality disorder | #1937 |
simulation study | #1937 |
exomes | #1938 |
stratified | #1939 |
general | #1942 |
25 years | #1945 |
literature review | #1947 |
neurobehavioral | #1949 |
traumatic brain injury | #1950 |
representing | #1950 |
trait loci | #1952 |
accumbens | #1953 |
normal children | #1954 |
efficacious | #1957 |
msp | #1958 |
neurotransmitter release | #1959 |
mems | #1961 |
intolerant | #1962 |
micronesia | #1963 |
896 | #1964 |
sdq | #1967 |
brain networks | #1968 |
vital signs | #1969 |
sorting | #1971 |
correctly | #1972 |
depression | #1972 |
clinical implications | #1972 |
connectivity | #1974 |
hoc | #1975 |
factors surveys | #1976 |
child depression | #1977 |
repeats | #1977 |
conflicting | #1978 |
listing | #1978 |
hippocampus humans | #1981 |
ptsd | #1981 |
chinese population | #1984 |
common mental disorders | #1984 |
phase 3 trial | #1986 |
pax5 | #1986 |
secondary analysis | #1987 |
brain | #1989 |
school | #1990 |
predisposing | #1991 |
current paper | #1994 |
genetic differences | #1996 |
226 | #1997 |
fmr | #1998 |
pattern | #1999 |
diagnosed | #2001 |
comparable | #2002 |
spouses | #2003 |
formulations | #2005 |
asian continental ancestry | #2005 |
harm avoidance | #2007 |
functional variants | #2010 |
behavioral symptoms | #2011 |
nos1 | #2012 |
absence | #2014 |
akt1 | #2014 |
muscle function | #2014 |
sms | #2015 |
noradrenergic | #2015 |
possibility | #2016 |
cognitive deficits | #2016 |
prescribers | #2021 |
schoolage children | #2023 |
159 | #2023 |
serve | #2026 |
phenomenology | #2030 |
sleep disturbances | #2030 |
memory verbal | #2031 |
brain responses | #2031 |
regional brain | #2032 |
neurodevelopmental disorders | #2033 |
morbid | #2036 |
prenatally | #2037 |
receptors nicotinic | #2037 |
diminished | #2040 |
retest reliability | #2040 |
asperger | #2041 |
erythematosus systemic | #2041 |
nicotinic acetylcholine | #2045 |
cognitive processing | #2046 |
227 | #2046 |
informants | #2048 |
erythematosus | #2049 |
functional | #2050 |
cognition | #2050 |
juvenile | #2052 |
contribute | #2054 |
adolescent behavior | #2056 |
external control | #2057 |
chapman | #2058 |
common diseases | #2061 |
insula | #2061 |
educated | #2062 |
stabilizers | #2064 |
ongoing | #2065 |
overweight obesity | #2066 |
demography | #2066 |
val158met polymorphism | #2067 |
preschool humans | #2068 |
massachusetts | #2069 |
functional mri | #2069 |
0008 | #2071 |
parental education | #2072 |
phenotypic | #2072 |
psychotic symptoms | #2077 |
degree | #2078 |
international consensus | #2078 |
wake disorders | #2079 |
descent | #2079 |
heterogeneity studies | #2082 |
psychomotor | #2084 |
male gender | #2085 |
5 ht2a | #2087 |
latent class | #2090 |
43 | #2090 |
factors child | #2093 |
49 | #2095 |
aud | #2096 |
wky shr | #2096 |
subsets | #2099 |
69 | #2100 |
dopaminergic | #2100 |
142 | #2102 |
general factor | #2106 |
age children | #2107 |
ht2a | #2108 |
adult population | #2108 |
causation | #2109 |
nicotinic | #2112 |
specific genetic | #2112 |
child relations | #2112 |
279 | #2115 |
brain dysfunction | #2115 |
83 | #2117 |
relative age | #2119 |
postpartum period | #2119 |
monoamine | #2119 |
poorer | #2119 |
84 | #2121 |
pgs | #2122 |
51 | #2122 |
career | #2122 |
sixth | #2124 |
pbls | #2126 |
identifies | #2126 |
dysfunctional | #2128 |
biased | #2129 |
ovid | #2130 |
functional polymorphism | #2132 |
rates | #2134 |
dbh | #2137 |
episode schizophrenia | #2137 |
psychosocial factors | #2140 |
interpretability | #2141 |
adversities | #2141 |
discrepant | #2142 |
relevant literature | #2143 |
methods participants | #2145 |
pvs | #2145 |
behavioral disorders | #2146 |
receptors adrenergic | #2147 |
105 | #2147 |
intraclass | #2147 |
juveniles | #2148 |
abnormalities | #2149 |
finemapping | #2150 |
represents | #2150 |
232 | #2150 |
glutamatergic | #2150 |
assessing | #2151 |
repositioning | #2151 |
rrr | #2153 |
mao | #2153 |
psychiatric patients | #2155 |
differentiated | #2164 |
abdominal obesity | #2164 |
clinical assessments | #2166 |
declarative memory | #2167 |
shr wky | #2167 |
differential diagnostic | #2168 |
differing | #2168 |
genetic association studies | #2168 |
glx | #2169 |
major depressive disorder | #2170 |
prevalences | #2171 |
mb | #2171 |
adversely | #2171 |
severity | #2172 |
tardive dyskinesia | #2172 |
aggregated | #2177 |
irt | #2180 |
externalizing | #2181 |
moderating | #2181 |
environmental factors | #2183 |
author | #2185 |
report measures | #2186 |
teachers | #2187 |
computerassisted imaging | #2188 |
thought | #2188 |
processing speed | #2189 |
differential expression | #2189 |
scale | #2192 |
regular | #2192 |
generalized anxiety disorder | #2192 |
serotonin 5 | #2193 |
imaging fmri | #2195 |
lifecycle | #2197 |
conceptual | #2197 |
pharmacological agents | #2199 |
achievement | #2200 |
confounding | #2201 |
ages | #2201 |
double | #2205 |
brain mapping | #2206 |
developing brain | #2206 |
abstract background | #2207 |
ottawa | #2209 |
169 | #2209 |
remained | #2209 |
surveys questionnaires | #2210 |
homozygosity | #2210 |
accidents | #2210 |
illness severity | #2211 |
antenatal | #2211 |
genetic relationship | #2212 |
occurrences | #2217 |
adverse event | #2217 |
intronic | #2219 |
hippocampal formation | #2220 |
complex diseases | #2220 |
biologically | #2220 |
completed | #2220 |
autism | #2221 |
val66met | #2222 |
visuospatial | #2225 |
cognitive task | #2225 |
20th | #2226 |
replicating | #2227 |
single | #2228 |
caudate putamen | #2229 |
trail making | #2230 |
clinical profile | #2232 |
attainment | #2234 |
community sample | #2235 |
controls age | #2238 |
hexokinase | #2241 |
prototypical | #2241 |
implications | #2242 |
qualities | #2244 |
insensitivity | #2245 |
consultation | #2246 |
preliminary data | #2248 |
hamilton | #2253 |
val66met polymorphism | #2254 |
pubertal development | #2257 |
genomic analysis | #2260 |
treatment guidelines | #2260 |
novo mutations | #2263 |
cognitive deficit | #2263 |
cigarette | #2264 |
earlier | #2264 |
criterion | #2265 |
pathways | #2266 |
rewards | #2266 |
bds | #2266 |
clinical measures | #2267 |
evident | #2273 |
overdiagnosis | #2274 |
gray matter volume | #2275 |
remain | #2275 |
cognitive development | #2275 |
axis | #2275 |
tend | #2276 |
random allocation | #2277 |
imaging male | #2277 |
mtl | #2277 |
apneahypopnea | #2279 |
systemic lupus | #2279 |
lithium | #2283 |
moderation | #2283 |
psychiatric illness | #2285 |
cognitive | #2287 |
controlling | #2290 |
minority | #2292 |
update | #2293 |
regions | #2294 |
diverse populations | #2294 |
physical health | #2294 |
socialization | #2295 |
retained | #2297 |
monitored | #2298 |
11 years | #2299 |
corticotropin | #2301 |
clinic | #2304 |
biology | #2304 |
239 | #2304 |
adjunctive | #2306 |
virtue | #2307 |
consisting | #2308 |
lupus | #2310 |
difficult | #2310 |
enormous | #2311 |
brain anatomy | #2313 |
pregnancy | #2313 |
edition | #2315 |
behaviors | #2317 |
adequate | #2318 |
performance reaction | #2319 |
brain systems | #2321 |
tests | #2321 |
fmri | #2325 |
casecontrol study | #2326 |
memory performance | #2328 |
higher prevalence | #2330 |
257 | #2331 |
organ size | #2332 |
questionnaires | #2332 |
subset | #2333 |
mind | #2334 |
covariate | #2335 |
archives | #2335 |
disorganization | #2335 |
early risk | #2336 |
depression female | #2340 |
utility | #2342 |
lesser extent | #2342 |
functional networks | #2344 |
nature | #2344 |
20th century | #2345 |
cingulate | #2346 |
schedule | #2350 |
time perception | #2353 |
providing | #2353 |
mapping child | #2358 |
powered | #2362 |
adolescent brain | #2364 |
endosome | #2365 |
factor structure | #2367 |
limited evidence | #2368 |
concurrently | #2368 |
smallest | #2369 |
symptoms schizophrenia | #2369 |
efforts | #2376 |
social cognitive | #2377 |
catecholamine | #2379 |
antipsychotic agents | #2379 |
tapping | #2384 |
predicts | #2385 |
ecologically | #2386 |
gyrus | #2388 |
drugs abuse | #2391 |
unresolved | #2393 |
convergence | #2395 |
raising | #2395 |
problem solving | #2398 |
essence | #2401 |
gray matter | #2401 |
frontal | #2403 |
pubmed | #2406 |
sirolimus | #2407 |
addictive | #2407 |
adolescent alcohol | #2408 |
distinguished | #2410 |
validate | #2412 |
preserved | #2414 |
genetic factor | #2417 |
statistical significance | #2418 |
alternative | #2418 |
modules | #2419 |
illumina | #2422 |
starting | #2423 |
classified | #2425 |
disease genetic | #2426 |
salience | #2426 |
143 | #2428 |
bdnf | #2429 |
term outcome | #2429 |
fmri data | #2431 |
confounders | #2431 |
241 | #2433 |
clinical trial | #2433 |
protein interactions | #2433 |
protein interaction | #2436 |
analyzes | #2440 |
careful | #2443 |
intellectual | #2447 |
dimorphism | #2448 |
timepoints | #2448 |
items | #2449 |
multiple studies | #2450 |
deconvolution | #2452 |
mvr | #2452 |
overweight children | #2456 |
systemic lupus erythematosus | #2456 |
prefrontal cortical | #2456 |
moderately | #2458 |
genetic susceptibility | #2459 |
myoinositol | #2459 |
brain maturation | #2460 |
anxiety symptoms | #2460 |
traumatic stress | #2461 |
logistic | #2461 |
concordance | #2461 |
autosomes | #2462 |
sex distribution | #2464 |
crossover study | #2464 |
factor bdnf | #2466 |
hungary | #2469 |
unique | #2473 |
unclear | #2473 |
relatedness | #2482 |
brain activation | #2486 |
reaction time | #2488 |
prescriptions | #2489 |
higher scores | #2489 |
psychomotor performance | #2491 |
cerebrum | #2494 |
normative data | #2495 |
hoc analysis | #2496 |
180 | #2496 |
caucasian | #2497 |
israeli | #2500 |
workplace | #2502 |
establish | #2504 |
original | #2504 |
random forest | #2507 |
interactome | #2509 |
randomized placebo | #2511 |
preschool diagnosis | #2512 |
21st | #2512 |
heterosis | #2513 |
thresholds | #2515 |
quotient | #2515 |
preceded | #2516 |
tricyclic antidepressants | #2518 |
evaluate | #2521 |
perceptual | #2523 |
temporal gyrus | #2526 |
12 years | #2528 |
rel | #2531 |
october | #2532 |
alterations | #2532 |
preliminary report | #2533 |
indicators | #2534 |
thinner | #2539 |
limitations | #2541 |
categories | #2545 |
neurosecretory | #2546 |
medication adherence | #2548 |
animals anxiety | #2550 |
psychotic features | #2553 |
risky | #2553 |
depressive disorders | #2554 |
neural responses | #2555 |
quantitative | #2555 |
exploratory study | #2555 |
bipolar affective disorder | #2557 |
memory tasks | #2557 |
income | #2560 |
risk loci | #2560 |
chronological | #2560 |
assisted magnetic | #2561 |
060 | #2562 |
273 | #2563 |
demographic characteristics | #2565 |
447 | #2565 |
sensation seeking | #2569 |
174 | #2570 |
discontinued | #2571 |
document | #2572 |
numerous | #2573 |
30 years | #2573 |
19 years | #2574 |
cool | #2575 |
depressed | #2576 |
socioeconomic | #2579 |
osmosis | #2580 |
smoking alcohol | #2581 |
adolescent females | #2584 |
elucidate | #2585 |
correction | #2585 |
pvalues | #2586 |
brothers | #2586 |
problems | #2586 |
pituitary adrenal | #2587 |
baseline | #2591 |
post traumatic | #2594 |
exist | #2595 |
disrupted | #2595 |
229 | #2596 |
internalizing externalizing | #2598 |
brain response | #2598 |
temporal pole | #2600 |
encouraging | #2601 |
iowa | #2603 |
simplex | #2603 |
n10 | #2605 |
neo | #2606 |
percentile | #2607 |
literature | #2608 |
infrequent | #2610 |
advances | #2611 |
increased activation | #2611 |
occipital | #2612 |
draft | #2614 |
lateralization | #2616 |
surveys humans | #2619 |
pooling | #2620 |
genotype | #2623 |
evidence role | #2624 |
multiple levels | #2624 |
kynurenine | #2625 |
psycinfo | #2625 |
mothers | #2630 |
imaging studies | #2633 |
bdnf gene | #2633 |
preliminary | #2634 |
institute | #2636 |
odors | #2638 |
182 | #2639 |
global functioning | #2642 |
fetal alcohol | #2642 |
genetic variants | #2644 |
behavior | #2644 |
preschool female | #2644 |
medical conditions | #2645 |
inability | #2645 |
future | #2648 |
borderline personality | #2652 |
brain derived | #2655 |
tmax | #2659 |
dysregulation | #2663 |
electronic health | #2664 |
puzzle | #2665 |
periodicals | #2665 |
n14 | #2666 |
089 | #2669 |
health disorders | #2669 |
genetic evidence | #2670 |
88 | #2670 |
chromosome | #2670 |
polysomnography | #2671 |
spectrum | #2675 |
pcps | #2675 |
mediating | #2676 |
partially | #2676 |
inconclusive | #2676 |
adolescent development | #2678 |
memory tests | #2678 |
physiotherapy | #2678 |
maternal behavior | #2679 |
increased activity | #2681 |
disadvantaged | #2685 |
adrenergic | #2687 |
widespread | #2688 |
conditional | #2689 |
age range | #2689 |
triad | #2689 |
listening | #2690 |
entry | #2692 |
reading | #2692 |
promoter region | #2694 |
evaluating | #2695 |
tfs | #2696 |
evidenced | #2698 |
immaturity | #2698 |
extended | #2700 |
chr | #2701 |
attenuate | #2702 |
neurite | #2702 |
interrogation | #2702 |
flares | #2703 |
delinquency | #2707 |
ext | #2707 |
hemispheric asymmetry | #2709 |
internalizing problems | #2710 |
404 | #2713 |
aggressive | #2714 |
occurring | #2714 |
quarter | #2718 |
positively correlated | #2719 |
purposes | #2721 |
choosing | #2723 |
thinking | #2724 |
internalizing | #2726 |
hold | #2727 |
teens | #2731 |
curve | #2731 |
awakening | #2732 |
thicker | #2733 |
doubt | #2733 |
systematic literature review | #2733 |
alcohol dependence | #2736 |
potential association | #2740 |
pdi | #2752 |
cortices | #2753 |
prepubertal | #2753 |
eventually | #2755 |
collaboration | #2760 |
naa | #2760 |
patients bipolar disorder | #2760 |
gt | #2761 |
manifestations | #2762 |
4 years | #2765 |
unadjusted | #2765 |
created | #2768 |
ccs | #2769 |
psychiatric diseases | #2773 |
reproducibility | #2773 |
phencyclidine | #2775 |
depression severity | #2776 |
25 | #2777 |
preventive measures | #2777 |
clinical heterogeneity | #2783 |
mechanisms underlying | #2783 |
bivariate | #2784 |
children symptoms | #2784 |
panic attacks | #2785 |
6 12 | #2788 |
tactile | #2790 |
dna copy | #2791 |
411 | #2791 |
dyslexia | #2792 |
neurotrophic factor | #2794 |
overt | #2794 |
constellation | #2796 |
auditory perception | #2796 |
suicidality | #2799 |
explained | #2802 |
958 | #2803 |
dependence | #2804 |
references | #2806 |
recognition visual | #2808 |
clinical experience | #2808 |
397 | #2809 |
monetary | #2809 |
misdiagnosis | #2809 |
goodness | #2810 |
predefined | #2812 |
disc1 | #2815 |
midnight | #2816 |
gene polymorphism | #2816 |
primary caregivers | #2817 |
subsequent | #2819 |
indexes | #2823 |
circuitry | #2823 |
1300 | #2824 |
telephone | #2824 |
comorbidities | #2825 |
pediatric obesity | #2827 |
intervention strategies | #2828 |
and or | #2830 |
refusal | #2833 |
disorder characterized | #2835 |
tested | #2838 |
discriminant validity | #2839 |
early recognition | #2839 |
adoption | #2841 |
treatment study | #2843 |
reelin | #2843 |
prefrontal cortex | #2844 |
socioeconomic status | #2846 |
emotional intelligence | #2849 |
early identification | #2850 |
matter volume | #2852 |
parent child | #2853 |
disabled | #2856 |
restless legs syndrome | #2857 |
suicide attempted | #2858 |
depression scale | #2863 |
continental ancestry | #2863 |
parenting parents | #2865 |
addresses | #2866 |
screened | #2866 |
mothers children | #2867 |
internal external | #2867 |
discordance | #2868 |
cognition humans | #2868 |
focus | #2869 |
silico | #2870 |
psychosocial stress | #2872 |
splicing | #2875 |
diagnosis differential | #2876 |
gwa | #2878 |
sixteen | #2880 |
measure | #2884 |
appeared | #2884 |
citations | #2885 |
age differences | #2885 |
shifting | #2885 |
rare variants | #2887 |
protective effects | #2889 |
trinucleotide | #2890 |
brain size | #2900 |
asr | #2901 |
alternate | #2902 |
debate | #2903 |
duplicate | #2905 |
low birth weight | #2906 |
alcohol disorder | #2907 |
newer | #2909 |
independent component analysis | #2911 |
etiologies | #2912 |
behavior children | #2913 |
precursor | #2914 |
cognitive control | #2916 |
amph | #2916 |
institutes | #2919 |
variability | #2919 |
biological mechanisms | #2919 |
age study | #2921 |
genetic contributions | #2922 |
115 | #2924 |
attentional | #2925 |
subject | #2928 |
486 | #2931 |
behavioral outcomes | #2931 |
adherence | #2932 |
92 | #2935 |
machine learning | #2941 |
causal relationship | #2942 |
disorders sleep | #2942 |
distinct | #2946 |
disorders patients | #2946 |
motor control | #2953 |
pcb | #2956 |
smoked | #2959 |
journal | #2965 |
facilitating | #2967 |
previous | #2968 |
331 | #2970 |
overlaps | #2971 |
markers | #2971 |
models neurological | #2976 |
stratification | #2981 |
qtl | #2983 |
725 | #2983 |
weight height | #2988 |
investigators | #2989 |
attempts | #2991 |
imaging mri | #2991 |
tic | #2997 |
performance measures | #2997 |
overweight | #2998 |
variants | #2999 |
subjective | #3000 |
bold | #3002 |
referral | #3005 |
centres | #3006 |
196 | #3006 |
377 | #3007 |
19th century | #3010 |
remission | #3011 |
genetic variation | #3011 |
genetic promoter regions | #3012 |
resonance imaging | #3016 |
987 | #3017 |
chen | #3018 |
worldwide | #3020 |
response relationship | #3021 |
inferior frontal gyrus | #3022 |
disease susceptibility | #3023 |
mouse models | #3024 |
choice | #3028 |
conference | #3030 |
models psychological | #3033 |
familiarity | #3034 |
emotion dysregulation | #3036 |
difficulties questionnaire | #3039 |
symptoms patients | #3039 |
female humans life | #3040 |
thomson | #3044 |
neural correlates | #3047 |
variants genes | #3053 |
developmental | #3054 |
treatment adherence | #3054 |
protective factor | #3057 |
improvement | #3058 |
pilot | #3061 |
280 | #3061 |
fear female | #3063 |
117 | #3064 |
ultimately | #3065 |
339 | #3068 |
216 | #3072 |
stress reactivity | #3073 |
p0004 | #3074 |
frontal lobe | #3076 |
appears | #3077 |
driving | #3078 |
cortical | #3078 |
positive | #3079 |
sociodemographics | #3081 |
males | #3089 |
key findings | #3092 |
pairwise | #3093 |
allelic | #3094 |
pregnancy women | #3095 |
predictable | #3098 |
stressful life | #3098 |
modified version | #3099 |
central nervous | #3104 |
intron | #3105 |
brain health | #3107 |
076 | #3107 |
naïve | #3110 |
siemens | #3111 |
interviewed | #3114 |
symptoms study | #3116 |
articles | #3123 |
amygdala hippocampus | #3123 |
marijuana abuse | #3124 |
mass screening | #3125 |
383 | #3127 |
ptsd symptoms | #3127 |
functional laterality | #3129 |
tcc | #3132 |
psychiatrist | #3133 |
temporal cortex | #3134 |
childhood adversity | #3135 |
pharmacies | #3137 |
maternal | #3142 |
accuracies | #3144 |
european countries | #3146 |
nation | #3146 |
exploratory | #3150 |
99 | #3150 |
ancestry | #3151 |
behavior social | #3152 |
pharmacokinetic | #3157 |
oxford | #3157 |
spd | #3165 |
explanations | #3165 |
biological processes | #3166 |
functional consequences | #3166 |
aggregation | #3168 |
hippocampal | #3169 |
teenagers | #3170 |
status humans | #3171 |
caution | #3171 |
report | #3174 |
hypophyseal | #3175 |
math | #3176 |
wealth | #3178 |
contrast | #3180 |
methyltransferase | #3187 |
imaging study | #3187 |
adolescents young adults | #3187 |
receiver | #3188 |
prodrug | #3189 |
view | #3190 |
published | #3190 |
emotion processing | #3195 |
collect | #3195 |
comprehension | #3201 |
attempt | #3202 |
initial treatment | #3202 |
erythematosus sle | #3205 |
answers | #3208 |
normative | #3209 |
naming | #3212 |
snvs | #3214 |
pathophysiological | #3216 |
gene polymorphisms | #3216 |
psychotherapy | #3222 |
environment | #3223 |
angeles | #3228 |
scanner | #3229 |
discontinuity | #3229 |
situation | #3229 |
65 | #3235 |
depression study | #3236 |
mediation analysis | #3237 |
htt | #3237 |
414 | #3239 |
abstinence | #3241 |
databases genetic | #3247 |
determine | #3250 |
features | #3254 |
210 | #3255 |
211 | #3257 |
correlated | #3257 |
publicly | #3265 |
caudate nucleus | #3265 |
interactive effects | #3266 |
humans magnetic | #3266 |
17p | #3266 |
moderator | #3269 |
370 | #3270 |
symbols | #3271 |
researchers | #3272 |
prefrontal cortex pfc | #3274 |
expertise | #3276 |
memory processing | #3281 |
longitudinal cohort | #3282 |
increased likelihood | #3282 |
cognitive functioning | #3289 |
condition | #3291 |
glutamate receptor | #3296 |
replication | #3297 |
surveys | #3299 |
strict | #3304 |
contributed | #3305 |
clinical severity | #3306 |
synaptic function | #3306 |
genomics | #3309 |
restrictions | #3314 |
corrected | #3315 |
attribute | #3316 |
spearman | #3321 |
digit | #3322 |
neuroimaging data | #3323 |
differently | #3325 |
fewer | #3331 |
earlier studies | #3333 |
mrt | #3334 |
metropolitan | #3336 |
ambiguity | #3336 |
clock gene | #3336 |
417 | #3340 |
6 | #3343 |
slide | #3345 |
revealing | #3348 |
clinical | #3351 |
hoc analyses | #3352 |
healthy control | #3354 |
affect | #3357 |
national institute | #3359 |
functional studies | #3361 |
april | #3362 |
friend | #3366 |
motivational | #3367 |
retest | #3369 |
067 | #3370 |
frontal regions | #3371 |
battery | #3371 |
glycolysis | #3371 |
treatment strategies | #3373 |
cortex pfc | #3375 |
088 | #3376 |
marker | #3379 |
functional neuroimaging | #3382 |
initially | #3384 |
sex chromosomes | #3385 |
typically developing | #3386 |
impaired performance | #3386 |
stressful life events | #3387 |
monozygotic | #3389 |
multimorbidity | #3390 |
clock genes | #3390 |
health children | #3392 |
accounting | #3393 |
cnp | #3393 |
ifg | #3398 |
358 | #3402 |
baseline followup | #3404 |
depression symptoms | #3405 |
traumatic brain | #3405 |
desirability | #3406 |
oxidase | #3411 |
pool | #3413 |
performing | #3413 |
aucs | #3415 |
lack | #3419 |
health surveys | #3422 |
therapeutic response | #3423 |
longitudinal data | #3426 |
stepwise | #3431 |
03 | #3433 |
pediatric population | #3436 |
definition | #3439 |
experiencing | #3439 |
exert | #3441 |
fluency | #3446 |
showing | #3448 |
children mothers | #3448 |
lca | #3448 |
schoolaged children | #3449 |
lowered | #3450 |
supports | #3455 |
psychotropic medication | #3455 |
inception | #3457 |
schooling | #3461 |
estimating | #3463 |
differentiate | #3464 |
cognitive behavioral | #3466 |
hallucinations | #3466 |
genomewide association study | #3466 |
male sex | #3472 |
bilaterally | #3473 |
scan | #3475 |
methylation | #3477 |
remaining | #3477 |
behavioral response | #3478 |
irr | #3480 |
transmission | #3482 |
postmortem | #3482 |
slower | #3488 |
exposure pregnancy | #3489 |
lesser | #3489 |
convergent | #3489 |
epidemiological study | #3492 |
applying | #3492 |
aged polymorphism | #3497 |
083 | #3497 |
short stature | #3497 |
alpha2 | #3497 |
social behaviors | #3497 |
matched healthy | #3502 |
p002 | #3506 |
identifier | #3506 |
brain function | #3506 |
antidepressants | #3512 |
checklist | #3514 |
sans | #3518 |
specificity | #3519 |
104 | #3519 |
113 | #3520 |
antipsychotic | #3524 |
spouse | #3525 |
basis | #3527 |
constitutes | #3527 |
pediatricians | #3527 |
asperger syndrome | #3529 |
reflect | #3529 |
clinical phenotype | #3533 |
rett syndrome | #3535 |
reliable | #3536 |
preferentially | #3536 |
enrichment analysis | #3538 |
social behavior | #3539 |
school aged | #3540 |
mother child | #3541 |
sleep wake | #3544 |
fact | #3544 |
cognitive behavioral therapy | #3544 |
coming | #3545 |
rts | #3546 |
documentation | #3547 |
score | #3548 |
dmn | #3550 |
344 | #3557 |
ecgs | #3558 |
neuronal function | #3558 |
preventive interventions | #3558 |
prevalence estimates | #3563 |
suggestions | #3564 |
genetic analysis | #3567 |
psychiatrists | #3568 |
prevent | #3569 |
prospectively | #3570 |
developmental stages | #3573 |
psychosocial interventions | #3579 |
genotyping | #3580 |
reliability | #3583 |
mse | #3585 |
collaborative | #3585 |
neurite outgrowth | #3587 |
mpfc | #3587 |
crh | #3603 |
interrater reliability | #3604 |
major gene | #3606 |
cardio | #3606 |
consists | #3609 |
299 | #3613 |
screen | #3614 |
modalities | #3617 |
methylation status | #3618 |
questions | #3618 |
348 | #3620 |
races | #3621 |
pharmacogenetics | #3622 |
objectives | #3623 |
reviewed | #3624 |
article | #3625 |
214 | #3626 |
101 | #3628 |
neglect | #3630 |
185 | #3631 |
hypothalamo | #3634 |
posttraumatic stress | #3640 |
prior | #3640 |
seeking | #3641 |
wgs | #3648 |
cohesion | #3653 |
enrolment | #3654 |
facilitate | #3660 |
negative | #3661 |
downward | #3662 |
study association | #3663 |
increased prevalence | #3666 |
socioeconomic factors | #3668 |
weight | #3669 |
93 | #3670 |
administration oral | #3672 |
captured | #3675 |
360 | #3681 |
1st | #3682 |
genotype data | #3686 |
behavior problems | #3690 |
frontal lobes | #3691 |
marijuana | #3695 |
online survey | #3696 |
nacetylcysteine | #3700 |
disorders animals | #3703 |
oe | #3705 |
problem behavior | #3707 |
effort | #3711 |
brain cognition | #3719 |
manipulations | #3722 |
9 years | #3729 |
situations | #3730 |
pha | #3732 |
070 | #3733 |
ultimate | #3734 |
daily life | #3735 |
neurotransmission | #3735 |
fifty | #3736 |
hapmap | #3737 |
depressed mood | #3737 |
population | #3738 |
international | #3744 |
therapy cbt | #3744 |
relative | #3745 |
offer | #3746 |
reply | #3750 |
persisted | #3751 |
shortterm | #3753 |
epigenesis genetic | #3755 |
depression risk | #3756 |
proportional | #3757 |
333 | #3758 |
neurophysiological | #3758 |
interim analysis | #3760 |
comprehensive assessment | #3767 |
315 | #3777 |
addiction | #3780 |
transitions | #3781 |
recognition psychology | #3782 |
cocaine disorders | #3783 |
promoter polymorphism | #3787 |
peers | #3787 |
1012 | #3791 |
nonresponse | #3794 |
predictive validity | #3797 |
discriminate | #3800 |
forecast | #3802 |
monozygotic twins | #3803 |
statistical analyses | #3806 |
355 | #3809 |
ways | #3814 |
scientific | #3822 |
dimensions | #3824 |
030 | #3825 |
neurotransmitter | #3829 |
acetylcysteine | #3835 |
inclusion | #3837 |
exchanger | #3844 |
male marijuana | #3844 |
developmental disorders | #3850 |
disease genes | #3850 |
children aged | #3850 |
risk development | #3851 |
elevations | #3851 |
midlife | #3852 |
36 | #3854 |
rely | #3856 |
test | #3858 |
animal dopamine | #3859 |
superior temporal | #3862 |
strong | #3863 |
drug administration | #3866 |
prospective | #3872 |
explain | #3874 |
208 | #3876 |
influences | #3876 |
74 | #3876 |
p001 | #3879 |
ireland | #3882 |
mark | #3883 |
globus | #3886 |
child cohort | #3888 |
reevaluation | #3888 |
tesla | #3890 |
p0003 | #3895 |
plasma membrane | #3898 |
neurology | #3898 |
histories | #3901 |
obstetric | #3905 |
congruent | #3913 |
clinicians | #3915 |
ethnicities | #3922 |
monotherapy | #3923 |
variable | #3924 |
illnesses | #3925 |
robust | #3929 |
dbd | #3930 |
drug targets | #3931 |
suicidal behavior | #3932 |
antidepressant treatment | #3935 |
specific factors | #3937 |
frontal gyrus | #3937 |
preexisting | #3937 |
females males | #3944 |
2nd | #3945 |
directions | #3947 |
controversy | #3951 |
integrate | #3953 |
nicotine | #3956 |
normalization | #3959 |
support | #3960 |
systematic review metaanalysis | #3962 |
indicating | #3967 |
older children | #3969 |
trauma | #3970 |
disease control | #3971 |
untreated | #3976 |
alcohol | #3978 |
brain functional | #3980 |
forecasts | #3981 |
factorial | #4000 |
categorization | #4000 |
preliminary evidence | #4000 |
vulnerabilities | #4003 |
medial prefrontal | #4004 |
primary aim | #4005 |
initiating | #4012 |
kappa | #4013 |
cortex | #4018 |
eqtls | #4021 |
construct | #4023 |
fusiform gyrus | #4032 |
represent | #4036 |
clinical improvement | #4046 |
common variants | #4047 |
diabetes risk | #4047 |
discussion | #4051 |
modeled | #4051 |
mathematics | #4051 |
consequences | #4052 |
relevant | #4057 |
jointly | #4058 |
contextual factors | #4058 |
criminal | #4060 |
divergent | #4062 |
intellectual disability | #4063 |
causal role | #4064 |
cag | #4068 |
magnetic resonance | #4068 |
serotonin uptake | #4068 |
forecasting | #4071 |
statistics | #4072 |
118 | #4074 |
portion | #4075 |
child age | #4076 |
outcomes children | #4078 |
birth order | #4082 |
belgium | #4086 |
genetic loci | #4088 |
heroin | #4090 |
study efficacy | #4090 |
clinical characteristics | #4096 |
lobe | #4098 |
temporal lobe | #4098 |
maternal depression | #4100 |
genetic variations | #4100 |
limbic | #4102 |
age matched | #4103 |
psychologists | #4103 |
list | #4105 |
evidence base | #4107 |
062 | #4109 |
eicosapentaenoic | #4113 |
traumatic | #4115 |
vary | #4117 |
comprises | #4121 |
plausible | #4121 |
epigenesis | #4128 |
cortical areas | #4130 |
relationship | #4136 |
principal components | #4139 |
244 | #4140 |
dosing | #4145 |
german | #4145 |
span | #4146 |
neuronal migration | #4148 |
sectional | #4150 |
mj | #4156 |
regression | #4158 |
extensively | #4160 |
259 | #4161 |
124 | #4164 |
indicative | #4166 |
pathophysiology | #4167 |
fm | #4169 |
somatization | #4170 |
risk depression | #4174 |
bioinformatics | #4177 |
mapping | #4178 |
sedation | #4180 |
340 | #4182 |
dopamine d3 | #4184 |
109 | #4187 |
mri scans | #4188 |
preventive | #4190 |
military | #4191 |
lupus erythematosus | #4192 |
morphometry | #4193 |
structural connectivity | #4194 |
study differences | #4195 |
268 | #4196 |
describes | #4198 |
116 | #4199 |
transporter | #4204 |
growing | #4213 |
children age | #4215 |
helpful | #4216 |
route | #4216 |
based sample | #4218 |
subgroups | #4219 |
suicidal thoughts | #4219 |
functional magnetic | #4223 |
copy variations | #4224 |
determining | #4227 |
valproic | #4230 |
calcineurin | #4237 |
administration | #4239 |
tap | #4245 |
rat model | #4247 |
1987 | #4251 |
predict | #4253 |
gpcr | #4253 |
differential female humans | #4254 |
emerge | #4256 |
mortem | #4259 |
representative | #4263 |
trajectory | #4263 |
confers | #4264 |
posttreatment | #4268 |
antipsychotic medication | #4269 |
225 | #4270 |
follow‐up | #4273 |
early intervention | #4276 |
paediatric | #4280 |
principal component analysis | #4282 |
contributors | #4285 |
polymorphisms genes | #4292 |
select | #4293 |
deletion | #4296 |
pressor | #4302 |
outpatients | #4305 |
demographic variables | #4309 |
child development | #4314 |
adequacy | #4315 |
potential targets | #4315 |
highest risk | #4319 |
mutual | #4324 |
cardiovascular effects | #4326 |
patients diagnosed | #4327 |
buprenorphine | #4332 |
occasion | #4341 |
cingulate cortex | #4348 |
occurs | #4350 |
chart review | #4352 |
catechol | #4353 |
acute treatment | #4353 |
segregation | #4358 |
dropouts | #4361 |
searched | #4362 |
adjunct | #4363 |
166 | #4369 |
cambridge | #4370 |
aging brain | #4372 |
logistic regression analysis | #4373 |
relation | #4375 |
exists | #4375 |
intolerance | #4378 |
mediate | #4378 |
066 | #4382 |
psychological adolescent | #4383 |
clarity | #4383 |
docosahexaenoic | #4391 |
transcriptomic | #4391 |
solving | #4391 |
human | #4393 |
volumetric | #4395 |
privacy | #4396 |
low dose | #4399 |
exon | #4404 |
sexual dimorphism | #4409 |
corpus striatum | #4410 |
impulse | #4412 |
diverse | #4413 |
survive | #4413 |
membrane glycoproteins | #4416 |
polychlorinated biphenyls | #4418 |
ethnic differences | #4424 |
intranasal | #4426 |
opioids | #4429 |
terminology | #4434 |
concurrent | #4438 |
morbidities | #4444 |
197 | #4445 |
bias | #4447 |
striatal dopamine | #4449 |
human studies | #4449 |
genotypes | #4454 |
62 | #4454 |
192 | #4461 |
symposium | #4462 |
locomotor | #4464 |
serotonergic | #4465 |
outgrowth | #4467 |
dna methylation | #4470 |
219 | #4471 |
entered | #4473 |
emissioncomputed | #4476 |
smell | #4477 |
synapse | #4482 |
compilation | #4486 |
ethical | #4490 |
criterion validity | #4491 |
fourth | #4495 |
informal | #4500 |
superior temporal gyrus | #4501 |
parametric | #4508 |
313 | #4509 |
valuation | #4516 |
disorders cognitive | #4516 |
visits | #4516 |
alcohol abuse | #4517 |
investigate | #4521 |
notion | #4525 |
laterality | #4526 |
postnatal day | #4540 |
considerable | #4540 |
multiple | #4541 |
children families | #4542 |
incentive | #4546 |
transmit | #4548 |
pharmacology | #4552 |
higher level | #4553 |
employment | #4553 |
birth | #4564 |
preschool children | #4564 |
emr | #4565 |
component | #4572 |
22 | #4573 |
neuronal differentiation | #4587 |
psd | #4587 |
address | #4593 |
origin | #4595 |
initiated | #4599 |
006 | #4603 |
≤ | #4609 |
february | #4610 |
009 | #4612 |
indices | #4613 |
israel | #4617 |
attributed | #4630 |
genomic data | #4633 |
ssris | #4634 |
television | #4636 |
head injury | #4638 |
q1 | #4643 |
clinical risk | #4643 |
question | #4648 |
unmet | #4651 |
trouble | #4651 |
regression model | #4652 |
marriage | #4658 |
microsatellite | #4660 |
deliveries | #4660 |
centers | #4660 |
anterior cingulate cortex | #4661 |
trajectories | #4662 |
243 | #4662 |
children study | #4665 |
homogeneity | #4667 |
fg | #4668 |
mitigate | #4668 |
european | #4669 |
healthy individuals | #4670 |
psychometric properties | #4673 |
routes | #4676 |
disease onset | #4679 |
subsequently | #4680 |
pregnancy risk | #4682 |
264 | #4684 |
names | #4689 |
hunt | #4696 |
accurate diagnosis | #4699 |
concerns | #4705 |
5 | #4706 |
cardiorespiratory | #4707 |
imply | #4710 |
autosomal | #4711 |
vector machine | #4715 |
hazards models | #4715 |
estimate | #4716 |
smd | #4717 |
mbr | #4719 |
sed | #4719 |
appropriateness | #4720 |
positional | #4725 |
cinahl | #4729 |
fusiform | #4730 |
eqtl | #4731 |
participants included | #4732 |
biological factors | #4735 |
drug addiction | #4736 |
prototypes | #4745 |
val | #4747 |
unemployment | #4747 |
pons | #4753 |
cooperative | #4755 |
drug | #4757 |
taiwan | #4757 |
77 | #4760 |
conflict | #4760 |
tasks | #4762 |
portions | #4763 |
heavily | #4763 |
fumarate | #4773 |
231 | #4774 |
mother | #4782 |
subjects risk | #4784 |
noncarriers | #4791 |
samples | #4791 |
sharing | #4795 |
mp | #4798 |
publication administration | #4798 |
cleaning | #4804 |
coronary artery disease | #4814 |
fractional anisotropy | #4820 |
modafinil | #4825 |
cognitive tests | #4825 |
excluding | #4832 |
surge | #4835 |
visual perception | #4836 |
experts | #4837 |
223 | #4838 |
continuity | #4843 |
sparse | #4849 |
recognized | #4853 |
imaging female | #4858 |
41 | #4865 |
rg | #4873 |
specific | #4874 |
207 | #4875 |
deterioration | #4880 |
wave | #4880 |
subsamples | #4881 |
young age | #4881 |
cigarettes | #4881 |
fp | #4882 |
omega3 | #4882 |
prisma | #4885 |
facts | #4890 |
cascades | #4891 |
eliminated | #4894 |
antiepileptic drugs | #4910 |
operating | #4914 |
002 | #4915 |
preclinical studies | #4916 |
early adolescence | #4923 |
achievements | #4923 |
additive | #4924 |
scored | #4929 |
bdi | #4929 |
parietal lobe | #4930 |
outcome measures | #4932 |
034 | #4933 |
brain activity | #4937 |
inventory | #4941 |
relating | #4947 |
delays | #4949 |
hemispheric | #4949 |
powerful | #4951 |
pooled analysis | #4951 |
snap | #4957 |
rule | #4959 |
diffusion tensor imaging | #4962 |
acetylcholine receptor | #4965 |
srs | #4967 |
212 | #4969 |
altered expression | #4972 |
eye tracking | #4973 |
explosion | #4978 |
empirical data | #4979 |
continental | #4983 |
lower | #4994 |
170 | #4995 |
022 | #5001 |
treatment modalities | #5005 |
timing | #5008 |
esr1 | #5015 |
aged nerve | #5017 |
caucasians | #5021 |
selective attention | #5021 |
disagreement | #5024 |
aug | #5025 |
rarely | #5027 |
serotonin receptors | #5029 |
variation | #5030 |
adolescent health | #5031 |
specialty | #5036 |
task | #5038 |
probabilistic | #5039 |
discuss | #5039 |
distinguish | #5040 |
correct | #5040 |
cingulate gyrus | #5047 |
anxiety depression | #5047 |
auc | #5047 |
sga | #5050 |
early | #5051 |
marital | #5051 |
convergent validity | #5051 |
predictor | #5052 |
2003 | #5055 |
analgesics | #5056 |
obesity | #5064 |
bidirectional | #5067 |
gender identity | #5067 |
18 years | #5070 |
continuation | #5077 |
cadherins | #5079 |
decreasing | #5085 |
reductions | #5086 |
chinese children | #5092 |
placebo patients | #5095 |
aes | #5097 |
epilepsy | #5099 |
09 | #5101 |
reached | #5101 |
103 | #5104 |
screening | #5104 |
relative contributions | #5105 |
qtc | #5106 |
volume reduction | #5107 |
ancestral | #5112 |
time points | #5118 |
relevance | #5119 |
variables | #5127 |
substances | #5129 |
single nucleotide polymorphisms | #5132 |
mediation | #5132 |
maladaptive | #5133 |
ppv | #5134 |
individuals risk | #5136 |
mechanisms | #5142 |
readers | #5143 |
mental retardation | #5145 |
inherent | #5146 |
difference | #5146 |
pharmacogenomics | #5147 |
involves | #5147 |
carrying | #5158 |
enrichment | #5160 |
administered | #5162 |
homozygote | #5166 |
dropout | #5168 |
biological | #5170 |
diffusivity | #5177 |
picture | #5178 |
ventral | #5181 |
reuptake inhibitors | #5182 |
extent | #5183 |
dopamine d1 | #5187 |
adjustment | #5190 |
disability | #5193 |
238 | #5193 |
predictive | #5195 |
weighted | #5197 |
pleiotropy | #5205 |
characteristic | #5212 |
remains | #5215 |
molecular biology | #5215 |
term | #5218 |
conclude | #5223 |
dopaminergic neurons | #5224 |
167 | #5226 |
nonsmokers | #5231 |
dutch | #5233 |
256 | #5234 |
fail | #5237 |
smoking behavior | #5240 |
interaction | #5242 |
accurately | #5245 |
119 | #5246 |
critical period | #5248 |
tolerated | #5255 |
generated | #5260 |
boundaries | #5261 |
americans | #5263 |
exceeded | #5264 |
delineation | #5266 |
genotypic | #5269 |
daytime sleepiness | #5278 |
ws | #5278 |
cell surface receptors | #5280 |
brain injuries | #5283 |
001 | #5286 |
participated | #5287 |
variety | #5289 |
normality | #5290 |
written | #5291 |
billion | #5295 |
trend | #5295 |
eye movements | #5296 |
motor | #5298 |
oligodendrocytes | #5299 |
thalamus | #5299 |
learning | #5301 |
234 | #5302 |
emotion recognition | #5306 |
life events | #5308 |
072 | #5308 |
52 | #5309 |
healthy participants | #5310 |
environmental | #5312 |
observer | #5313 |
dense | #5316 |
hints | #5321 |
definite | #5322 |
treatment initiation | #5323 |
genomic imprinting | #5333 |
credibility | #5335 |
inferences | #5339 |
individual level | #5345 |
social interactions | #5345 |
predictive tests | #5345 |
classic | #5351 |
prenatal | #5353 |
word | #5354 |
estimated | #5359 |
cerebellum | #5363 |
nonresponders | #5368 |
nervosa | #5369 |
interplay | #5375 |
eventrelated potentials | #5376 |
higher frequency | #5380 |
penetrance | #5380 |
lost | #5382 |
suicide attempts | #5382 |
internet addiction | #5390 |
sweden | #5391 |
huntington disease | #5392 |
domains | #5396 |
potential confounders | #5402 |
37 | #5403 |
label | #5403 |
empirical | #5410 |
register | #5411 |
daily | #5413 |
0007 | #5419 |
average | #5424 |
tensor imaging | #5432 |
224 | #5436 |
pcp | #5449 |
172 | #5451 |
wiley | #5452 |
adjunctive therapy | #5454 |
modifiers | #5464 |
hour | #5467 |
york | #5468 |
risk individuals | #5468 |
× 10 | #5471 |
aim | #5474 |
settings | #5475 |
borderline | #5478 |
environmental effects | #5484 |
brains | #5486 |
copy | #5488 |
recall | #5491 |
confirms | #5494 |
locomotor activity | #5499 |
homozygotes | #5502 |
year | #5505 |
clinics | #5517 |
commission | #5518 |
termed | #5519 |
promoter regions | #5525 |
verbal fluency | #5525 |
fdr | #5534 |
320 | #5536 |
anxiety behavior | #5537 |
155 | #5547 |
modulate | #5547 |
closely | #5549 |
elevated | #5549 |
prevention | #5551 |
flanking | #5552 |
restraint | #5552 |
occur | #5553 |
154 | #5559 |
copy variation | #5562 |
health conditions | #5563 |
icd10 | #5564 |
frontal cortex | #5565 |
baseline treatment | #5565 |
european ancestry | #5567 |
15 | #5567 |
213 | #5574 |
predominance | #5578 |
significance | #5578 |
mediators | #5579 |
240 | #5579 |
spatial memory | #5581 |
subacute | #5584 |
175 | #5590 |
locus | #5592 |
epidemiological | #5593 |
scientists | #5596 |
narcolepsy | #5597 |
nrg1 | #5607 |
anhedonia | #5608 |
amygdala | #5623 |
percent | #5628 |
heavier | #5631 |
total | #5640 |
allocation | #5657 |
lower risk | #5663 |
perinatal | #5663 |
divided | #5666 |
exploring | #5670 |
probability | #5677 |
calculate | #5678 |
proportional hazards | #5684 |
1999 | #5686 |
40 years | #5686 |
gene variants | #5687 |
vbm | #5688 |
markov | #5688 |
published data | #5689 |
oculomotor | #5690 |
brain development | #5694 |
normal | #5696 |
databases | #5696 |
systems biology | #5703 |
primary outcome measure | #5713 |
cognitive functions | #5713 |
58 | #5723 |
signal detection | #5725 |
pleasure | #5727 |
thirty | #5728 |
focused | #5728 |
psychological surveys | #5735 |
020 | #5739 |
19 | #5745 |
definitions | #5746 |
cognitive tasks | #5751 |
missing data | #5755 |
divorce | #5758 |
approaches | #5761 |
nac | #5762 |
interactive | #5765 |
aged children | #5767 |
additional | #5773 |
deficient | #5778 |
oral | #5779 |
72 | #5780 |
rats inbred | #5786 |
susceptibility locus | #5788 |
extracted | #5792 |
206 | #5796 |
preferential | #5797 |
16 | #5799 |
139 | #5802 |
deaths | #5811 |
intracranial | #5814 |
nuclear | #5815 |
0002 | #5819 |
0005 | #5820 |
aaa | #5823 |
133 | #5826 |
nerve net | #5827 |
98 | #5827 |
ethnic groups | #5834 |
multidimensional | #5836 |
fell | #5841 |
dependency | #5846 |
cannabis | #5849 |
deletions | #5857 |
current understanding | #5860 |
signaling peptides | #5862 |
gene expression profiles | #5869 |
fetuses | #5872 |
membership | #5874 |
auditory | #5875 |
retrospective chart review | #5879 |
sexual behavior | #5880 |
synaptophysin | #5887 |
16 years | #5894 |
small | #5898 |
september | #5901 |
imputation | #5910 |
council | #5910 |
appendix | #5916 |
characterizing | #5917 |
activity level | #5919 |
broad | #5919 |
ethics | #5923 |
parietal | #5925 |
region | #5928 |
linked | #5928 |
statement | #5928 |
individuality | #5929 |
rights | #5930 |
prolactin | #5931 |
medical treatment | #5933 |
rapamycin | #5937 |
biphenyls | #5940 |
striatal | #5955 |
community | #5956 |
electroencephalography evoked | #5964 |
clearance | #5965 |
132 | #5966 |
cmax | #5969 |
091 | #5971 |
missed | #5974 |
explore | #5994 |
website | #6000 |
exclusively | #6001 |
threshold | #6003 |
moderating role | #6005 |
rois | #6005 |
matched | #6006 |
chromosomal | #6009 |
module | #6011 |
functional connectivity | #6013 |
newcastle | #6017 |
extreme | #6020 |
Jalankan laporan | |
Prominent publications by Stephen V Faraone∗
IMPORTANCE: Attention-deficit/hyperactivity disorder (ADHD) is a heritable neurodevelopmental disorder. It has been linked to reductions in total brain volume and subcortical abnormalities. However, owing to heterogeneity within and between studies and limited sample sizes, findings on the neuroanatomical substrates of ADHD have shown considerable variability. Moreover, it remains unclear whether neuroanatomical alterations linked to ADHD are also present in the unaffected siblings of ...
Dikenal sebagai Unaffected Siblings | Putamen Volume | Participants Adhd | Hyperactivity Disorder | Total Brain |
Motor coordination problems in children and adolescents with ADHD rated by parents and teachers: effects of age and gender
[ PUBLICATION ]
Summary.Objective. ADHD is frequently accompanied by motor coordination problems. However, the co-occurrence of poor motor performance has received less attention in research than other coexisting problems in ADHD. The underlying mechanisms of this association remain unclear. Therefore, we investigated the prevalence of motor coordination problems in a large sample of children with ADHD, and the relationship between motor coordination problems and inattentive and hyperactive/impulsive ...
Dikenal sebagai Motor Coordination Problems | Children Adhd | Boys Girls | Hyperactivity Child Child | Parents Prevalence |
Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia
[ PUBLICATION ]
We examined the status of the neural network mediating the default mode of brain function, which typically exhibits greater activation during rest than during task, in patients in the early phase of schizophrenia and in young first-degree relatives of persons with schizophrenia. During functional MRI, patients, relatives, and controls alternated between rest and performance of working memory (WM) tasks. As expected, controls exhibited task-related suppression of activation in the default ...
Dikenal sebagai Default Network | Patients Relatives | Rest Task | Wm Performance | Mpfc Dlpfc |
Patterns of Psychopathology and Dysfunction in High-Risk Children of Parents With Panic Disorder and Major Depression
[ PUBLICATION ]
OBJECTIVE: The purpose of the study was to evaluate 1) whether an underlying familial predisposition is shared by all anxiety disorders or whether specific risks are associated with specific disorders, and 2) whether panic disorder and major depression have a familial link.
METHOD: The study compared four groups of children: 1) offspring of parents with panic disorder and comorbid major depression (N=179), 2) offspring of parents with panic disorder without comorbid major depression ...
Dikenal sebagai Major Depression | Panic Disorder | Offspring Parents | Risk Children | Factors Social |
OBJECTIVE: Attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and obsessive-compulsive disorder (OCD) are common neurodevelopmental disorders that frequently co-occur. The authors sought to directly compare these disorders using structural brain imaging data from ENIGMA consortium data.
METHODS: Structural T1-weighted whole-brain MRI data from healthy control subjects (N=5,827) and from patients with ADHD (N=2,271), ASD (N=1,777), and OCD (N=2,323) from 151 ...
Dikenal sebagai Adhd Asd | Cortical Thickness | Children Adolescents | Brain Volume | Disorder Ocd |
BACKGROUND: Neuroimaging studies have shown structural alterations in several brain regions in children and adults with attention deficit hyperactivity disorder (ADHD). Through the formation of the international ENIGMA ADHD Working Group, we aimed to address weaknesses of previous imaging studies and meta-analyses, namely inadequate sample size and methodological heterogeneity. We aimed to investigate whether there are structural differences in children and adults with ADHD compared with ...
Dikenal sebagai Brain Volume | Adults Adhd | Attention Deficit | Hyperactivity Disorder | Subcortical Structures |
AIMS: To determine comorbidity patterns in treatment-seeking substance use disorder (SUD) patients with and without adult attention deficit hyperactivity disorder (ADHD), with an emphasis on subgroups defined by ADHD subtype, taking into account differences related to gender and primary substance of abuse.
DESIGN: Data were obtained from the cross-sectional International ADHD in Substance use disorder Prevalence (IASP) study.
SETTING: Forty-seven centres of SUD treatment in 10 ...
Dikenal sebagai Disorder Patients | Psychiatric Comorbidity | Attention Deficit | Seeking Substance | Presence Adhd |
CONTEXT: Controversy exists about the appropriate criteria for a diagnosis of adult attention-deficit/hyperactivity disorder (ADHD).
OBJECTIVE: To examine the structure and symptoms most predictive of DSM-IV adult ADHD.
DESIGN: The data are from clinical interviews in enriched subsamples of the National Comorbidity Survey Replication (n = 131) and a survey of a large managed health care plan (n = 214). The physician-administered Adult ADHD Clinical Diagnostic Scale (ACDS) was used to ...
Dikenal sebagai Adult Adhd | Hyperactivity Disorder | Illness Surveys | Clinical Diagnostic | Symptoms Childhood |
The Massachusetts General Hospital studies of gender influences on attention-deficit/hyperactivity disorder in youth and relatives
[ PUBLICATION ]
With the single exception of SUDs, no statistically significant gender-by ADHD interactions were identified in the multiple, outcomes evaluated. These results suggest that with the exception of SUDs, ADHD expresses itself similarly in boys and girls relative to comparison subjects of the same gender, indicating that ADHD-associated impairments are correlates of ADHD in both genders. Gender differences, such as the higher prevalence of symptoms of inattention and lower rates of ...
Dikenal sebagai Girls Adhd | Hyperactivity Disorder | Gender Differences | Higher Prevalence | Symptoms Inattention |
OBJECTIVE: To complete an exploratory uncontrolled study of the effects of lisdexamfetamine dimesylate (LDX) on growth of children treated for attention-deficit/hyperactivity disorder (ADHD).
METHOD: Height, weight, and body mass index (BMI) from 281 children ages 6 to 13 years from longitudinal assessments up to 15 months were compared to norms from the Centers for Disease Control.
RESULTS: At study entry, children were taller and heavier than average. Growth delays were largest for ...
Dikenal sebagai Lisdexamfetamine Dimesylate | Height Weight | Growth Children | Ldx Bmi | Centers Disease Control |
Psychopathology in Adolescent Offspring of Parents With Panic Disorder, Major Depression, or Both: A 10-Year Follow-Up
[ PUBLICATION ]
OBJECTIVE: The authors examined the specificity and course of psychiatric disorders from early childhood through adolescence in offspring of parents with confirmed panic disorder and major depressive disorder.
METHOD: The authors examined rates of psychiatric disorders at 10-year-follow-up (mean age, 14 years) in four groups: offspring of referred parents with panic and depression (N=137), offspring of referred parents with panic without depression (N=26), offspring of referred parents ...
Dikenal sebagai Panic Disorder | Offspring Parents | Parental Depression | Disruptive Behavior | Year Follow |
BACKGROUND: The goal of this study was to investigate the occurrence, severity and clinical correlates of emotional lability (EL) in children with attention deficit/hyperactivity disorder (ADHD), and to examine factors contributing to EL and familiality of EL in youth with ADHD.
METHODS: One thousand, one hundred and eighty-six children with ADHD combined type and 1827 siblings (aged 6-18 years) were assessed for symptoms of EL, ADHD, associated psychopathology and comorbid psychiatric ...
Dikenal sebagai Symptoms Adhd | Emotional Lability | Hyperactivity Disorder | Attention Deficit | Odd Disruptive Behavior |
A Controlled Study of Behavioral Inhibition in Children of Parents With Panic Disorder and Depression
[ PUBLICATION ]
OBJECTIVE: "Behavioral inhibition to the unfamiliar" has been proposed as a precursor to anxiety disorders. Children with behavioral inhibition are cautious, quiet, introverted, and shy in unfamiliar situations. Several lines of evidence suggest that behavioral inhibition is an index of anxiety proneness. The authors sought to replicate prior findings and examine the specificity of the association between behavioral inhibition and anxiety.
METHOD: Laboratory-based behavioral observations ...
Dikenal sebagai Behavioral Inhibition | Major Depression | Children Parents | Panic Disorder | Controlled Study |
Traumatic Brain Injury and Schizophrenia in Members of Schizophrenia and Bipolar Disorder Pedigrees
[ PUBLICATION ]
OBJECTIVE: Schizophrenia following a traumatic brain injury could be a phenocopy of genetic schizophrenia or the consequence of a gene-environment interaction. Alternatively, traumatic brain injury and schizophrenia could be spuriously associated if those who are predisposed to develop schizophrenia have greater amounts of trauma for other reasons. The authors investigated the relationship between traumatic brain injury and psychiatric diagnoses in a large group of subjects from families ...
Dikenal sebagai Traumatic Brain Injury | Bipolar Disorder | Subjects Schizophrenia | Mental Illness | Genetic Vulnerability |
Orang -orang kunci untuk Hyperactivity Disorder
Stephen V Faraone∗:Dampak ahli
Konsep yang manaStephen V Faraone∗memiliki pengaruh langsung:Hyperactivity disorder, Bipolar disorder, Attention deficit, Deficit hyperactivity, Disorder adhd, Anxiety disorders, Disorder hyperactivity, Children adhd.
Stephen V Faraone∗:Dampak Kol
Konsep yang terkait dengan karya penulis lain yang manafor which Stephen V Faraone∗ memiliki pengaruh:Bipolar disorder, Attention deficit, Children adhd, Executive function, Mental health, Schizophrenia patients.
Tools
Apakah ini profil Anda? Klaim profil Anda Salin URL Sematkan tautan ke profil Anda |